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Investigation of muscle diseases has changed dramatically with the understanding 
of genetic basis of a wide range of muscle diseases. Muscle biopsy has become a 
powerful tool not only to provide diagnosis but to make tissue available for genetic 
studies and to basic scientists for biomedical research. Accurate interpretation of 
muscle biopsy to detect cell dysfunction/ damage/death or absence / abnormality of 
a protein or genetic defect by the sophisticated technologies is important to guide 
treatment of various muscle diseases. In this book on muscle biopsy various chapters 
deal with the procedure and interpretation of muscle biopsy, its use in the culture of 
myotubes and membrane transport studies.Muscle biopsy is an important technique 
to investigate mitochondrial dysfunction and the mitochondrial DNA integrity in 
oxidation. Phosphorylation in various metabolic diseases like obesity, type 2 diabetes 
mellitus and peripheral vascular disease is explored in the other chapters with detailed 
descriptions on methodology. This book provides the advances in the basic techniques 
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Preface 
With this book, 'Muscle Biopsy', I published my first book as an editor on diagnostic
issues of muscle biopsies - the work which I have cherished for the last 25 years. The 
use and importance of doing and interpreting a muscle biopsy has come a long way
after the first biopsy was performed by Duchenne to diagnose a myopathic condition.
Starting as a relatively less attractive field, myology, particularly myopathology, has
progressed into one of the most coveted subjects by neurologists, pathologists and 
basic scientists. With advances in enzyme histochemistry, molecular pathology and
gene analysis, the importance of a muscle biopsy in the diagnosis of primary and
secondary neuromuscular disorders is increasing. 
The diagnostic algorithm on a muscle biopsy begins with a systematic and thorough 
analysis of histochemical and enzyme histochemical stains. The first two chapters of
the book deal with these basics of muscle biopsy. The next set of two chapters deals 
with basic research techniques of cultures of myotubes and membrane transport. 
These chapters give an in-depth review of basic techniques seldom covered in any
other book on muscle biopsy and will be of great help to basic scientists. 
Mitochondrial disease pathology and pathogenesis has made tremendous progress 
over the last few years and has given answers to many unexplained neuromuscular
and systemic ailments. Mitochondria have also established a role in pathogenesis of
diabetes and obesity. Keeping this in mind, we have included three chapters which 
deal with different aspects of mitochondrial diseases. 
I am greatly thankful to all the authors of this book for their contributions and hope 
the readers benefit from the material. 
Challa Sundaram 
Department of Pathology, 
Nizam’s Institute of Medical Sciences, Hyderabad, 
India
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Percutaneous Muscle Biopsy: 
 History, Methods and Acceptability 
 Harnish P. Patel, Cyrus Cooper and Avan Aihie Sayer 
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton  
UK 
1. Introduction 
Advances in histological, biochemical, physiological and molecular biological assays, as well 
as in microscopy and image analysis have allowed multiple analyses in muscle tissue (1-5). 
Muscle biopsy is invaluable in providing a definitive diagnosis of a wide range of 
myopathies (muscular dystrophies, glycogen storage diseases, inflammatory myopathies 
and congenital myopathies) and denervating disorders and gives important information on 
the course of the disease, informs treatment, disease stage as well as prognosis. Results of 
histopathological analyses should then be interpreted in context of the clinical history, 
examination and laboratory serum markers (1;6). Furthermore, access to muscle tissue 
provides the opportunity to assess morphological characteristics such as fibre composition, 
fibre cross sectional area and capillarisation (e.g. in ageing muscle) (7-9) as well as mRNA, 
protein abundance and muscle enzyme activity (10). Ultrastructural analyses to gauge 
response to intervention can be performed (11) as can studies of physiological characteristics 
of muscle such as single fibre contraction properties (2;8). 
2. History of muscle biopsy 
Methodologies enabling the study of muscle tissue have relied on obtaining tissue through 
post mortem or open muscle biopsy techniques that require general anaesthesia. Although 
open muscle biopsy provides large specimens that enables direct visualization of disease 
distribution and can include a peripheral nerve, the technique involves co-ordination 
between surgical and anaesthetic colleagues, requires an inpatient bed stay and is therefore 
time and resource demanding. Moreover, this technique can result in significant scarring.  
Microscopic analysis of muscle obtained through percutaneous biopsy can be credited to the 
French Neurologist Guillaume-Benjamin-Amand Duchenne (1806-1875), lauded for 
describing muscular dystrophy amongst his many other accolades. Fuelled by his 
passionate interest in muscular diseases and electrophysiology, he constructed a needle 
possessing a trocar that made it possible to obtain muscle tissue and was the first clinician to 
perform percutaneous or ‘semi-open’ muscle biopsy in living subjects without anaesthesia 
(12). 
Numerous muscle biopsy needles have since been described (13;14). However, the 
percutaneous needle introduced by Bergstrom in 1962 (15), similar in characteristic to the 
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needle described by Duchenne, gained popularity through widespread use in diagnostic as 
well as research (study of normal muscle in relation to physiological change) purposes in 
both children and adults (3;4;16). Although continuously being refined (17;18), each iteration 
of the needle is true to its origins i.e. possess a sharp trocar, a cutting cannula that needs 
sharpening perhaps every 10 uses and a pushing rod to expel the tissue post biopsy (Figure 
1). Muscle yields obtained from the needle biopsy have been reported to vary from 25-75 mg 
(2) 70 - 140mg (4) and up to 143-293 mg after repeated sampling (19). 
An alternative instrument to the Bergstrom biopsy needle is the Weil-Blakesley conchotome 
(Figure 2) (20-22). This instrument, designed like a forcep was described by Henriksson in 
1979 (21) and consists of a sharp biting tip encompassing a hollow that can vary from 4-6 
mm in width. In similar fashion to the Bergstrom needle, it is inserted through a skin 
incision 5-10mm in length but does not require a sharp trocar to aid muscle penetration. In 
addition, its design allows controlled tissue penetration and offers a degree of 
manoeuvrability (22). These features allow biopsy on a wider range of muscles and permits 
sampling of muscle groups where the pressure required for the needle procedure to 
penetrate muscle may not be advisable because of overlying neurovascular or underlying 
bony structures e.g. at the tibialis anterior (22;23). An additional benefit is that, unlike the 
Bergstrom needle, the conchotome biting tip does not need regular sharpening and has been 
reported to maintain sharpness for up to 4 years (17). Muscle yields from the conchotome 
technique in the earliest report by Henriksson (21) ranged from 26 to 296mg. In our practice, 
muscle weights ranged at a comparable 20-290mg (24). 
3. Micro-biopsy 
The ‘semi-open’ techniques described above requiring an incision may be considered too 
painful and the potential for scarring may be off putting for some. Furthermore, semi-open 
techniques may be impractical to study time course responses to intervention e.g. exercise or 
drug administration. As a consequence, minimally invasive techniques such as micro-biopsy 
have been explored (19;25;26). The device used for skeletal muscle micro-biopsy is a version 
of the popular spring loaded one-handed automated biopsy systems used to perform 
biopsies of the breast, prostate, kidney or liver. The assembly consists of a disposable core 
biopsy needle e.g. 16G Magnum ® (Bard Ltd, UK) and an insertion cannula that will allow 
multiple biopsies to be performed via a single insertion site (Figure 3). The needle 
penetration depth can be pre-set by the operator after which release of a trigger unloads the 
spring and fires the needle into the muscle, excising a small piece of tissue. The validity of 
this method compared with the Bergstrom needle in histomorphometric analyses has been 
tested (19). 
The semi-open muscle biopsy and micro-biopsy techniques are common, simple and easily 
learned procedures that have superseded open muscle biopsy in clinical as well as research 
practice (4;6;17). Any potential risks are reduced if performed correctly and with strict 
attention to asepsis. Muscles that can be subject to biopsy include the deltoid, biceps, triceps, 
tibialis anterior, gastrocnemius, soleus and the sacrospinal muscles (3;22;23;27;28). However, 
the most common site for biopsy both in clinical and research practice is the outermost 
portion of the vastus lateralis. This site, approximately two-thirds down a line from the 
 
Percutaneous Muscle Biopsy: History, Methods and Acceptability 5 
anterior superior iliac spine to the patella is readily accessible and does not contain an 
overlying neurovascular bundle. Furthermore, extensive normative fibre histo-
morphometric data obtained from vastus lateralis biopsy exists in the literature that allows 
the recognition of normal and abnormal and facilitates comparison between studies (2;6). 
4. Vastus lateralis muscle biopsy (Figure 4)  
The biopsy technique using the Weil-Blakesley conchotome and the Bergstrom needle is 
described below. The technique for micro-biopsy is reviewed by Hayot et al (19); apart from 
the fact that a skin incision is not required, the procedure shares the same principle as for 
the conchotome and needle methods and is illustrated in Figure 5. 
Equipment needed for percutaneous muscle biopsy 
1. Weil-Blakesley conchotome with either 4mm or 6mm biting tip (Gebrüder Zepf 
Medizintechnik, Dürbheim, Germany) (Figure 2) or Bergstrom needle with either 4mm or 
6mm cutting trocar (Dixons surgical instruments Ltd, UK) (Figure 1) 
2. 10ml and 20ml syringes 
3. Scalpel size 11 
4. Sterile gauze squares and sterile saline-soaked gauze squares 
5. Sterile drape with adhesive aperture (Steri-Drape ™, 3M Health Care, USA) 
6. Chlorhexidine or iodine based skin disinfectant 
7. 5-10ml 2% Lidocaine without epinephrine 
8. Sterile 10ml Universal Container 
9. Quarter inch steri-strips 
10. Stretchable bandage and elastic tape for compression 
11. Ice 
Optional (dependent on planned analyses) 
1. Liquid nitrogen and suitable cryovials 
2. Isopentane cooled in liquid nitrogen 
3. Cork disc 
4. OTC mount 
5. Fixative e.g. formalin, 3% Glutaralhedyde/4% formaldehyde 
6. Dissecting microscope to orientate tissue sample so that sections with fibres in true 
cross-section can be obtained 
7. Suitable blunt edged forceps for post procedure tissue handling 
In the clinical setting, muscle biopsies are conducted based on patient symptoms and the 
distribution of muscular weakness and generally do not require standardised conditions but 
do require the biopsy site to be free of previous muscle injury, contractures or prior 
instrumentation/therapy e.g. injection sites (1;6). In research or in quantitative studies, 
standard conditions should apply to all procedures. For example, studies may require 
participants to be fasted pre biopsy or the exclusion of diabetic subjects (24). 
There is little guidance on the use of aspirin or other anti-platelet agents pre biopsy. 
Whereas warfarin and related anticoagulants would need to be stopped for at least one to 
two weeks prior to the procedure, aspirin was stopped 4-7 days prior to uneventful muscle  
 
Muscle Biopsy 4 
needle described by Duchenne, gained popularity through widespread use in diagnostic as 
well as research (study of normal muscle in relation to physiological change) purposes in 
both children and adults (3;4;16). Although continuously being refined (17;18), each iteration 
of the needle is true to its origins i.e. possess a sharp trocar, a cutting cannula that needs 
sharpening perhaps every 10 uses and a pushing rod to expel the tissue post biopsy (Figure 
1). Muscle yields obtained from the needle biopsy have been reported to vary from 25-75 mg 
(2) 70 - 140mg (4) and up to 143-293 mg after repeated sampling (19). 
An alternative instrument to the Bergstrom biopsy needle is the Weil-Blakesley conchotome 
(Figure 2) (20-22). This instrument, designed like a forcep was described by Henriksson in 
1979 (21) and consists of a sharp biting tip encompassing a hollow that can vary from 4-6 
mm in width. In similar fashion to the Bergstrom needle, it is inserted through a skin 
incision 5-10mm in length but does not require a sharp trocar to aid muscle penetration. In 
addition, its design allows controlled tissue penetration and offers a degree of 
manoeuvrability (22). These features allow biopsy on a wider range of muscles and permits 
sampling of muscle groups where the pressure required for the needle procedure to 
penetrate muscle may not be advisable because of overlying neurovascular or underlying 
bony structures e.g. at the tibialis anterior (22;23). An additional benefit is that, unlike the 
Bergstrom needle, the conchotome biting tip does not need regular sharpening and has been 
reported to maintain sharpness for up to 4 years (17). Muscle yields from the conchotome 
technique in the earliest report by Henriksson (21) ranged from 26 to 296mg. In our practice, 
muscle weights ranged at a comparable 20-290mg (24). 
3. Micro-biopsy 
The ‘semi-open’ techniques described above requiring an incision may be considered too 
painful and the potential for scarring may be off putting for some. Furthermore, semi-open 
techniques may be impractical to study time course responses to intervention e.g. exercise or 
drug administration. As a consequence, minimally invasive techniques such as micro-biopsy 
have been explored (19;25;26). The device used for skeletal muscle micro-biopsy is a version 
of the popular spring loaded one-handed automated biopsy systems used to perform 
biopsies of the breast, prostate, kidney or liver. The assembly consists of a disposable core 
biopsy needle e.g. 16G Magnum ® (Bard Ltd, UK) and an insertion cannula that will allow 
multiple biopsies to be performed via a single insertion site (Figure 3). The needle 
penetration depth can be pre-set by the operator after which release of a trigger unloads the 
spring and fires the needle into the muscle, excising a small piece of tissue. The validity of 
this method compared with the Bergstrom needle in histomorphometric analyses has been 
tested (19). 
The semi-open muscle biopsy and micro-biopsy techniques are common, simple and easily 
learned procedures that have superseded open muscle biopsy in clinical as well as research 
practice (4;6;17). Any potential risks are reduced if performed correctly and with strict 
attention to asepsis. Muscles that can be subject to biopsy include the deltoid, biceps, triceps, 
tibialis anterior, gastrocnemius, soleus and the sacrospinal muscles (3;22;23;27;28). However, 
the most common site for biopsy both in clinical and research practice is the outermost 
portion of the vastus lateralis. This site, approximately two-thirds down a line from the 
 
Percutaneous Muscle Biopsy: History, Methods and Acceptability 5 
anterior superior iliac spine to the patella is readily accessible and does not contain an 
overlying neurovascular bundle. Furthermore, extensive normative fibre histo-
morphometric data obtained from vastus lateralis biopsy exists in the literature that allows 
the recognition of normal and abnormal and facilitates comparison between studies (2;6). 
4. Vastus lateralis muscle biopsy (Figure 4)  
The biopsy technique using the Weil-Blakesley conchotome and the Bergstrom needle is 
described below. The technique for micro-biopsy is reviewed by Hayot et al (19); apart from 
the fact that a skin incision is not required, the procedure shares the same principle as for 
the conchotome and needle methods and is illustrated in Figure 5. 
Equipment needed for percutaneous muscle biopsy 
1. Weil-Blakesley conchotome with either 4mm or 6mm biting tip (Gebrüder Zepf 
Medizintechnik, Dürbheim, Germany) (Figure 2) or Bergstrom needle with either 4mm or 
6mm cutting trocar (Dixons surgical instruments Ltd, UK) (Figure 1) 
2. 10ml and 20ml syringes 
3. Scalpel size 11 
4. Sterile gauze squares and sterile saline-soaked gauze squares 
5. Sterile drape with adhesive aperture (Steri-Drape ™, 3M Health Care, USA) 
6. Chlorhexidine or iodine based skin disinfectant 
7. 5-10ml 2% Lidocaine without epinephrine 
8. Sterile 10ml Universal Container 
9. Quarter inch steri-strips 
10. Stretchable bandage and elastic tape for compression 
11. Ice 
Optional (dependent on planned analyses) 
1. Liquid nitrogen and suitable cryovials 
2. Isopentane cooled in liquid nitrogen 
3. Cork disc 
4. OTC mount 
5. Fixative e.g. formalin, 3% Glutaralhedyde/4% formaldehyde 
6. Dissecting microscope to orientate tissue sample so that sections with fibres in true 
cross-section can be obtained 
7. Suitable blunt edged forceps for post procedure tissue handling 
In the clinical setting, muscle biopsies are conducted based on patient symptoms and the 
distribution of muscular weakness and generally do not require standardised conditions but 
do require the biopsy site to be free of previous muscle injury, contractures or prior 
instrumentation/therapy e.g. injection sites (1;6). In research or in quantitative studies, 
standard conditions should apply to all procedures. For example, studies may require 
participants to be fasted pre biopsy or the exclusion of diabetic subjects (24). 
There is little guidance on the use of aspirin or other anti-platelet agents pre biopsy. 
Whereas warfarin and related anticoagulants would need to be stopped for at least one to 
two weeks prior to the procedure, aspirin was stopped 4-7 days prior to uneventful muscle  
 
Muscle Biopsy 6 
 
 
Fig. 1. A. Components of the biopsy needle include 1. Trocar, 2. Cutting cannula, 3. Clearing 
probe/rod. B. Assembled for biopsy, with cutting cannula inserted within the trocar. A 20 
ml syringe can be connected to the cutting cannula to increase the yield of tissue by suction. 
C. Cutting window visible. D. Window with cutting cannula fully depressed. 
biopsy in our research study (24). It is likely that the drug free duration would need to be 
longer for ADP receptor blockers e.g. clopidogrel. Obviously, risks of stopping such 
secondary prevention drugs must be considered case-by-case. 
Participants are asked to lay supine, comfortably on a bed with the preferred thigh exposed 
from the groin crease. The operator should be positioned adjacent to the thigh however, a 
position adjacent to the contra-lateral thigh with the operator reaching over can also be 
assumed according to individual preference. The leg should remain straight and relaxed 
 
Percutaneous Muscle Biopsy: History, Methods and Acceptability 7 
 
Fig. 2. The Weil-Blakelsley Cochotome with a 6mm bitting tip (From Patel HP et al [24]) 
 
Fig. 3. Spring loaded micro-biopsy system consisting of trigger housing, biopsy needle and 
the insertion cannula (not shown). (Illustration kindly provided by M Hayot, Service Central de 
Physiologie Clinique, Montpellier, France)  
 
Muscle Biopsy 6 
 
 
Fig. 1. A. Components of the biopsy needle include 1. Trocar, 2. Cutting cannula, 3. Clearing 
probe/rod. B. Assembled for biopsy, with cutting cannula inserted within the trocar. A 20 
ml syringe can be connected to the cutting cannula to increase the yield of tissue by suction. 
C. Cutting window visible. D. Window with cutting cannula fully depressed. 
biopsy in our research study (24). It is likely that the drug free duration would need to be 
longer for ADP receptor blockers e.g. clopidogrel. Obviously, risks of stopping such 
secondary prevention drugs must be considered case-by-case. 
Participants are asked to lay supine, comfortably on a bed with the preferred thigh exposed 
from the groin crease. The operator should be positioned adjacent to the thigh however, a 
position adjacent to the contra-lateral thigh with the operator reaching over can also be 
assumed according to individual preference. The leg should remain straight and relaxed 
 
Percutaneous Muscle Biopsy: History, Methods and Acceptability 7 
 
Fig. 2. The Weil-Blakelsley Cochotome with a 6mm bitting tip (From Patel HP et al [24]) 
 
Fig. 3. Spring loaded micro-biopsy system consisting of trigger housing, biopsy needle and 
the insertion cannula (not shown). (Illustration kindly provided by M Hayot, Service Central de 
Physiologie Clinique, Montpellier, France)  
 
Muscle Biopsy 8 
 
A. The leg is exposed from the groin crease down to the ankle. B The biopsy area, approximately 2/3 
down a line from the anterior superior iliac spine to the patella is marked. C&D The biopsy site over 
the vastus lateralis is shaved of hair, infiltrated with local anaesthetic and cleaned with antiseptic. 
E. The biopsy site is isolated with a sterile drape that has a 10 cm adhesive aperture. F. The skin and 
overlying fascia is then punctured with a size 11 scalpel. The conchotome tip is inserted into the track 
made by the scalpel, opened, closed and rotated through 90 to excise tissue. G&H. The 5-10mm 
wound is closed with steri-strips after which a dry dressing and compression bandage are applied. 
Fig. 4. The muscle biopsy procedure using the Weil-Blakesley conchotome  
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A. Infiltration with local anaesthesia. B. Placement of biopsy needle into the trigger housing. C. Skin 
puncture with the insertion cannula. D. Insertion of the biopsy needle through the insertion cannula 
and trigger release. E. Removal of the of the muscle specimen aided by a sterile scalpel (insertion 
cannula can remain in situ to permit repeated sampling). F. Weighing of the sample. (Reproduced with 
permission of the European Respiratory Society ©) 
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Muscle Biopsy 8 
 
A. The leg is exposed from the groin crease down to the ankle. B The biopsy area, approximately 2/3 
down a line from the anterior superior iliac spine to the patella is marked. C&D The biopsy site over 
the vastus lateralis is shaved of hair, infiltrated with local anaesthetic and cleaned with antiseptic. 
E. The biopsy site is isolated with a sterile drape that has a 10 cm adhesive aperture. F. The skin and 
overlying fascia is then punctured with a size 11 scalpel. The conchotome tip is inserted into the track 
made by the scalpel, opened, closed and rotated through 90 to excise tissue. G&H. The 5-10mm 
wound is closed with steri-strips after which a dry dressing and compression bandage are applied. 
Fig. 4. The muscle biopsy procedure using the Weil-Blakesley conchotome  
 
Percutaneous Muscle Biopsy: History, Methods and Acceptability 9 
 
A. Infiltration with local anaesthesia. B. Placement of biopsy needle into the trigger housing. C. Skin 
puncture with the insertion cannula. D. Insertion of the biopsy needle through the insertion cannula 
and trigger release. E. Removal of the of the muscle specimen aided by a sterile scalpel (insertion 
cannula can remain in situ to permit repeated sampling). F. Weighing of the sample. (Reproduced with 
permission of the European Respiratory Society ©) 
Fig. 5. Micro-biopsy procedure with the Magnum ® biopsy system (Bard Ltd, UK)19  
throughout the procedure but the thigh can be tensed momentarily to accentuate the outline 
of the vastus lateralis to mark the biopsy site. Thereafter the skin surrounding the mark is 
shaved and cleaned with an alcohol swab.  
 
Muscle Biopsy 10
The skin and overlying fascia is then infiltrated with 5mls of 2% lidocaine local anaesthetic. 
The subcutaneous bleb is allowed to dissipate during which time the operator should dawn 
a sterile gown, gloves and create a sterile field on a suitable trolley. After opening the pack 
containing the Conchotome or biopsy needle, the skin should be sterilized with povidone 
iodine (Betadine) or a 2% Chlorhexidine gluconate/isopropyl alcohol solution according to 
local infection control protocols. A sterile drape with an adhesive aperture is then used to 
maintain a sterile field. With a size 11 scalpel, a 5-10mm incision is made on the skin and 
down to the fascia through which the closed biting tip of the conchotome is inserted. The 
conchotome is inserted at right angles to the long axis of the femur, facing away from the 
femur and to a depth averaging 2-5cm. The free hand of the operator can hold the thigh 
surrounding the biopsy site while the tip of the conchotome is opened and closed (scissor 
action) to interpose muscle tissue. The conchotome is then rotated through 90-180 to cut the 
muscle. Sampling takes a few seconds and can be repeated within the single site, where 
necessary, to obtain sufficient muscle tissue given the high probability of sampling adipose 
tissue initially (Figure 4 A-H). The biopsies should be placed on sterile saline-dampened 
gauze and then transferred into a universal container or petri dish and placed on ice for the 
remainder of the procedure. 
Operator and skin preparation prior to using the using the needle biopsy or the micro-
biopsy gun is exactly the same as described for the conchotome (17;29). Constituents of the 
needle include include the trocar/needle, the cutting cannula and the clearing probe/rod 
(Figure 1A 1,2,3 respectively). The instrument should be assembled by inserting the 
cutting cannula into the trocar and checked to ensure alignment and sliding action. The 
width of a size 11 scalpel to make a skin incision and a track down to the fascia should 
suffice. The trocar is inserted through the incision, past the fascia where the operator 
should get a sensation of overcoming resistance; at this point the window of the trocar 
(Figure 1C) should be fully in the muscle. The cutting cannula is withdrawn a few 
centimetres and the needle angled to allow tissue to enter the instrument. Alternatively, 
an assistant can apply suction via a syringe applied to the cutting cannula (Figure 1B) to 
draw muscle into the cutting chamber before fully advancing the cannula to guillotine a 
section of muscle (18;30) (Figure 1D) The free hand of the operator can be used to steady 
the thigh. The yield of muscle can be increased by rotating the instrument by 90 and 
repeating the procedure (18). 
Post procedure, direct pressure should be applied to the wound for 5-10 minutes prior to 
closure with steri-strips (Leukostrip, Smith and Nephew, UK). Sterile absorbent gauze is placed 
on the steri-strips and a clear adhesive film (Bioclusive™, Johnson and Johnson, UK) placed on 
the gauze. A two-layer compression bandage is then tied for up to 6 hours. The subject is 
asked to lay down for up to half an hour post procedure and is observed. The procedure, 
using the conchotome or the Bergstrom needle can take between 15 and 20 minutes; the 
majority of said time spent in preparation. 
4.1 Post muscle biopsy patient/participant advice 
Following the procedure it is common to experience some thigh stiffness that can be 
alleviated by gentle exercise e.g. walking. There are no real restrictions to mobility but in 
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our practice we ask participants to avoid 1. vigorous activity for 72 hours (hill climbing, 
running, heavy lifting) and 2. Immersion in water for 48-72 hours (24). Participants can 
shower if the biopsy site was protected from water for example, wrapping polythene 
plastic/cling film around the thigh. Written instructions for post biopsy care, spare 
dressings and emergency contact details should be given to each participant or patient. To 
ensure full wound healing, that can take up to two weeks, the dressing should be changed 
after 4 days and steri-strips removed at day 7 post procedure. All those having the 
procedure should be warned about transient numbness around the biopsy site that may 
persist for up to two weeks as well as the remote possibility of wound infection that would 
necessitate a medical consult.  
5. Acceptability and adverse events 
When performed correctly and according to protocol, the semi-open and micro-biopsy 
techniques result only in minor discomfort for the subject that is qualitatively described as a 
‘’pushing sensation” or a “deep pressure” (29) with very low pain scores (Table 1) (24). Post 
biopsy, there may be local soreness, stiffness or cramp that do not seem to limit normal 
activity including recreational sports e.g. golf, bowls (18;24) (Table 1). One participant in our 
research study reported running a Marathon two weeks after a conchotome vastus lateralis 
biopsy (24). 
Where authors have reported complications, they have commonly been wound 





VAS pain score (mm) Median (IQR) 
During the procedure 7(1-34) 
1 day post procedure 4(0-16) 
7 days post procedure 1(0-4) 
  
Daily activity resumed N (%) 
After one day 60(65%) 
After 2 days 26(28%) 




Table 1. Pain visual analogue scale (VAS) score and resumption of daily activity in 93 
research participants subject to the conchotome muscle biopsy. Pain scale was marked at 
0mm -‘no pain’ and at 100mm – ‘pain as bad as it can be’. Typically pain scores were low 
during and post procedure. The majority of the participants resumed daily activity one-day 
post procedure (Adapted from Patel HP et al [24]) 
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biopsy (20) or did not follow post biopsy recommendations and put an undue amount of 
strain onto the thigh shortly after the procedure (22). Pain only occurs if the fascia is 
caught in the needle or a nerve is sampled inadvertently and may persist for one to two 
weeks (6). There have been no reports in the literature of serious wound infections or 
disability post procedure.  
Minimally invasive muscle biopsy techniques described above are both feasible and 
acceptable in clinical and research practice with good safety profiles. The choice of 
instrument depends on experience and preference, tissue requirement, location of muscle as 
well as clinical assessment of disease involvement. When performed correctly, all yield 
muscle tissue satisfactory for most histochemical and histological analyses. In addition, the 
semi-open techniques allow detailed morphological, biochemical and molecular biological 
analyses to be conducted on muscle tissue. 
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Approach to the Interpretation of Muscle Biopsy 
C. Sundaram and Megha S. Uppin 
Department of Pathology, Nizam’s Institute of Medical Sciences, Hyderabad 
India 
1. Introduction 
The history of muscle biopsy dates back to 1860 when Duchenne first performed a biopsy on 
a patient with symptoms of myopathy. Introduction of enzyme histochemical methods by 
Victor Dubowitz in 1970 revolutionised the role of muscle biopsy in the diagnosis of various 
primary and secondary muscle diseases.1 Diagnosis of various subtypes of dystrophies was 
further made easy with beginning of immunohistochemical methods in 1980s. Twenty first 
century has brought in a new spectacular progress in utility of muscle biopsy with 
commencement of molecular methods. Significance of muscle biopsy is rising with 
application of new techniques. The treatment of neuromuscular disorders is also 
undergoing a parallel and dramatic change with promising genetic therapeutic approaches. 
Accurate diagnosis of the underlying neuromuscular disease is the need of the day and 
muscle biopsy forms a gold standard in diagnosis of these diseases. 
The indications and techniques of muscle biopsy are discussed in detail in another chapter. 
Close interaction between pathologist and clinician is necessary for optimal utilization of 
muscle biopsy sample to get diagnostic information. The muscle biopsy should be planned 
only after relevant clinical and family history, physical examination findings, laboratory 
tests including electromyography (EMG), creatine phosphokinase (CPK) and relevant 
biochemical or serological tests. 
2. Site of muscle biopsy 
It is necessary to sample a muscle which is clinically involved. This is decided by clinical 
examination, course of progression of disease and sometimes by imaging studies. It is 
imperative to biopsy a muscle which is moderately involved. Biopsy from severely affected 
muscle will only show fat and fibrosis and minimally involved muscle may lack diagnostic 
histological features. Biopsy has to be taken from muscle belly and avoided from tendon 
insertion site as it will show central nuclei, variation in fibre size and endomysial fibrosis 
mimicking myopathy. Muscle site traumatized by EMG needle, sites of recent injections and 
previous surgery should also be avoided. 2 
In most of the proximal myopathies and generalised/systemic diseases; vastus lateralis is 
the standard muscle biopsied by international consensus. The site is suitable for biopsy as it 
is away from major vessels and nerves. 3 The other muscles that are good choices for biopsy 
are biceps and gastrocnemius. Tibialis anterior is sampled when indicated by imaging 
studies. Deltoid muscle biopsy is usually avoided as it is a site for injections and may not be 
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The indications and techniques of muscle biopsy are discussed in detail in another chapter. 
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only after relevant clinical and family history, physical examination findings, laboratory 
tests including electromyography (EMG), creatine phosphokinase (CPK) and relevant 
biochemical or serological tests. 
2. Site of muscle biopsy 
It is necessary to sample a muscle which is clinically involved. This is decided by clinical 
examination, course of progression of disease and sometimes by imaging studies. It is 
imperative to biopsy a muscle which is moderately involved. Biopsy from severely affected 
muscle will only show fat and fibrosis and minimally involved muscle may lack diagnostic 
histological features. Biopsy has to be taken from muscle belly and avoided from tendon 
insertion site as it will show central nuclei, variation in fibre size and endomysial fibrosis 
mimicking myopathy. Muscle site traumatized by EMG needle, sites of recent injections and 
previous surgery should also be avoided. 2 
In most of the proximal myopathies and generalised/systemic diseases; vastus lateralis is 
the standard muscle biopsied by international consensus. The site is suitable for biopsy as it 
is away from major vessels and nerves. 3 The other muscles that are good choices for biopsy 
are biceps and gastrocnemius. Tibialis anterior is sampled when indicated by imaging 
studies. Deltoid muscle biopsy is usually avoided as it is a site for injections and may not be 
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involved in all diseases. It is always better to standardize the biopsy from a particular site in 
the laboratory as the fiber type distribution varies from each site. Biopsies obtained from 
unusual sites during surgery pose problems for orientation, fiber typing etc.  
3. Technique of biopsy 
The biopsy can be a needle biopsy or open biopsy. The needle biopsies are dealt within 
another chapter in detail. Though needle biopsies have largely replaced open biopsies in 
most parts of the world, certain laboratories still favour open biopsy technique due to 
feasibility of the procedure and it is usually free of any surgical complications and most 
importantly because a bigger piece of muscle is available for examination. The sample is 
kept on a saline soaked gauze piece and transported to the laboratory immediately. It 
should not be floating in the saline to avoid artefacts. 
4. Processing of sample 
Orientation of the fibers is of utmost importance since most of the information is provided 
by transverse sections. The biopsy should be oriented under a dissecting microscope and 
sample is divided as follows: 
1. For electron microscopy, 2-3mm fragments are kept in cacodylate buffered 
glutaraldehyde and preserved at 4oC. 
2. For cryosections, biopsy piece is fresh frozen in isopentane cooled in liquid nitrogen  
(-170 oC to -180oC) and then sections are cut in cryostat at -18oC to -20oC. These sections are 
stained with Hematoxylin and Eosin (H&E), Masson trichrome, Modified Gomori’s 
trichrome (MGT). The various enzyme histochemial stains done include myosine 
adenosine triphosphatase (ATPase) preincubated at PH 9.4, 4.6 and 4.3, succinate 
dehydrogenase (SDH) and Nicotinamide adenine dinucleotide-Tetrazolium reductase 
(NADH-TR). Other stains like Per-iodic acid Shiff (PAS), Oil red O, acid phosphatase, 
cytochrome oxidase, acid maltase and myophosphorylase are done as and when indicated. 
3. A part of biopsy is used for routine processing after fixing in buffered formalin 
4. For molecular biology, biochemical and genetic analysis, a small tissue is preserved in -
80oC. 1,3,4 
5. The fresh unfixed muscle is used for  
a. Detection and quantification of proteins by Gel electrophoresis 
b. Quantification of individual proteins to confirm a deficient or altered protein and 
provide a precise quantitative measurement by western blot 
c. Demonstrate gene mutations by Polymerase chain reaction (PCR), fluorescent in 
situ hybridisation (FISH) and others. These techniques are particularly useful in the 
diagnosis of muscular dystrophies. 
The biochemical evaluation of muscle for respiratory enzymes and mitochondria are useful in 
the evaluation of mitochondrial diseases. These are dealt with in greater detail in other chapters. 
5. Normal anatomy 
Normal muscle is composed of a number of fascicles which are bound by epimysium and 
each fascicle in turn is composed of muscle fibers and wrapped by collagen, called 
perimysium.(Figure 1) The arterioles, nerve bundles, venules and muscle spindles are 
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located in the perimysium. In a child, the muscle fibers are rounded and in an adult, the 
fibers are polygonal opposed to each other with very little intervening stroma. Myocytes are 
syncitial and the nuclei are seen subsarcolemmaly. However, 3-4% of internal nuclei are 
normal. Satellite cells are seen closely applied to the periphery of myofibers. The connective 
tissue within the fascicle is called endomysium and contains capillary sized blood vessels. 
 
Fig. 1. (A) Fascicular architecture of the muscle with endomysium, perimysium. (H&EX40) 
(B) The polygonal muscle fibers with subsarcolemmal nuclei (H&EX200)  
The interpretation of muscle biopsy will be dealt with according to the type of stain used. 
The summary of stains and their interpretation is given in Table 1. 
Stain Use
Hematoxylin and Eosin General architecture and histology
Masson Trichrome Collagen, fibrosis
Modified Gomori’s trichrome Red ragged fibers, nemaline rods, nuclei, myelinated fibers 
Per iodic acid Schiff Glycogen
Oil red O Neutral lipid
Acid Phosphatase Lysosomal enzymes, necrotic fibers
Crystal violet Amyloid
ATPase PH 9.4 Type 1 fibers pale
Type 2 fibers dark
ATP ase 4.6 Type 1 fibers dark
Type 2 fibers pale
NADH Sarcoplasmic structural details
SDH Oxidative enzyme activity
Cytochrome C Oxidase Mitochondrial enzyme activity
Table 1. Summary of various stains used in interpretation of muscle biopsy 
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6.1 Hematoxylin and eosin 
This stain helps in evaluation of general architecture of the muscle and variation in the 
morphology of individual fibers. 
H&E is basically used to look at the following changes in muscle: 
1. Variation in fascicular architecture 
2. Variation in fiber size and shape 
3. Necrosis and degeneration of muscle fibers 
4. Nuclear characteristics 
5. Type and distribution of inflammatory infiltrate 
6. Interstitial changes 
The architecture of muscle fascicles is assessed on a scanner and the adipose tissue 
infiltration and fibrosis are noted. The pathological changes if any are noted. Diffuse pattern 
of involvement is seen in dystrophy, focal in neurogenic and patchy in inflammatory 
myopathies. Extent of adipose tissue infiltration and fibrosis depend upon the duration  
of disease and degree of muscle fiber atrophy and contribute to loss of fascicular 
architecture. 
In a normal muscle, there is minimal variation in fiber size which depends on age, gender 
and muscle. The fiber type variation may be atrophy or hypertrophy and it may selectively 
involve type 1 or type 2 fibers. The involvement may be diffuse or focal. 
 
Fig. 2. (A) Large group atrophy H&EX40 (B) Small group atrophy H&EX40 in neurogenic 
lesions  
 
Approach to the Interpretation of Muscle Biopsy 19 
 
Fig. 3. Perifascicular atrophy in dermatomyositis H&EX40  
The atrophic fibers may involve entire fascicle (large group atrophy), small groups of 
muscle fibers (small group atrophy) or as single fibers. Sometimes all the fibers may be 
atrophic. These patterns are seen in neurogenic atrophy. (Figure 2) When the atrophic fibers 
are distributed at the periphery of a fascicle, it is called perifascicular atrophy which is 
characteristically seen in dermatomyositis, especially juvenile type. (Figure 3) Diffusely 
distributed atrophic fibers are seen in dystrophies. Atrophy involving selectively type 1 
fibers is seen in congenital myopathies, myotonic dystrophy and rheumatoid arthritis.  
Fiber hypertrophy is seen in athletes and as compensatory phenomenon in neurogenic 
atrophies also. They are important findings in dystrophy, especially Limb girdle muscular 
dystrophy (LGMD). Hypertrophy beyond a particular size leads to splitting. Fiber splitting 
result in a group of small fibers may be mistaken for small group atrophy. (Figure 4) 
6.2 Fiber shape 
In normal adult muscle, the muscle fibers are polygonal and in an infant the fibers are 
rounded. In infants and children there is very little endomysial connective tissue. The fibers 
become rounded in muscular dystrophies and become angulated and atrophic in denervation. 
6.3 Position and number of nuclei 
In a normal muscle, nuclei are subsarcolemmal. They are small, oval and dark staining. 
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Fig. 4. Split fibers H&EX200  
of internal nuclei suggests a myopathy and transverse section is best to assess the same. 
Dystrophies show about 10-30% internal nuclei and myotonic dystrophy is characterized by 
profuse number of internal nuclei of about 60%. 
Myotubular/centronuclear myopathy shows more than 30% of fibers showing single 
centrally placed nulei. (Figure 5) Chronic neuropathies like Charcot-Marie-Tooth disease 
also shows large number of central nuclei. Not only increase in number, the character of 
nuclei may also vary in various conditions. Vesicular nuclei with prominent nucleoli and 
transparent nucleoplasm are seen in regenerating fibers, in myopathies and in central 
nucleus of myotubular/centronuclear myopathy. Tigroid nuclei with granular and clumped 
chromatin are usually seen in neuropathies and in myotonic dystrophy. Pyknotic nuclei 
which are dark staining and shrunken are seen in groups with clumping of chromatin. 
These are seen in neurogenic atrophies and limb girdle dystrophies. 
6.4 Necrosis, degeneration and regeneration 
A necrotic fiber is pale stained on H&E and infiltrated by phagocytes. This is called 
myophagocytosis. (Figure 6) This is usually seen in myopathies especially dystrophies  
like Duchenne muscular dystrophy (DMD). These fibers are highlighted by acid 
phosphatase and esterase reactions. Sometimes necrotic fibers are seen in inflammatory 
myopathies, paraneoplastic necrotizing myopathies, after rhabdomyolysis and in acute 
neuropathies. 
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Fig. 5. (A) Muscle fibers showing central nuclei (B) The longitudinal section of the muscle 
showing central row of nuclei  
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Fig. 5. (A) Muscle fibers showing central nuclei (B) The longitudinal section of the muscle 
showing central row of nuclei  
 
 
Fig. 6. (A) Myophagocytosis H&EX200 (B) Hyaline fibers H&EX200  
 
Muscle Biopsy 22
A hyalinised fiber is a fiber which has lost its cross striations, has homogenous pale 
cytoplasm. (Figure 6) Usually these fibers are rounded. They are usually seen in 
dystrophies. They are highlighted on MGT and Masson trichrome stains. 
The granular fiber on H&E shows a coarse granular bluish cytoplasm and represents the 
ragged red fibers of mitochondrial myopathy on MGT. 
Splitting of fibers is seen when a hypertrophic fiber crosses a particular size limit. The nuclei 
first migrate along the split and large fiber results in a number of small fibers. Fiber splitting 
is seen normally at tendinous insertion. It is a feature of LGMB and other myopathies and 
some chronic neuropathies like Charcot-Marie-Tooth disease. 
6.5 Interstitial changes 
In a normal muscle, the fibers are opposed to each other with very little connective tissue in 
the endomysium. In muscular dystrophies following myophagocytosis, there is pericellular 
fibrosis. Fibrosis occurs due to a variety of extracellular matrix proteins and fibrosis occurs 
in all types of dystrophies, some form of neurogenic atrophies and central core disease also. 
Adipose tissue infiltrates usually occurs after muscle atrophy. It is more common in DMD 
but occurs in other dystrophies and late stages of neurogenic atrophies and congenital 
myopathies. The degree of fibrosis is well brought out by Masson trichrome stain. (Figure 7) 
 
 
Fig. 7. Pericellular fibrosis highlighted by Masson trichrome. MTX100 
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6.6 Inflammatory cell infiltrates 
Normal muscle is devoid of any inflammatory cells. Cellular infiltrates are seen in 
inflammatory myopathies like dermatomyositis, inclusion body myositis (IBM). (Figure 8) 
Necrotic muscle fibers are invaded by mononuclear cells which are seen in almost all 
dystrophies. Inflammatory cells can occur in toxic, necrotizing and dystrophic muscle 
diseases especially fasioscapulohumeral dystrophy (FSHD), DMD, dysferlinopathy and 





Fig. 8. (A) Inflammation around non necrotic fibers in IBM H&EX40 (B) Perivascular 
inflammation in dermatomyositis. H&EX40  
The infiltrate is composed of B ells, CD4 positive cells and dendritic cells in 
dermatomyositis; CD 8 positive cells, dendritic cells and macrophages in polymyositis and 
IBM which can be demonstrated by immunohistochemistry. 
The modified Gomori’s trichrome (MGT) stain is useful to stain the red ragged fibers; the 
hallmark of mitochondrial myopathy. (Figure 9) Red ragged fibers are also seen in other 
conditions like dystrophies (LGMD), dermatomyositis, older individuals and Zidovudine 
associated myopathy in HIV patients. 5,6  
Tubular aggregates and cytoplasmic bodies are nonspecific and are seen with MGT as red. 
(Figure 10) Tubular aggregates are seen in periodic paralysis, dysferlinopathy, exertional 
myalgia etc. Cytoplasmic bodies are seen in collagen vascular disease, IBM and others. 
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Fig. 9. Red ragged fibers of mitochondrial myopathy MGTX200  
 
Fig. 10. Tubulofilamentous inclusions MGTX400 
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Rod bodies characteristically stain red with MGT.(Figure 11) The rods are delicate and 
accumulate subsarcolemmaly. They stain negative with ATPase, NADH and SDH as they 
lack myosin and mitochondria. Rods are characteristic of nemaline myopathy but also seen 
in central core disease and various other diseases which include neurogenic disorders 
(amyotrophic lateral sclerosis, spinal muscular atrophy, undefined), inflammatory 
myopathies (dermatomyositis, polymyositis, periarteritis nodosa), metabolic myopathy 
(mitochondrial myopathy), muscular dystrophy (LGMD) and some undefined myopathies. 7 
 
Fig. 11. Rod bodies seen in subsarcolemmal and perinuclear position in a case of nemaline 
myopathy. MGTX400 
MGT also stains nuclei and myelinated fibers.  
The per-iodic-acid Schiff (PAS) and Oil red O demonstrate glycogen and neutral lipid 
respectively. (Figure 12) These two stains are useful for metabolic myopathies. Acid 
phosphatase identifies lysosomal enzymes and hence identifies necrotic fibers. Masson 
trichrome is useful to demonstrate fibrosis and fibrinoid necrosis. Congo red and crystal 
violet stains demonstrate amyloid. 
Vacuoles 
Vacuoles are of two types- one type contains some material within and the other appears as 
just empty spaces. The former are called as rimmed vacuoles and on H&E they contain 
basophilic granular material and on MGT they appear as having red granules.(Figure 13) 
They appear in number of conditions like IBM, distal myopathies, oculopharyngeal 
muscular dystrophies, myofibrillar myopathies and others. In glycogen storage disease, 
vacuoles appear on H&E. The vacuoles are seen in acid maltase deficiency of childhood 
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Fig. 12. (A) Vacuolated cytoplasm in glycogen storage disease.H&EX100.Inset: Intracellular 
glycogen content. PASX200 (B) Small vacuoles in the sarcoplasm of muscle fibers in lipid 
storage myopathy. Inset: lipid droplets stained red by Oil Red O. Oil Red OX200 
 
Fig. 13. (A) Rimmed vacuoles showing basophilic rimming. H&EX200 (B) Rimmed vacuoles 
showing red granular rimming. MGTX400 
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The diagnosis can be established by demonstrating absence of acid maltase and 
phoshphorylase respectively. Excess glycogen accumulation in vacuoles and in the fibers 
can be demonstrated by PAS stain in glycogenoses. Similarly, lipid accumulation is 
demonstrated in vacuoles or in the fibers in carnitine deficiency or in disorders of 
mitochondrial beta oxidation. They show cytochrome C oxidase enzyme deficiency.  
7. Enzyme histochemistry 
ATPase: In myosine ATPase preincubated at PH 9.4, type 1 fibers are pale and type 2 fibers 
are dark. At PH 4.6 and 4.3, the reaction is reversed and type 1 fibers are dark and type 2a 
and 2b fibers are light with variable intensity. Owing to these staining characteristics on 
ATPase, this stain is used to demonstrate abnormalities in fiber types and distribution of the 
two types of fibers. (Figure 14) 
 
Fig. 14. ATPase at PH 9.4 showing checkerboard pattern with pale Type 1 fibers and dark 
Type 2 fibers. ATPX100 
In muscles like vastus lateralis, type 1, 2a and 2b are one third each. Type 1 and 2 fibers are 
intermixed in a checkerboard pattern. Type 1 fibers of more than 55% is said to be type 1 
predominance and similarly type 2A and type 2B each of 55% constitute predominance of 
that fiber subtype. Type 2 predominance is called when type 2 fibers are more than 80%. 
Type 1 predominance indicates a myopathy; either dystrophy or congenital myopathy 
whereas type 2 predominance in motor neuron disease. 
Type I predominance is normally seen in gastrocnemius and deltoid and hence caution 
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Fig. 13. (A) Rimmed vacuoles showing basophilic rimming. H&EX200 (B) Rimmed vacuoles 
showing red granular rimming. MGTX400 
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The diagnosis can be established by demonstrating absence of acid maltase and 
phoshphorylase respectively. Excess glycogen accumulation in vacuoles and in the fibers 
can be demonstrated by PAS stain in glycogenoses. Similarly, lipid accumulation is 
demonstrated in vacuoles or in the fibers in carnitine deficiency or in disorders of 
mitochondrial beta oxidation. They show cytochrome C oxidase enzyme deficiency.  
7. Enzyme histochemistry 
ATPase: In myosine ATPase preincubated at PH 9.4, type 1 fibers are pale and type 2 fibers 
are dark. At PH 4.6 and 4.3, the reaction is reversed and type 1 fibers are dark and type 2a 
and 2b fibers are light with variable intensity. Owing to these staining characteristics on 
ATPase, this stain is used to demonstrate abnormalities in fiber types and distribution of the 
two types of fibers. (Figure 14) 
 
Fig. 14. ATPase at PH 9.4 showing checkerboard pattern with pale Type 1 fibers and dark 
Type 2 fibers. ATPX100 
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Type 1 predominance indicates a myopathy; either dystrophy or congenital myopathy 
whereas type 2 predominance in motor neuron disease. 
Type I predominance is normally seen in gastrocnemius and deltoid and hence caution 
should be exercised in interpreting biopsies from these sites. 
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In addition to type predominance, fiber type grouping which is characteristic of neurogenic 
lesions is also best assessed on ATPase stain.  
Atrophy of particular type of fibers is also evaluated by ATPase. Selective type 1 fiber 
atrophy is seen in congenital myopathies and myotonic dystrophy. Selective type 2 atrophy 
is common and is seen in many conditions. These include steroid myopathy, disuse, 
polymyalgia rheumatica, collagen vascular diseases, pyramidal tract disease, mental 
retardation, myasthenia gravis etc. 1,2 Type 2 atrophy usually involves type 2B or both type 
2A and type 2B; however only type 2A atrophy is uncommon. 1  
Fiber specific hypertrophy is very uncommon. 
Subtle changes in fiber size are best made out by plotting histograms. 1 
SDH and NADH 
These enzyme histochemical stains bring about various structural abnormalities of muscle 
fibers and being oxidative enzymes are important in diagnosis of mitochondrial myopathies. 
The abnormal fibers of mitochondrial myopathy are seen as “blue ragged fibers “on SDH 
and NADH and they are the counterpart of red ragged fibers on MGT. (Figure 15) COX is a 
mitochondrial enzyme and its activity is absent in mitochondrial myopathy or 
abnormalities. A combination of COX-SDH brings about more number of abnormal fibers in 
mitochondrial myopathy. 8   
 
Fig. 15. (A) Blue ragged fibers of mitochondrial myopathy. SDHX100 Inset: The same fibers 
on higher magnification. SDHX400 (B) The same muscle showing more abnormal fibers on 
COX-SDHX40 
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NADH-TR highlights the sarcoplasmic reticulum and oxidative enzyme activity, Structural 
abnormalities like cores, targets, whorles, lobulated fibers are best seen on NADH-TR. SDH 
is an oxidative enzyme and mitochondrial abnormalities are highlighted by SDH. Cores and 
lobulated fibers are also seen on SDH.(Figure 16) Acid maltase, myophsprylase are done as 
and when indicated clinically (glycogen storage diseases).The myofibrillar abnormalities 








Fig. 16. Central cores in a case of central core disease. SDHX100 
Central cores are seen as pale areas of staining on oxidative enzyme staining like NADH 
and SDH. The cores are usually single and central but may be eccentric and multiple. They 
are not seen on H&E, ATPase, MGT but seen on phosphorylase. The rim of the core is 
devoid of mitochondria and hence lacks oxidative enzyme activity. Central cores are seen 
usually in type 1 fibers. Central cores are seen in many fibers in central core disease. Central 
cores are not limited to central core disease as they are seen in hypertrophic 
cardiomyopathy associated with missense mutations in the beta myosine heavy chain gene, 
MHY7 9, autosomal dominant myopathy associated with ACTA 1 gene mutations. 10 
Multiple minicores seen on oxidative enzyme reactions both in transverse and longitudinal 
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sections are seen in multiminicore disease (MmD) and it is a histopathologic continuum 
with central core disease. Many cases of MmD are caused by recessive mutations in the 
selenoprotein NI (SENPI) gene 11 and same due to recessive RYR1 mutations. 12,13  
Target fibers are characterised by three distinct zones where central zone is devoid of 
oxidative enzyme activity, middle zone of intense activity and outer zone of intermediate 
activity. They are usually seen in type 1 fibers when the three zones are not clearly 
demarcated, the target fibers resemble central cores and they are called targetoid fibers. 
Target fibers are a feature of chronic neuropathies. 
Moth eaten fibers show irregular disruption of myofibrillar network. These are seen on 
NADH or SDH and may be mistaken for minicores or cores. Moth eaten fibers are seen in 
dystrophies including LGMD, congenital muscular dystrophy and various myopathies 







Fig. 17. (Left) Moth eaten fiber on H&E X400 and (Right) on SDHX200 
Ring fibers and whorled/coiled fibers are due to various patterns of disarray of myofibrils. 
They are seen in various dystrophies. (Figure 18) Ring fibers are seen in myotonic dystrophy 
whereas whored fibers are seen in LGMD and chronic neuropathies. 
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Fig. 18. Whorled fibers in a case of limb girdle muscular dystrophy H&EX200. Inset: The 
same fiber on SDHX400 
Lobulated fibers show intense oxidative enzyme activity at the periphery of the fiber and 
usually involve type 1 fibers. They are nonspecific and are seen in many conditions which 
include LGMD particularly calpainopathy, congenital muscular dystrophy, mitochondrial 
myopathy and others. 
8. Conclusion 
Muscle biopsy is essential for accurate diagnosis and treatment. Optimal utilization of the 
sample with appropriate stains and study of the pathologic features is important for making 
a diagnosis. Accurate interpretation of muscle biopsy guides appropriate 
immunohistochemical and molecular genetic studies. 
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Cell culture is a widely used technique in biomedical research. It permits the analysis of 
cell specific functions which can relate to changes in certain disease states at the single cell 
level. A number of cell culture models have been established. These include immortalised 
cell lines which replicate indefinitely in culture and retain the ability to differentiate and 
primary cell lines which can be isolated directly from the host tissue and grown in 
culture. However, primary cell lines have limited replicative potential and become 
senescent in culture. In the case of muscle cells, cell lines can provide a valuable means of 
investigating physiology in the absence of confounding factors (such as circulating 
hormones, adipokines and other bioactive molecules) which arise when dealing with the 
body as a whole.  
Human primary cell lines provide additional benefits in research, when compared to 
immortalised cell lines, as primary cultures have been shown to retain the metabolic 
characteristics of the tissue donor and thus reflect alterations in metabolism as seen in 
specific disease states such as obesity and type 2 diabetes mellitus (Gaster et al., 2004; 
Steinberg et al., 2006). Of particular interest to the treatment of myopathies is the use of 
human primary myotube cultures which can be isolated from muscle extracts in normal and 
diseased states. We (Chen et al., 2005; McAinch et al., 2006b; McAinch et al., 2007; Steinberg 
et al., 2006) and others (Bell et al., 2010; Mott et al., 2000; Thompson et al., 1996) have shown 
that the resultant myotube cultures retain phenotypic traits of the donor related to defects in 
fatty acid oxidation, impairment of insulin stimulated glucose uptake, leptin and/or 
adiponectin resistance. Thus, there is increased clinical relevance associated with the use of 
primary cell cultures in researching disease pathogenesis, making human primary cell 
cultures an invaluable tool in assessing aberrant cellular metabolism and how this may be 
targeted experimentally to alleviate metabolic dysregulation.  
In this chapter we aim to provide the reader with a detailed explanation of the 
methodological considerations in isolating and culturing of human primary myotubes and 
their subsequent experimental uses.  
 3 
Generation and Use  
of Cultured Human  
Primary Myotubes 
Lauren Cornall, Deanne Hryciw,  




Cell culture is a widely used technique in biomedical research. It permits the analysis of 
cell specific functions which can relate to changes in certain disease states at the single cell 
level. A number of cell culture models have been established. These include immortalised 
cell lines which replicate indefinitely in culture and retain the ability to differentiate and 
primary cell lines which can be isolated directly from the host tissue and grown in 
culture. However, primary cell lines have limited replicative potential and become 
senescent in culture. In the case of muscle cells, cell lines can provide a valuable means of 
investigating physiology in the absence of confounding factors (such as circulating 
hormones, adipokines and other bioactive molecules) which arise when dealing with the 
body as a whole.  
Human primary cell lines provide additional benefits in research, when compared to 
immortalised cell lines, as primary cultures have been shown to retain the metabolic 
characteristics of the tissue donor and thus reflect alterations in metabolism as seen in 
specific disease states such as obesity and type 2 diabetes mellitus (Gaster et al., 2004; 
Steinberg et al., 2006). Of particular interest to the treatment of myopathies is the use of 
human primary myotube cultures which can be isolated from muscle extracts in normal and 
diseased states. We (Chen et al., 2005; McAinch et al., 2006b; McAinch et al., 2007; Steinberg 
et al., 2006) and others (Bell et al., 2010; Mott et al., 2000; Thompson et al., 1996) have shown 
that the resultant myotube cultures retain phenotypic traits of the donor related to defects in 
fatty acid oxidation, impairment of insulin stimulated glucose uptake, leptin and/or 
adiponectin resistance. Thus, there is increased clinical relevance associated with the use of 
primary cell cultures in researching disease pathogenesis, making human primary cell 
cultures an invaluable tool in assessing aberrant cellular metabolism and how this may be 
targeted experimentally to alleviate metabolic dysregulation.  
In this chapter we aim to provide the reader with a detailed explanation of the 
methodological considerations in isolating and culturing of human primary myotubes and 





2. Current applications of human primary myotubes 
2.1 Skeletal muscle cell culture  
The skeletal muscle is a highly metabolically active tissue and has a profound influence over 
systemic metabolic function through the regulation of carbohydrate and fatty acid 
metabolism (Baron et al., 1988; Zurlo et al., 1990). Historically, the study of cellular 
mechanisms regulating skeletal muscle physiology was limited by difficulties in 
maintaining metabolically viable isolated muscle extracts and the ability to manipulate 
specific variables in vivo. The development of cell culture models has provided an 
invaluable tool by which cellular physiology can be studied. Over the last several decades 
cell culture techniques have evolved and the resultant studies have contributed greatly to 
the current understanding of cellular metabolism. A vast number of cell types are cultured 
to investigate pertinent research questions. Typically the cells used in these models will 
either be an immortalised cell line or a primary cell line, each of which has distinct 
advantages. Herein, we provide a brief discussion of the development of both immortalised 
and primary skeletal muscle cell culture models. 
2.1.1 Immortalised cell lines  
Undifferentiated immortalised skeletal muscle cell lines have an indefinite myogenic 
potential, with cells continuing to undergo mitotic divisions when maintained in the 
appropriate culture conditions. Accordingly, these cell lines expand rapidly in culture to 
provide a readily repeatable experimental model and can provide an alternative to isolating 
primary cell lines. A key consideration with the use of immortalised cell lines is the 
retention of physiological functions similar to that of the tissue source (Obinata, 2001). 
Therefore it is important that immortalised cell lines are adequately characterised to 
demonstrate that differentiated cell lines recapitulate the physiology of the original tissue. 
Clonal cell lines were initially derived from transgenic animal models, tumour cells, 
treatment of cells with carcinogens or arose through mutations of specific cells within 
primary cultures (Efrat et al., 1988; Obinata, 2001; Richler & Yaffe, 1970; Todaro & Green, 
1963; Todaro et al., 1963). These cells do not readily respond to the normal apopotic signals 
and continue to replicate and divide beyond the life span of un-mutated cells. Isolation and 
cloning of these myogenic cells enables clonal cell lines to be formed. Despite their benefits 
in experimental molecular and cellular biology, the relative lack of clonal cell lines and the 
difficulty in generating new cell lines has inhibited research capacity. More recent 
techniques utilised to produce immortalised cell lines involve cellular transfection with 
immortalising genes or oncogenes (Condon et al., 2002; Douillard-Guilloux et al., 2009; Jat et 
al., 1991). Such methods utilise transfection of genes including telomerase, SV40 Large T-
antigen, cyclin-dependent kinase 4 and Bmi to induce immortalisation of a number of cell 
types (Condon et al., 2002; Di Donna et al., 2003; Douillard-Guilloux et al., 2009). These 
methods are limited initially by the number of cells stably expressing the transfected DNA 
needed to generate a viable population of the immortalised cell line. Additionally, cellular 
incorporation of the immortalising gene can occur at different sites in theoretically identical 
cells which can lead to variable gene expression and cellular behaviours. The use of clonal 
cell lines is further confounded by the potential for the introduced DNA to alter the cellular 
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phenotype and therefore cellular physiology (Ridley et al., 1988). This issue may also be 
apparent in certain cell lines derived from transgenic animal models and tumour cells which 
reflect the host’s expression of certain genes and proteins (Efrat et al., 1988). This may be 
partially overcome by the generation of conditionally immortalised cell lines in which the 
effect of the immortalising agent is abrogated under certain culture conditions, such as 
changes in serum concentrations or temperature (Macpherson et al., 2004; Obinata, 2001).  
Immortalised cell lines that are commonly used for investigating skeletal muscle physiology 
are L6 and C2C12 skeletal muscle myotubes which are derived from rat and mouse origin, 
respectively (Blau et al., 1985; Yaffe, 1968; Yaffe & Saxel, 1977). These cell lines can be 
terminally differentiated into skeletal muscle myotubes by altering the culture environment 
to low serum conditions and thus provide a relevant method of investigating muscle 
physiology.  
The L6 cell line was initially described by Yaffe (1968). This cell line was established from 
newborn rat thigh muscle treated with the carcinogen 20(3) methylcholanthrene in the growth 
medium during the first two growth passages (Yaffe, 1968). In initial experiments, the L6 cell 
line was maintained in vitro for more than 18 months without losing the ability to fuse to form 
differentiated myotubes (Yaffe, 1968). In subsequent studies, Richler & Yaffe (1970) observed 
the L6 cell line to develop into multinucleate, cross-striated myotubes which retain contractile 
properties. The clonal mouse C2C12 cell line is a diploid sub-clone generated by Blau et al., 
(1985) as a derivative of the cell line described by Yaffe & Saxel (1977). This cell line was 
developed by Yaffe & Saxel (1977) from thigh muscle of CH3 mice and was shown to retain 
the capacity to proliferate and differentiate in culture.  The C2C12 cell line has subsequently 
been used in muscle physiology studies due to its rapid proliferation and ability to 
differentiate to form contractile myotubes which express myogenic proteins (Blau et al., 1985; 
Yaffe & Saxel, 1977). The initial characterisation of both the L6 and C2C12 cell lines indicating 
pronounced differentiation and retention of contractile properties suggest that these cell lines 
are appropriate models for studying muscle physiology. 
2.1.2 Primary cell lines 
Adult myotubes are not capable of mitotic divisions and therefore primary skeletal muscle 
culture systems rely on the ability to induce activation and subsequent myogenic 
differentiation of quiescent satellite cells from within the muscle fibre (Berggren et al., 2007; 
Blau & Webster, 1981). Unlike immortalised cell lines, once isolated, primary skeletal muscle 
cultures are fated for senescence and cease to proliferate after a relatively short period in 
culture. Consistent with this Machida et al., (2004) showed that with passaging the 
myogenic potential (as measured by myogenic markers, proliferation and differentiation 
potential) of rat primary cells to decrease. However primary cells do retain phenotypic traits 
of the donor cells, and are able to be cultured from small muscle samples of approximately 
50 mg to counter this limitation (Berggren et al., 2007; McAinch et al., 2007). For example, 
studies investigating the phenotype of human primary skeletal muscle myotubes have 
shown the retention of aberrant glucose metabolism in primary myotubes cultured from 
insulin resistant Pima Indians (Thompson et al., 1996). Further studies have demonstrated 
that phenotypic traits of impaired insulin signalling (Bell et al., 2010), fatty acid uptake and 
oxidation (Bell et al., 2010; Mott et al., 2000), action of the anti -obesogenic and -diabetic 
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phenotype and therefore cellular physiology (Ridley et al., 1988). This issue may also be 
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cultures are fated for senescence and cease to proliferate after a relatively short period in 
culture. Consistent with this Machida et al., (2004) showed that with passaging the 
myogenic potential (as measured by myogenic markers, proliferation and differentiation 
potential) of rat primary cells to decrease. However primary cells do retain phenotypic traits 
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substrate metabolism within skeletal muscle (McAinch & Cameron-Smith, 2009; McAinch et 
al., 2006b; McAinch et al., 2007) are also retained. Thus, cultured primary myotubes enable 
the study of muscle cell structure and function in any number of physiological and 
pathophysiological states. Moreover, cultured myotubes enable the investigation of many 
metabolic abnormalities that exist in vivo, while eliminating confounding environmental 
influences on the muscle (such as circulating hormones, adipokines and other bioactive 
factors). Myogenic satellite cells can be isolated from a number of tissues including skeletal 
muscle (Blau & Webster, 1981; Chen et al., 2005; Gaster et al., 2001a; McAinch & Cameron-
Smith, 2009). When cultured in specific conditions, quiescent satellite cells isolated from 
donor skeletal muscle can be stimulated to re-enter the cell cycle and proliferate before 
being terminally differentiated to recapitulate the phenotype of skeletal muscle from the 
donor.  
As such primary skeletal muscle myotubes have multiple research applications including 
but not limited to; 1) the study of the effects of myopathies and systemic metabolic diseases 
on skeletal muscle function, 2) tissue regeneration and renewal for tissue engineering 
purposes, 3) gene therapy and 4) drug screening (Berggren et al., 2007; Chen et al., 2005; 
Kessler et al., 1996; Loro et al., 2010; McAinch & Cameron-Smith, 2009; McAinch et al., 
2006a; McAinch et al., 2006b; McAinch et al., 2007; Stern-Straeter et al., 2008).  
The following sections outline the process of culturing human primary myotubes from their 
isolation from muscle biopsies to their growth and maintenance in culture and finally a brief 
look at their current and future applications. At this point we are compelled to mention that 
methodological variations arise at almost every stage of primary myotube culture, especially 
in regards to medium composition and the differentiation protocol. Whilst we endeavour to 
consider the differences in protocols and the implications of these, we primarily report the 
established methods of our laboratory. Therefore some optimisation may be necessary on 
behalf of the end user where experimental outcomes differ significantly.  
3. The muscle biopsy 
A number of techniques can be used to obtain a skeletal muscle biopsy including needle 
biopsy and surgical excision (Dietrichson et al., 1987; Tarnopolsky et al., 2011). Successful 
isolation of myogenic satellite cells can be undertaken from small samples of muscle 
biopsies ranging in size from 50-100 mg (wet weight) (McAinch et al., 2007). This suggests 
that the typical muscle yield from suction-enhanced needle biopsies is sufficient to culture 
viable primary myotubes (Melendez et al., 2007; Tarnopolsky et al., 2011). The use of needle 
biopsy has additional benefits in the relative ease of obtaining muscle biopsies, enabling 
sampling from a number of accessible skeletal muscles with only the use of local anaesthetic 
(Dietrichson et al., 1987). The suction-enhanced method described by Tarnopolsky et al., 
(2011) is described briefly as follows.  
The area from which the muscle biopsy is to be obtained is sterilised and the skin and 
subcutaneous tissue is numbed with a local anaesthetic. A small stab incision (4-5 mm) is 
made in the skin at the biopsy site. With the aperture closed, the biopsy needle is advanced 
through this incision to penetrate at least 1 cm beyond the fascia. This motion will be 
associated with the sensation of deep pressure within the muscle. Once the needle is in 
position within the muscle, the aperture is opened, and if using a suction enhanced 
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technique, suction is applied using a sterile 60 ml syringe (approximately 20 ml per sample). 
It is important to note that the equipment used by these authors is modified to 
accommodate the suction procedure. However, the biopsy size is significantly increased by 
using suction compared to no suction (approximately 125 mg compared to 35 mg, 
respectively. However significant variation in muscle biopsy size exists). The needle is then 
closed to isolate the muscle biopsy. The needle can then be rotated to obtain another muscle 
sample as above. The authors describe taking up to 3 samples in quick succession in the one 
biopsy to obtain adequate muscle sample and is associated with minimum discomfort. The 
needle is removed using a twisting motion during withdrawal. Pressure is applied to the 
skin incision and it is closed with a single suture or a tape closure (although a suture may be 
associated with a lesser degree of scarring) and then pressure is reapplied for 10-15 minutes 
often with concomitant icing. It is then important the area be kept clean by the subject in the 
period following the procedure. If closed with a suture, the suture is removed 6 days after 
the biopsy procedure. 
Alternately, skeletal muscle samples can be obtained by open biopsies during surgical 
procedures. This has the benefits of enabling visualisation of the muscle extract prior to 
excision and allows for an increase in extract size and/or more controlled sample size in 
comparison to needle biopsy techniques (Derry et al., 2009; Edwards et al., 1983). In these 
instances patients are usually under general anaesthetic and a muscle sample is taken from a 
pre-existing surgical incision, removing the need for an additional surgical incision and 
superficial trauma. Despite this, it is typically accepted that the needle biopsy procedure 
presents a more efficient means of obtaining a muscle biopsy (Derry et al., 2009; Edwards et 
al., 1983).  
In our hands, skeletal muscle extracts are obtained from patients undergoing routine 
bariatric surgery for obesity or obesity and type 2 diabetes mellitus by the attending 
surgeon. In brief, patients undergo a 12-18 hour fast prior to surgery. They are anaesthetised 
via short acting propofol and maintained via a volatile anaesthetic mixture of fentanyl and 
rocuronium. Skeletal muscle extracts are obtained via surgical excision from the rectus 
abdominis muscle by the attending surgeon (McAinch et al., 2007). Skeletal muscle samples 
extracted from donors to be used for cell culture are trimmed of any visible fat or connective 
tissue and approximately 50 mg of the muscle biopsy is suspended in serum-free alpha 
minimum essential media (Gibco, distributed by Invitrogen, Carlsbad, CA). These samples 
are immediately placed on ice for transportation and undergo no further processing prior to 
satellite cell isolation. Muscle samples stored in cell culture medium can be maintained at 4 
°C for up to 24 hours prior to isolation of the satellite cell population with minimal adverse 
effects on cellular yield and viability (Blau & Webster, 1981).  
4. Tissue culture methods 
4.1 Isolation of myogenic satellite cells 
The myogenic satellite cell population of skeletal muscle fibres was first characterised by 
Mauro in 1961. This study correctly identified and proposed satellite cells to be important in 
muscle regeneration and growth (Mauro, 1961). Degenerative myopathies or muscle injury 
stimulates quiescent satellite cells to re-enter the cell cycle (Charge & Rudnicki, 2004). Active 
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growth of satellite cells is seen to be favourable in the treatment of myopathies and in tissue 
engineering processes.  
Here we describe the process of isolation of these myogenic satellite cells from skeletal 
muscle extracts which is modified from the methods of Blau & Webster (1981). These 
methods have been adapted by our laboratory in accordance with optimisation by Gaster et 
al., (2001a). All processing of skeletal muscle extracts for cell culture should be carried out in 
a sterile isolated environment, free of biological contaminants. Accordingly, biological safety 
cabinets should be sterilised under UV light for 20 minutes and cleaned with 70% ethanol 
prior to use to minimise the risk of contaminating the sample with extraneous cell types. All 
equipment used must be sterilised. 
Satellite cells are isolated from skeletal muscle extracts of 50-100 mg through enzymatic 
dissociated in 0.05% trypsin-EDTA (Gibco, distributed by Invitrogen, Carlsbad, CA) via a 
series of incubations. Skeletal muscle extracts are washed twice in approximately 5 ml of alpha 
minimum essential medium and then washed 3 times in approximately 5 ml of ice-cold 1x 
Dulbecco’s phosphate buffered saline (Gibco, distributed by Invitrogen, Carlsbad, CA). Any 
remaining connective tissue is removed at this stage. Subsequently, the skeletal muscle extract 
is manually homogenised in 3 ml of 0.05% trypsin-EDTA in a tissue culture dish using a sterile 
scalpel. The desired size for muscle fragments is less than 1 mm3 (Blau & Webster, 1981). The 
resultant homogenate is then combined with an additional 12 ml of 0.05% trypsin-EDTA in a 
sterile vial, sealed and agitated on an orbital mixer for 20 minutes. Thereafter, the supernatant 
is aspirated and combined with 5 ml of foetal bovine serum in a 50 ml falcon tube before being 
placed on ice. Care must be taken at this step to ensure the finely homogenised muscle extract 
is not aspirated with the supernatant. An additional 15 ml of 0.05% trypsin-EDTA is added to 
the extract and again agitated as specified above for 20 minutes. The supernatant is combined 
with the initial yield in the 5 ml of foetal bovine serum. Three repetitions of this process are 
necessary to fully dissociate the muscle fibres. The supernatant (trypsin and foetal bovine 
serum mixture) is next filtered through a BD Falcon™ 100-µm nylon cell strainer (BD 
Biosciences, Bedford, MA). To isolate the cellular fraction of the supernatant, it is transferred to 
a sterile 50 ml falcon tube and is centrifuged for 7 minutes at 0.5 x g. The resulting pellet of 
cells will localise at the bottom of the tube and appear reddish-brown in colour. The cellular 
fraction is gently resuspended in 5 ml of growth medium (alpha minimum essential medium 
supplemented with 10% foetal bovine serum (v/v), 0.5% penicillin streptomycin (v/v) (Gibco, 
distributed by Invitrogen, Carlsbad, CA) and 0.5% amphotericin B (v/v) (Sigma-Aldrich, St 
Louis, MO)) via repeated pipette mixing.  
Following the above protocol should yield approximately 5 x 103 viable, proliferating 
satellite cells from a 0.1 cm3 muscle sample (Blau & Webster, 1981). 
4.2 Myoblast culture and maintenance  
As the cellular population isolated does not consist solely of myogenic satellite cells, the cell 
suspension is initially cultured on an uncoated 25 cm2 tissue culture flask (Greiner Bio-One, 
Monroe, NC) for 20 minutes in a controlled humidified environment of 37 °C and 5% carbon 
dioxide. This increases the satellite cell content of the cultured sample and minimises 
contamination by fibroblasts which preferentially adhere to the surface of the tissue culture 
vessel. Gaster et al., (2001a) provide evidence of increased sample purity after pre-plating 
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showing a time dependent increase in satellite cell fraction. However, increased duration of 
pre-plating is associated with a greater total loss of satellite cells and therefore we choose a 
duration of 20 minutes. After the 20 minute incubation period, gently aspirate the cell 
suspension taking care not to disturb the base of the flask to which the majority of 
fibroblasts will have attached. This flask is then discarded. The aspirated cell suspension is 
then seeded onto a 25 cm2 flask coated with an extracellular matrix (Geltrex™ Reduced 
Growth Factor Basement Membrane Matrix; Invitrogen, Carlsbad, CA; allow extracellular 
matrix coating to dry in a sterile environment before seeding cells) to simulate the basement 
membrane under endogenous conditions. Extracellular matrices containing laminin and 
collagen IV, such as Geltrex™, have been shown to promote preferential satellite cells 
adhesion over fibroblast adhesion to enhance the satellite cell fractional content (Kuhl et al., 
1986). Cells are then incubated in a cell culture CO2 incubator in the conditions described 
above. Viable cells will adhere to the coated base of the tissue culture flask over the next 24 
hours. These cells are considered to be at passage 1. The isolation and initial culturing of the 
myogenic satellite cells is depicted in figure 1. 
 
Fig. 1. Schematic representation of the isolation and initial culturing of myogenic satellite 
cells. 1, site of muscle biopsy is chosen; 2, biopsy extracted; 3, muscle biopsy is manually 
minced in trypsin-EDTA; 4, first enzymatic dissociated in trypsin under constant agitation; 
5, supernatant is combined with foetal bovine serum; 6, second enzymatic dissociated in 
trypsin under constant agitation; 7, supernatant is combined with foetal bovine serum; 8, 
third enzymatic dissociated in trypsin under constant agitation; 9, supernatant is combined 
with foetal bovine serum; 10, supernatant/foetal bovine serum solution is filtered; 11, 
cellular fraction is pelleted via centrifugation, 12, cellular pellet is resuspended in growth 
medium; 13, isolated cells are seeded into a 25 cm2 tissue culture flask for pre-plating and 
then transferred to an extracellular matrix coated flask and maintained at 37 °C and 5% 
carbon dioxide. 
24 hours after the initial seeding, the cells are washed twice with 1x phosphate buffered 
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growth medium (5 ml) should be refreshed every other day subsequent to a washing step 
with approximately 5 ml 1x phosphate buffer saline. Continue to maintain the growth of the 
cells until approximately 70% confluence is reached. This may take 2-3 weeks and therefore 
it is essential to monitor cell growth to ensure they do not become over-confluent within this 
period. If myoblastic cells become over-confluent, spontaneous differentiation to mature 
myotubes will occur and the mitogenic properties of the cells will be lost. At 70% 
confluency, dissociate the cells from the flask through the addition of 1.5 ml of 0.05% 
trypsin-EDTA and subsequent incubation at 37 °C, 5% CO2 for 3 minutes. At this point cells 
will appear suspended in the media and therefore successful dissociation can be confirmed 
via microscopic examination. Next, inactivate the trypsin with 3 ml of growth medium, 
gently ejected over the base of the flask to remove any remaining adherent cells. Isolate the 
cellular fraction through centrifugation (5 minutes at 0.4 x g) and resuspend the cell pellet in 
50 ml growth medium. Gently mix to ensure homogenous cell distribution and then seed 
onto five extracellular matrix coated 75 cm2 cell culture flasks. These cells are designated to 
be at passage 2. Cells are again grown to approximately 70% confluent following the same 
procedure as describe for cells at passage 1, before dissociation and isolation via 
centrifugation. At this point we usually cryopreserve four of the 75 cm2 flasks and maintain 
one for continued growth to passage 3. Cryopreservation enables establishment of a number 
of stored cell vials for future experimental use to assist in the investigation of your chosen 
research field. The process of cryopreservation is given in section 4.2.1. The remaining flask 
is passaged once more as above and seeded onto ten extracellular matrix coated 75 cm2 
flasks (split ratio 1:10). At 70% confluence cells are trypsinised and isolated via 
centrifugation (5 minutes at 0.4 x g) and can at this point be cryopreserved.  
It is common throughout this process for cell lines isolated from different individuals to 
exhibit a distinct growth pattern which may be reflected in considerably longer or shorter 
times taken to reach confluence. Moreover, myoblasts may initially exhibit slow growth 
patterns, however once maintained in culture for a number of days, growth rates may 
increase rapidly. Therefore, regularly observing the confluence of the myoblasts is critical to 
ensure that passaging takes place at the appropriate confluence. Similarly to the dissociable 
growth patterns of myotubes derived from different individuals, myotubes may also differ 
in appearance depending on the donor. This can complicate the determination of confluence 
and therefore each cell line needs to be judged on an individual basis relative to area for 
growth.  
4.2.1 Cryopreservation of myoblastic cells 
Cryopreservation of cell stocks is an important practice in any laboratory as it helps to 
protect against loss of cell lines through bacterial or fungal contamination. Furthermore, as 
primary cell lines can be passaged finitely before becoming senescent, cryopreservation of 
cell lines ensures that cell stocks are maintained. It is important that viable cells are chosen 
for cryopreservation and that the cells are not depleted of myogenic properties due to 
becoming over-confluent at an earlier passage.  
The cryopreservation method used in our laboratory for human primary myoblasts are 
described herein. Using this method we have established stocks of a large number of viable 
cell lines derived from muscle extracts. One 75 cm2 flask at 70% confluent provides sufficient 
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cells for distribution to two cryotubes. Thus, the four flasks from passage 2 can be frozen-
down in eight cryotubes whilst the ten flasks from cells at passage 3 enable twenty 
cryotubes to be frozen. This facilitates the rapid expansion of stores of subcultures. In order 
to ensure consistency between studies, we cryopreserve all cells prior to experimental use. 
Cells are cryopreserved in a solution containing 25% growth medium (v/v), 25% foetal 
bovine serum (v/v) and 50% filter sterilised freezing medium. Freezing medium can be 
made through the addition of 10% dimethyl sulfoxide (v/v; Sigma-Aldrich, St Louis MO) to 
standard growth medium (as defined in section 4.1). Dimethyl sulfoxide  is a freezing agent 
which acts to reduce the freezing point of the medium to facilitate gradual cryopreservation 
and  prevents ice crystals forming during freezing and lysing the cells. Dimethyl sulfoxide is 
photosensitive and therefore it is important to protect the freezing medium from light at all 
stages. Freezing medium is then filter sterilised prior to use though a 0.2-µm nylon cell filter. 
Dissociated cells and isolate the cellular fraction via centrifugation as outlined in section 4.2 
and then resuspend the pellet in growth medium (25% of total volume). Add to this the 
foetal bovine serum (25% of total volume). Add the pre-made freezing medium to the cell 
solution (50% of total volume) and gently mix. Aliquot 1 ml of this solution into each 
labelled cryotube. The specific volumes to be used depends on the number of flasks to be 
cryopreserved, however as a guide for two 75 cm2 flask use 1 ml of growth medium, 1 ml of 
foetal bovine serum and 2 ml of freezing medium. To minimise cell death, cells are 
incrementally frozen at -20 °C for 30 minutes and then enclosed in a foam box for freezing at 
-80 °C overnight, before finally being stored in liquid nitrogen until required. Alternatively 
use a cryopreservation freezing container such as “Mr. Frosty” (Nalgene® Labware as part 
of Thermo Fisher Scientific, New York) which results in a controlled decrease in 
temperature of 1 °C per minute. Gradually decreasing the temperature during the freezing 
process aids in preserving cell viability and hence is critical to successful cryopreservation of 
a viable myoblastic cell population. However, it is also important to note that dimethyl 
sulfoxide is cytotoxic and therefore once cells are combined with the freezing medium it is 
important to progress to the freezing stage as rapidly as possible.  
Conversely, the thawing procedure must take place as rapidly as possible again due to the 
toxic nature of dimethyl sulfoxide. We recommend immersing the bottom two thirds of the 
cryotube in a waterbath heated to 37 °C. Take care not to let the water reach the level of the 
lid as this will increase the risk of contamination of the subculture. When partially thawed 
the sample should be removed from the waterbath and rapidly combined with 
approximately 1–2 ml of growth medium to dilute the dimethyl sulfoxide and gently pipette 
mixed to facilitate thawing. Once fully thawed, combine the cell solution with 9 ml of 
growth medium and centrifuge at 0.4 x g for 5 minutes to pellet the cellular fraction. Pour 
off the growth medium to remove the dimethyl sulfoxide and gently resuspend the pellet in 
growth medium. Myoblasts can then be seeded onto 75 cm2 or 175 cm2 tissue culture flasks, 
depending on the volume of cells required for experimentation. As a rough guide one 75 
cm2 tissue culture flask at 80% confluence provides adequate cells for ten 6-well tissue 
culture plates or ten 100 mm tissue culture dishes. We recommend that experimentation be 
conducted at passage 4 or 5 to avoid senescence. For our purposes cells cryopreserved at 
passage 3 will be at passage 4 when thawed and subcultured. Thus at 80% confluence these 
cells must be seeded onto the appropriate vessel for differentiation and experimentation at 
passage 5. Therefore, when thawing cells it is important to be aware of the volume of cells 
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4.3 Myotube formation 
The process of myoblast fusion is critical to the development of mature multinucleate 
skeletal muscle myotubes. During the process of myoblast differentiation, the myogenic 
cells exit the cell cycle and mitotic activity ceases (Linkhart et al., 1981; Yaffe, 1968). 
Myogenic commitment is under the synergistic regulation of a vast number of myogenic 
promoters (including MyoD, myogenin, Myf5, myogenic regulatory factor 4, myocyte 
specific enhancement factor 2) and inhibitors (including ID, Msx1, Twist and BMP-4) 
(reviewed by Brand-Saberi & Christ, 1999; Charge & Rudnicki, 2004). Table 1 further 
highlights the expression patterns of myogenic markers associated with different stages of 
myogenic development.  
Extracellular factors also mediate myotube differentiation. Such factors include the cell-cell 
interactions and proximity and cellular interactions with the extracellular matrix. 
Concordant with this, studies by Osses & Brandan (2002) and Langen et al. (2003) show that 
the extracellular matrix enhances myogenic differentiation of clonal C2C12 myoblasts. In 
vitro, protocols used to induce myoblast fusion vary greatly between studies. This has the 
potential to confound the comparison of results between studies. Predominately, 
differentiation protocols vary in the duration and the composition of media used to induce 
myogenic differentiation. 
 





































Adapted from review by Deasy et al., (2001) 
MRF; Myogenic regulatory factor. 
Table 1. Expression of myogenic markers at different stages of myotube formation.  
Myoblast fusion and subsequent myotube formation has been reported to occur over a 
period of 4-8 days (Gaster et al., 2001b). In our hands, a differentiation protocol of 4 days is 
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sufficient to induce myoblasts elongation and fusion to produce multinucleate myotubes. 
The results of Gaster et al., (2001b) substantiate this, showing that on the day after culture 
conditions were changed to induce differentiation, myoblast fusion to form myotubes had 
begun and there was an increase in creatine kinase activity and fast myosin heavy chain 
content up until day 4 when these markers began to decline. This study also reported the 
presence of developing myofibrils and cross-striations at day 8 of differentiation (Gaster et 
al., 2001b), however no data is reported evaluating these parameters before this time. 
Therefore, it is hard to compare the presence of the developing contractile apparatus with 
functional measures such as creatine kinase activity and fast myosin heavy chain content 
which were seen to decline from day 4 onwards. Contrary to this Stern-Straeter et al., (2008) 
observed increased expression of myogenic genes from day 4 of differentiation but peaked 
at day 16. Creatine kinase activity in this study was also seen to peak at day 16 (Stern-
Straeter et al., 2008). These results suggest a longer differentiation period may facilitate 
further maturation of the myotube cultures and therefore provide a more physiological 
representation of skeletal muscle. However, longer durations of differentiation can lead to 
myotube detachment and subsequent cellular death. Moreover, it has been shown in rats 
that the source of skeletal muscle biopsy (that is, soleus compared to extensor digitorum 
longus) affected the rate at which the isolated cells differentiated (Lagord et al., 1998). This 
suggests that the source of muscle will alter the myogenic properties of the derived human 
primary myotubes.  
Aside from variations in the duration of culturing, myoblast fusion can be induced under a 
number of conditions such as a reduction in sera concentration and substitution of foetal 
bovine serum with horse serum, which contains less growth factors (Gaster et al., 2001a; 
Gaster et al., 2001b; Linkhart et al., 1981; McAinch et al., 2007). Further, addition of growth 
factors (vitronectin, B27 supplement, basic fibroblast growth factor, cardiotropin-1, brain-
derived neitrophic factor, glial derived neurotrophic factor and neutrophin 3 and 4)  (Das et 
al., 2009) and provision of soluble basement membrane in the absence of additional growth 
factors and serum (Langen et al., 2003) can also be used to promote differentiation.  
In view of these variations, some contention exists as to the optimal protocol for myoblast 
differentiation. Accordingly, the differentiation process may need to be optimised by the 
end user for their specific needs. Differentiation can be confirmed via a number of different 
measures including analysis of sarcomere formation, creatine kinase activity, myosin heavy 
chain and alpha actin content and expression of myogenic markers MYoD (up-regulated in 
earlier stages of differentiation), myogenin, desmin, and myogenic regulatory factor 4 (Blau 
& Webster, 1981; Stern-Straeter et al., 2008; Stern-Straeter et al., 2007). Such analyses enable 
individual optimisation of the differentiation process to suit the demands of specific studies.  
For our purposes the optimised differentiation protocol is as follows. At approximately 70-
80% confluent, cells which have previously been seeded onto extracellular matrix coated 
tissue culture vessels are washed in 1x phosphate buffered saline. A simple substitution of 
10% foetal bovine serum for 2% horse serum is made in the replacement medium. All other 
components remain the same as for the growth medium (that is, differentiation media 
contains 2% horse serum (v/v), 0.5% penicillin streptomycin (v/v) and 0.5% amphotericin B 
(v/v)). Cells are washed and differentiation media is changed every other day until day 4 is 
reached. When visualised microscopically cells will appear elongated and fusion will be 
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At the conclusion of the optimised differentiation protocol, myotubes are ready for 
experimental purposes. However, the specific protocol used in the final stages of myotube 
culturing is dependent on the end use of the myotubes. That is, the way the myotubes are 
subcultured and subsequently lysed will depend on the experiment to be conducted. Here 
we will briefly examine some of the key considerations in designing experiments for 
analysis of different metabolic parameters. 
5.1 mRNA analysis of genetic markers 
The analysis of gene expression provides an invaluable source of information regarding 
changes in the expression of key regulatory genes. Gene expression often provides the basis 
for additional studies aimed at assessing the effects of experimental interventions on cellular 
signalling. The growth of human primary myotubes for gene expression purposes has 
several subtle differences to that of other outcomes. Myotubes grown for the analysis of 
messenger RNA abundance are typically grown in 6-well tissue culture plates (Greiner Bio-
One, Monroe, NC) as decreased cell volume is typically needed for successful RNA 
extraction. Given the lower area for growth (approximately 9.6 cm2 per well) confluence is 
often reached in a shorter period and therefore it is important to regularly check confluence 
to ensure differentiation is conducted at 70-80% confluence. Being over-confluent will risk 
the cells detaching during the experimental period. Subsequent to experimentation, the next 
key consideration is the process by which the cells are to be lysed. The experimental 
treatments should be ceased by rapidly washing each well 3 times in approximately 2 ml of 
ice-cold 1x phosphate buffered saline. Myotubes should be placed immediately on ice to 
inhibit RNase activity after the third wash and then rapidly lysed. We find the lysis of cells 
with TRIzol® reagent (Invitrogen, Carlsbad, CA) is highly efficient and provide a high yield 
of quality RNA (as determined spectrophometrically). RNA is a particularly unstable 
molecule and it is important to ensure that the sample is not contaminated with RNases 
during the extraction procedure. TRIzol® reagent acts to solubilise cellular membranes and 
debris whilst inhibiting RNase activity and maintains RNA integrity (Santella, 2006). 
However, due to the corrosive TRIzol® (including the vapour phases) cells should be 
transferred on ice to an RNA designated fumehood prior to the addition of this reagent. 
Using filtered pipette tips add 800 µl of TRIzol® to each well. Gentle agitate the TRIzol® to 
ensure that the entire surface of the well is covered and then repeatedly eject the TRIzol® 
over the base of the well to ensure myotubes are lysed. Transfer cellular lysates to a labelled 
tube. At this point the cellular lysates can be stored at -80 °C until ready to continue with the 
RNA extraction.  
Total cellular RNA is then extracted through the addition of 200 µl of chloroform (Sigma 
Aldrich, St Louis, MO) to the cellular lysates. Mix via short vortex and then allow to sit on 
ice for 5 minutes. Centrifuge the TRIzol®/chloroform for 15 minutes at 16,000 x g to 
separate the phases. Three distinct phases should be visible; a bottom phase containing the 
TRIzol® and cellular debris, a thin opaque interphase and a clear RNA containing 
supernatant. If the separation of phases does not occur, re-vortex the tube and allow to sit on 
ice before centrifuging again as above. The RNA containing supernatant is then aspirated 
into a fresh tube containing an equal volume of isopropanol to supernatant (approximately 
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600 µl; Sigma Aldrich, St Louis, MO) and 10 µl of 5 M sodium chloride (Ajax Finechem, 
Seven Hills, Australia). Care must be taken not to contaminate the RNA sample with the 
interphase and therefore it is recommended that 80% of the supernatant volume be 
aspirated. At this point incubate the samples at –20 °C for a minimum of 2 hours (can be left 
overnight) to precipitate the RNA pellet. Subsequent to the incubation period, centrifuge the 
samples at 16,000 x g for 20 minutes to isolate the pellet. Take care to orient all tubes in the 
same manner to enhance the ease of RNA extraction, as the RNA pellet may be small and 
difficult to visualise. Aspirate the isopropanol/sodium chloride solution taking care not to 
aspirate the RNA pellet. Wash the pellet once with 400 µl of 75% molecular grade ethanol 
(Sigma Aldrich, St Louis, MO) and centrifuge for 8 minutes at  8,000 x g. Again aspirate the 
ethanol taking care not to aspirate the RNA pellet and then allow the pellet to air-dry for 5-8 
minutes on ice. Resuspend the RNA pellet in 5 µl of sterile diethylpyrocarbonate treated 
water (Invitrogen, Carlsbad, CA). The resuspension of the pellet can be enhanced by heating 
the diethylpryocarbonate treated water to 65 °C. Transfer 1 µl of RNA to a fresh tube 
containing 19 µl of diethylpyrocarbonate treated water for spectrophotometric 
determination of RNA content at 260 nm and 280 nm. RNA purity can be determined from 
OD260/OD280 ratio. Samples with an OD260:OD280 ratio of 1.9 – 2.1 can be considered of 
high quality and relatively free of contaminates (Santella, 2006). RNA samples should be 
stored at –80 °C until required.  
RNA can then be reverse transcribed to complementary DNA via the use of such kits as the 
iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). Resultant complementary 
DNA can then analysed for messenger RNA expression of genes of interest by such 
techniques as ‘real-time’ polymerase chain reaction (Heid et al., 1996). Data from ‘real-time’ 
polymerase chain reaction can be analysed by either absolute quantification or relative 
quantification (Livak & Schmittgen, 2001). Absolute quantification determines the input 
copy number of the gene of interest usually against known standards, whilst relative 
quantification enables determination of the expression of the gene of interest relative to a 
reference gene (Livak & Schmittgen, 2001). 
5.2 Protein 
The growth of myotubes for analysis of protein markers requires a greater cell density than 
is required for analysis of gene expression. Accordingly, when growing for analysis of 
protein expression, myotubes should be subcultured and grown to confluence on 100 mm 
tissue culture dishes (Greiner Bio-One, Monroe, NC) coated with extracellular matrix prior 
to differentiation. As for messenger RNA analysis cells destined for protein expression 
studies need to be differentiated at approximately 70-80% confluence to ensure an adequate 
yield. To stop experimental treatments cells should be washed twice with ice-cold 1x 
phosphate buffered saline. To avoid dilution of the protein fraction it is important to remove 
excess phosphate buffered saline with either suction or transfer pipettes. When lysing cells 
for protein expression the addition of a protease inhibitor to the lysis buffer is necessary to 
inhibit proteolytic protein degradation. For muscle cultures we find that an 
immunoprecipitation lysis buffer (10 mM Tris pH 7.5, 5 mM EDTA, 150  mM NaCl, 1% NP-
40) containing complete mini protease inhibitor cocktail tablet per 10 ml working stock 
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aspirated. At this point incubate the samples at –20 °C for a minimum of 2 hours (can be left 
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difficult to visualise. Aspirate the isopropanol/sodium chloride solution taking care not to 
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RNA can then be reverse transcribed to complementary DNA via the use of such kits as the 
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reference gene (Livak & Schmittgen, 2001). 
5.2 Protein 
The growth of myotubes for analysis of protein markers requires a greater cell density than 
is required for analysis of gene expression. Accordingly, when growing for analysis of 
protein expression, myotubes should be subcultured and grown to confluence on 100 mm 
tissue culture dishes (Greiner Bio-One, Monroe, NC) coated with extracellular matrix prior 
to differentiation. As for messenger RNA analysis cells destined for protein expression 
studies need to be differentiated at approximately 70-80% confluence to ensure an adequate 
yield. To stop experimental treatments cells should be washed twice with ice-cold 1x 
phosphate buffered saline. To avoid dilution of the protein fraction it is important to remove 
excess phosphate buffered saline with either suction or transfer pipettes. When lysing cells 
for protein expression the addition of a protease inhibitor to the lysis buffer is necessary to 
inhibit proteolytic protein degradation. For muscle cultures we find that an 
immunoprecipitation lysis buffer (10 mM Tris pH 7.5, 5 mM EDTA, 150  mM NaCl, 1% NP-
40) containing complete mini protease inhibitor cocktail tablet per 10 ml working stock 





Adherent skeletal muscle myotubes are lysed using 100 µl of immunoprecipitation lysis 
buffer and complete mini-protease inhibitor cocktail tablet. Mechanically detached adherent 
cells from the base of the 100 mm cell culture dish with a cell scraper (Greiner Bio-One, 
Monroe, NC). To proceed with protein extraction, centrifuge the cellular lysate at 17,000 x g 
for 4 minutes. Carefully aspirate the supernatant, aliquot and store at -80 °C. Freeze-thaw 
cycles should be avoided. 
Protein abundance can then be quantified against known albumin standards with a working 
range of 20-2000 µg/ml in accordance with the assay microplate procedure using a Pierce 
Bicinchoninic Acid kit (Pierce Biotechnology distributed by Thermo Fisher Scientific, 
Scoresby, Australia) at 562 nm.  We have previously found that the protein content from a 
single 100 mm tissue culture dish is low and in order to have sufficient protein to measure 
multiple markers it may be necessary to have a number of replicates for each experimental 
condition which can be combined to increase the overall protein concentration. If this is the 
case up to four 100 mm dishes can be lysed using 100 µl of lysis buffer transferred from 
plate to plate along with the cellular lysates. This helps to reduce sample dilution with the 
lysis buffer.  
5.3 Glucose and fatty acid uptake  
Aberrant glucose and fatty acid metabolism is observed in human primary myotubes 
isolated from individuals with obesity and type 2 diabetes mellitus compared to control 
(Bell et al., 2010; Mott et al., 2000; Thompson et al., 1996). Therefore, determination of 
glucose and fatty acid uptake in these cells can be a useful tool in screening new 
pharmacological agents aimed at ameliorating perturbed substrate metabolism. The process 
described below outlines the key methodological considerations for growing human 
primary myotubes for glucose and fatty acid uptake assays.  
5.3.1 Glucose uptake 
Prior to differentiation, skeletal muscle myotubes should be grown to approximately 70% 
confluence in 12 well tissue culture plates. At confluence, differentiation should be 
undertaken for 4 days. Previous results indicate that basal glucose uptake decreases upon 
myoblast fusion (Klip et al., 1984; Mitsumoto et al., 1991). In contrast insulin-stimulated 
glucose uptake increases subsequent to myoblast fusion particularly in the serum deprived 
L6 myotubes (Klip et al., 1984; Mitsumoto et al., 1991). Therefore for this particular assay we 
recommend a differentiation period of 4 days however this may need to be optimised 
depending on the specific outcome of the study. The protocol for measuring glucose uptake 
is adapted from that of Ciaraldi et al., (1995). 
At confluence, myotubes are pre-incubated in serum free alpha-minimum essential medium 
for 4 hours and subsequently washed three times in uptake buffer (150 mM NaCl, 5 mM 
KCL, 1.2 mM MgSO4, 2.5 mM NaH2PO4, 1.2 mM CaCl2, 10 mM HEPES, 0.1% bovine serum 
albumin, pH 7.4). Myotubes should then be incubated with the compound of interest in 1 ml 
of uptake buffer for the given time period. Initiate the glucose uptake reaction through the 
addition of radiolabelled glucose (2—[3H]-deoxy-D-glucose) at 1 µCi/ml and 2-deoxy-D-
glucose (Perkin Elmer, Waltham, MA) at 10 µM per well and incubate at 37 °C and 5% CO2 
for 15 minutes. Subsequently, aspirate the reaction buffer and rinse the myotubes four times 
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rapidly with ice cold 1x phosphate buffered saline to stop the reaction. Solubilise the 
myotubes with 500 µl of 0.1 M sodium hydroxide for 30 minutes at room temperature. This 
process can be enhanced by gentle agitation. The cellular lysates should then be divided 
with 400 µl being combined with 4 ml of scintillation fluid in scintillation vials for 
determination of incorporated radiolabelled glucose. The remainder of the lysates should be 
used to determine cellular protein content. Non-specific glucose uptake can be determined 
in the presence of cytochalasin B (10 µM/l) to block glucose transporter mediated glucose 
uptake (Ceddia et al., 2005; Fletcher et al., 2000; Michael et al., 2001). Cytochalasin B has 
been shown to be a potent inhibitor of cellular glucose uptake (Kletzien et al., 1972). Non-
specific glucose uptake is subtracted from the total glucose uptake values and the net 
glucose uptake value is expressed relative to cellular protein content in picomoles of 2-
deoxy-glucose taken up by the myotubes per mg protein per minute.   
5.3.2 Fatty acid uptake 
The process of determining fatty acid uptake is similar to that of glucose uptake and 
accordingly, human primary myotubes should be grown and differentiated in the same 
manner. Differentiated myotubes should then be exposed to the experimental conditions. 
Fatty acid uptake can then be measured in the presence of [1-14C] palmitate (Perkin Elmer, 
Waltham, MA) and non-radiolabelled palmitate (Pimenta et al., 2008). In brief, the palmitate 
uptake is assayed through the addition of 0.2 µCi/ml [1-14C] palmitate and 20 µM non-
labelled palmitate (Fediuc et al., 2008) in serum free alpha-minimum essential medium for 4 
minutes. Palmitate should be conjugated to fatty acid free bovine serum albumin at a molar 
ratio of 1. Cells should be lysed in 500 µl of 0.1 M NaOH for 30 minutes and palmitate 
uptake is determined relative to cellular protein content as above.   
5.4 Fatty acid oxidation 
In addition to determining substrate uptake it is also possible to determine the rate of fatty 
acid oxidation in human primary myotubes. This allows a more thorough assessment of 
cellular bioenergetics as corresponding results of enhanced uptake and oxidation may be 
indicative of improve metabolic function, whilst results of enhanced uptake but impaired 
oxidation may suggest that the intervention has elicited detrimental effects. Palmitate 
oxidation is determined from the production of radioactive 14CO2  from [1-14C] palmitate. 
This outcome can be determined through measurements of radiolabelled CO2 or water with 
many variations existing in technique (Fediuc et al., 2006; Fediuc et al., 2008; Pathmaperuma 
et al., 2010; Petersen et al., 2005; Pimenta et al., 2008; Watt et al., 2006). One such method is 
described herein and has been adapted from previously described work of Petersen et al., 
(2005) in L6 skeletal muscle myotubes. 
Myotubes should be grown in 100 mm tissue culture dishes until approximately 80% 
confluence at which point growth medium should be substituted for differentiation medium 
containing 2% horse serum. On day 4 of differentiation, pre-incubate the myotubes in serum 
free alpha minimum essential medium contain 0.1% bovine serum albumin for 2 hours. 
Following a washing step with 1x phosphate buffered saline, myotubes can be exposed to 
experimental conditions in alpha minimum essential medium containing 0.1% foetal bovine 
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[1-14C] palmitate with the respective experimental conditions. A 2 hour treatment period has 
been shown to be sufficient in determining fatty acid oxidation however the period of 
exposure can be modified to suit the experimental design and therefore should be optimised 
by the end user. Subsequent to experimental exposure 1 ml of the incubation medium is 
added to a 20 ml scintillation vial containing 1 ml of 1 M H2SO4 and a 0.5 ml microcentrifuge 
tube containing 1 M benzethonium hydroxide to trap liberated 14CO2 over a one hour 
period. The microcentrifuge tube containing the trapped 14CO2 is then placed in a 
scintillation vial and counted to determine the rate of fatty acid oxidation. 
6. Future applications 
6.1 Three-dimensional skeletal muscle tissue constructs 
Bioengineering of skeletal muscle constructs employs the use of myogenic progenitor cells 
and specialised scaffolding to form three-dimensional tissue constructs. Given the limited 
regenerative capacity of adult skeletal muscle, bioengineered skeletal muscle provides a 
therapeutically relevant method of reducing morbidity associated with various myopathies. 
Congruent with this, the long term goal of three-dimensional tissue culturing predominately 
centres around the provision of viable tissue transplants for regenerative purposes after 
acute injury or disease for instance the fabrication of three-dimensional cardiac muscle 
constructs. Like adult myotubes, mature cardiac myocytes are terminally differentiated cells 
and thus cannot regenerate subsequent to damage. Therefore the ultimate goal of 
bioengineered heart muscle supports myocardial regeneration after myocardial infarction, 
chronic heart failure or in the repair of congenital heart defects (Eschenhagen et al., 2002). 
This has the potential to reduce morbidity and mortality associated with cardiovascular 
diseases. Surgical tissue transplants are widely used in muscle regeneration after muscle 
injury, however muscle transplantation is associated with significant donor site morbidity, 
and loss of muscle volume and function (Bach et al., 2004). Implantable bioengineered 
skeletal muscle constructs remove the need for large muscle extracts from healthy donor 
tissue and thus pre-engineered tissue constructs provide an appealing treatment method for 
skeletal muscle pathologies. Bian & Bursac (2008) propose distinct advantages associated 
with the use of bioengineered muscle constructs as being the ability to engineer constructs 
with architecture specific for the site of damage, the ability to precondition fabricated 
muscle for the specific mechanical and metabolic demands of the site and the administration 
of specific growth factors and hormones to support growth after implantation. However, 
despite these potential benefits, the field of bioengineered tissues is still in its relative 
infancy, with muscle constructs exhibiting morphological differences to native muscle with 
respect to the level of differentiation and organisation of the cell microstructure, making 
direct comparison with native muscle problematic (Baar, 2005).  
The architectural, electrical and functional integrity of fabricated muscles must be similar to 
that of native muscle in order to compensate for structural and functional deficits within the 
endogenous muscle. Accordingly, the construct needs to be contractile, demonstrate electro-
physiological stability, be flexible yet mechanically robust and have angiogenic potential.     
Currently, bioengineered muscle constructs are small in size with Huang et al., (2005) 
generating myooids of 177 ± 10.5 µm in diameter with the cross-sectional area of individual 
myotubes being only 10 µm. This is similar to results of Powell et al., (2002) who generated 
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human bioartificial muscles with individual myotubes being less than 10 µM in diameter. 
Furthermore, the current methods of generating muscle constructs result in myooids which 
exhibit significant deficits in force production compared to that of native muscle (Dennis et 
al., 2001). The absence of fibroblasts in constructs generated from C2C12 cells also resulted in 
a force deficit manifesting in a 35% reduction in peak twitch force after tetanic stimulation 
(Khodabukus & Baar, 2009). The authors noted that addition of 3T3 fibroblasts to C2C12 
myotubes (ratio 1:5) prior to seeding attenuated this force deficit but lead to a 50% decrease 
in specific force. Taken together these results imply that further work needs to be done 
before bioengineered muscle constructs can be used for functional regeneration of human 
skeletal muscle. Nonetheless, in spite of the functional limitations, much can be gained 
through investigations of muscle formation using three-dimensional models of myotube 
growth (Bach et al., 2004).  
Three-dimensional skeletal muscle tissue constructs provide a useful model for the study of 
muscle structure and function in physiological and pathophysiological states, drug 
screening and gene therapy despite current limitations in their fabrication (Bach et al., 2004; 
Vandenburgh, 2010; Vandenburgh et al., 2008). The use of three-dimensional constructs 
provides a method with enhanced physiological relevance due to the relative absence of 
cellular monolayers within their endogenous micorenvironments. Interestingly, Larkin et 
al., (2006) describe a method of co-culturing pre-formed self-organising primary rat tendon 
constructs with isolated myoblasts in place of artificial tendons, to form a functional 
myotendinous junction in the three-dimensional constructs formed. Functional testing of 
these constructs revealed the myotendinous junction could withstand tensile forces beyond 
the physiological range (Larkin et al., 2006). Rivron et al., (2008) further review recent 
advances in the ability to generate pre-vascularised tissue constructs in vitro which has the 
capacity to readily anastamose to the host vasculature and thus can enhance viability of 
implanted tissue constructs. These advances within the tissue engineering field represent 
promising progress in the development of functional muscles for regenerative purposes. 
However due to the differences between native muscle and bioengineered muscle 
constructs, the challenges which still exist in the formation of de novo skeletal muscle cannot 
be ignored. Specific challenges still exist in supporting growth of sufficient differentiated 
muscle tissue for regenerative purposes, the capacity to supply sufficient oxygen and 
nutrients to the core of the construct, the need for these tissue constructs to remain viable 
and be vascularised and innervated in vivo (Bach et al., 2004; Birla et al., 2005; Davis et al., 
2007; Gawlitta et al., 2007). Overcoming these challenges to achieve maximal therapeutic 
benefits centres largely around the ability to accurately recapitulate the endogenous 
environment for growth in vitro. Strategies to enhance myoblast proliferation and 
differentiation to support these needs are currently in great demand. One such method may 
be the application of mechanical stretch during construct formation. Endogenously, the 
electrical impulses generated by the central nervous system are critical developmental 
stimuli prompting the formation of mature muscle fibres with de-innervated muscle 
showing reduced numbers of secondary myotubes (Ross et al., 1987). In cell culture models 
electrical stimulation has been shown to enhance activation of quiescent satellite cells, 
myoblast alignment, protein synthesis, proliferation and differentiation (Donnelly et al., 
2010; Tatsumi et al., 2001; Vandenburgh & Karlisch, 1989). Sarcomere formation and the 
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stimulation in C2C12 myotubes grown in three-dimensional constructs (Langelaan et al., 
2010; Park et al., 2008). An 8 day mechanical stretch/relaxation protocol in bioengineered 
human muscles also augmented the myofibre diameter and area suggesting adaptation to a 
phenotype more similar to that of native muscle (Powell et al., 2002). In line with enhanced 
myotube diameter, Huang et al., (2005) showed that treatment with the trophic factor 
insulin-like growth factor 1 significantly increased force production of myooids. In further 
research insulin-like growth factor 1 was shown to induce myotube hypertrophy which was 
associated with a concomitant increase in active force production (Vandenburgh et al., 2008).  
This further supports the notion that extracellular paracrine factors are also important in 
enhancing construct formation.  Levenberg et al., (2005) also demonstrated that the co-
culture of myoblasts with embryonic fibroblasts and endothelial cells promoted the 
formation of vessel-like structures within the resultant muscle constructs which has the 
capacity to advance vascularisation in vivo. These findings highlight the significant progress 
being made in relation to the field bioengineering muscle constructs which resemble native 
muscle.  
6.1.1 Growth of bioengineered tissue constructs 
The growth of three-dimensional tissue cultures relies on the manipulation of the in vitro 
environment to support self-organisation of myotubes into bioengineered constructs which 
resemble the basic structure of in vivo skeletal muscle. Parallel alignment of the myotubes 
along a uni-directional axis is important if force is to be generated by the construct. The 
ability of the muscle constructs to generate adequate force to restore muscle function is 
likely dependent on the provision of an extracellular matrix that facilitates interactions of 
myofibres in a manner similar to that of native muscle (Bian & Bursac, 2008). Several forms 
of scaffold can be used to support organisation including non-biodegradable and 
biodegradable scaffolds, of which biodegradable scaffolds are preferable as their controlled 
degradation supports the development of native extracellular matrix and allows for the 
formation of densely packed myotubes in new muscle tissue (Koning et al., 2009; Rossi et al., 
2010). Biodegradable scaffolds which have been employed for myooid growth include 
polygycolic acid, alginate and hyaluronic acid hydrogels (Kamelger et al., 2004), fibrin 
(Huang et al., 2005), collagen (Hinds et al., 2011) and lamina gels (Dennis et al., 2001). 
Biomimetic extracellular scaffolds have been shown to enhance myotube fusion and 
markers of differentiation in two-dimensional cell culture models (Osses & Brandan, 2002). 
These findings can be extrapolated and applied to three-dimensional tissue culture and thus 
highlights the importance of the extracellular matrix used.   
Moreover, the scaffold needs to be biocompatible if the tissue is to be implanted in vivo as 
this prevents the host’s immune system initiating an immune response against the foreign 
substance (Rossi et al., 2010) which otherwise has the potential to increase the muscle 
damage sustained. Indeed, recent advances in both skeletal and cardiac muscle engineering 
have seen bioengineered constructs successfully implanted subcutaneously in rodents (Birla 
et al., 2005; Levenberg et al., 2005). Birla et al., (2005) initially cultured neonatal cardiac 
myocytes on laminin coated plates before the bioengineered cardiac constructs were 
implanted subcutaneously. The authors show the implants become vascularised and cell 
viability is maintained for at least 3 weeks in vivo (Birla et al., 2005). Levenberg et al., (2005) 
report similar findings with the bioengineered muscle continuing to differentiate in vivo and 
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anastamoses of vessels fabricated in vitro with the host’s vasculature, as evidenced by the 
presence of erythrocytes within the lumen of these vessels. Importantly, the explanted 
constructs showed spontaneous contractility and force production was augmented 
compared to in vitro cultured controls (Birla et al., 2005). Moreover, skeletal muscle grafts 
cultured in collagen/Matrigel™ hydrogel have been used in myocardial repair subsequent 
to infarct induced by coronary ligation which was associated with cellular differentiation 
and vascularisation 4 weeks after implantation (Giraud et al., 2008). These findings 
represent significant progression towards the end goal of developing implantable tissue 
constructs and are an important intersect between applications for skeletal and cardiac 
muscle regeneration.   
An additional consideration regarding the appropriateness of various scaffolds culture 
techniques is the provision of sufficient bioactive signals to replicate the endogenous niche 
to regulate satellite cells quiescence and myoblast proliferation and differentiation. 
Reproducing a microenvironment which accurately emulates the endogenous niche of 
muscle cells is complicated by the distinctive combination of cellular, biochemical and 
biophysical systems which define the biochemical and structurally properties of the 
endogenous microenvironment (Cosgrove et al., 2009). Eberli et al., (2009) support the 
importance of adequately replicating the microenvironment showing that the addition of 
fibroblast growth factor, epidermal growth factor, dexamethasone and insulin to collagen 
coated dishes enhances the formation of differentiated human primary myotubes. However, 
this issue is confounded due to the extensiveness of the list of factors which regulate 
myogenesis and myotube formation.  
The use of Matrigel™ (BD Biosciences San Jose, CA), a bioactive extracellular matrix derive 
from the mouse Engelbreth-Holm-Swarm tumour lineage may partially address this issue. 
Matrigel abundantly produces extracellular matrix factors which support cellular growth 
and differentiation (reviewed by Kleinman & Martin (2005)). Given these effects, Matrigel™ 
is an appealing substrate to support the fabrication of three-dimensional tissue constructs. 
Consistent with this, Hinds et al., (2011) found that the use of a hydrogel matrix consisting 
of Matrigel and fibrin enhanced myotube formation and density within the construct which 
was positively correlated with force production. Whilst no single extracellular matrix has 
been identified conclusively as superior, the use of fibrin gels with aprotinin, a plasminogen 
inhibitor and the naturally occurring cross-linking agent, genipin, have been shown to 
enhance force production and time-to-failure of constructs by way of controlled degradation 
of this matrix (Khodabukus & Baar, 2009). Moreover, fibrin gels provide a more flexible 
scaffold medium into which cells migrate and proliferate both on top of and within the 
fibrin gel to increased specific force production (Dennis et al., 2001; Huang et al., 2005). 
Furthermore, controlled fibrinolysis of the fibrin gel and secretion of extracellular matrix 
proteins by the muscle cells allows the muscle construct to develop a phenotype more 
representative of native muscle (Ross & Tranquillo, 2003). When considered in conjunction 
with the findings of Hinds et al., (2011) this suggests enhanced fibrin gels to be an appealing 
substrate for fabrication of bioengineered muscle and accordingly is the method we choose 
to report herein due to these advantages and also the relative inexpensiveness of substrates 
and ease at which myooids can be formed.  
The methods described are based on previous research in skeletal muscle myotubes (Huang 
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extended period for which the constructs can be maintained in culture (Khodabukus & Baar, 
2009). The protocol reported below is based on the optimised procedure.  
Myotubes are cultured on polydimethylsiloxane (SYLGARD 184 Elastomer kit; OBA, 
Dandenong, Australia) coated 35 mm tissue culture dishes or 6-well tissue culture plates. 
Prepare the polydimethylsiloxane according to the manufacturer’s instructions in a ratio of 
10:1 base to curing agent.  In brief, using a syringe aspirate 1.5 ml of the base agent and 
slowly coat the base of each dish, taking care to avoid the formation of air bubbles. Add 150 
µl of the curing agent and gently mix with the pipette tip. Allow the dish to cure for 48 
hours at room temperature. This process can be quickened by incubating in a humidity-free 
incubator at 60 °C. Place two 6 mm long braided silk sutures (Fine Science, North 
Vancouver, Canada) at either end of the dish with an interposing gap of 12 mm between the 
end of each suture. Secure the sutures in place with 0.1 mm-diameter stainless steel 
minutien pins (Fine Sciences, North Vancouver, Canada) as shown in Figure 2. Place 
multiple pins along the length of the suture to ensure that they are firmly fixed in place.  
 
(Cornall et al., Unpublished observation) 
Fig. 2. Arrangement  of sutures in the polydimethylsiloxane coated well of a 6-well tissue 
culture plate. As the sutures are to provide the only point of force to which the myotubes 
align against the suture needs to be firmly affixed with multiple minutien pins along the 
length of the suture.  
At this point it is important to sterilise the dishes to avoid contamination of the myooids 
constructs. This can be done by soaking the dishes in 70% ethanol for 20 minutes. Following 
this, aspirate the ethanol and rinse the dish with 1 ml of 1x phosphate buffered saline. The 
dishes can also be exposed to UV light for 1 hour to assist with sterilisation. 
The next step is the preparation of the fibrin gel. Once all components have been diluted to 
the appropriate concentrations, determine the number of dishes and prepare a master mix of 
growth medium, genipin (Sigma Aldrich, St Louis, MO), thrombin (Sigma Aldrich, St Louis, 
MO) and aprotinin (Sigma Aldrich, St Louis, MO). C2C12 myotubes growth medium is made 
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with a base of Dulbecco’s modified eagle medium supplemented with with 10% foetal 
bovine serum (v/v), 1% penicillin streptomyocin (v/v) and 0.5% amphotericin B. For each 
dish add 463 µl of growth medium containing 10 µl Genipin (stock concentration 10 
mg/ml), 25 µl Thrombin (stock concentration 200 U/ ml) thrombin and 2 µl Aprotinin (stock 
concentration 10 mg/ ml).  Gently agitate the dish until the entire surface is covered, ensure 
no air bubbles form around the sutures and pins. Quickly, add 200 µl of 20 mg/ml 
fibrinogen (Sigma Aldrich, St Louis, MO) to each dish and gently mix.  Allow the gel to 
polymerise for 1 hour. Seed the cells into each of the dishes (100,000 cell per dish) in growth 
medium to a final volume of 2 ml. Allow the cells 24 hours to attach prior to changing the 
growth medium every other day. Myoblasts will migrate through the fibrin gel to proliferate 
both within and on top of the gel. After 2 days the gel should begin to contract and the 
myotube will begin to realign themselves between the points of force between the 2 sutures. 
This process should complete around day 7. The myotubes are then differentiated for 2 days 
in reduced serum differentiation medium (2% horse serum). Continue to maintain the 
forming myooids in growth medium containing 7% foetal bovine serum until construct 
formation is completed.  
 
Fig. 3. Formation of three-dimensional C2C12 tissue constructs at different time points after 
initial seeding of the cells. Note the progressive contraction of the gel and subsequent 
alignment of the construct between the two sutures resulting in the formation of a densely 
packed three-dimensional tissue construct. At day 16 the dimensions of the construct were 
determined as approximately 25 mm length and 1 mm in width and the myooid was 





extended period for which the constructs can be maintained in culture (Khodabukus & Baar, 
2009). The protocol reported below is based on the optimised procedure.  
Myotubes are cultured on polydimethylsiloxane (SYLGARD 184 Elastomer kit; OBA, 
Dandenong, Australia) coated 35 mm tissue culture dishes or 6-well tissue culture plates. 
Prepare the polydimethylsiloxane according to the manufacturer’s instructions in a ratio of 
10:1 base to curing agent.  In brief, using a syringe aspirate 1.5 ml of the base agent and 
slowly coat the base of each dish, taking care to avoid the formation of air bubbles. Add 150 
µl of the curing agent and gently mix with the pipette tip. Allow the dish to cure for 48 
hours at room temperature. This process can be quickened by incubating in a humidity-free 
incubator at 60 °C. Place two 6 mm long braided silk sutures (Fine Science, North 
Vancouver, Canada) at either end of the dish with an interposing gap of 12 mm between the 
end of each suture. Secure the sutures in place with 0.1 mm-diameter stainless steel 
minutien pins (Fine Sciences, North Vancouver, Canada) as shown in Figure 2. Place 
multiple pins along the length of the suture to ensure that they are firmly fixed in place.  
 
(Cornall et al., Unpublished observation) 
Fig. 2. Arrangement  of sutures in the polydimethylsiloxane coated well of a 6-well tissue 
culture plate. As the sutures are to provide the only point of force to which the myotubes 
align against the suture needs to be firmly affixed with multiple minutien pins along the 
length of the suture.  
At this point it is important to sterilise the dishes to avoid contamination of the myooids 
constructs. This can be done by soaking the dishes in 70% ethanol for 20 minutes. Following 
this, aspirate the ethanol and rinse the dish with 1 ml of 1x phosphate buffered saline. The 
dishes can also be exposed to UV light for 1 hour to assist with sterilisation. 
The next step is the preparation of the fibrin gel. Once all components have been diluted to 
the appropriate concentrations, determine the number of dishes and prepare a master mix of 
growth medium, genipin (Sigma Aldrich, St Louis, MO), thrombin (Sigma Aldrich, St Louis, 
MO) and aprotinin (Sigma Aldrich, St Louis, MO). C2C12 myotubes growth medium is made 
 
Generation and Use of Cultured Human Primary Myotubes 
 
55 
with a base of Dulbecco’s modified eagle medium supplemented with with 10% foetal 
bovine serum (v/v), 1% penicillin streptomyocin (v/v) and 0.5% amphotericin B. For each 
dish add 463 µl of growth medium containing 10 µl Genipin (stock concentration 10 
mg/ml), 25 µl Thrombin (stock concentration 200 U/ ml) thrombin and 2 µl Aprotinin (stock 
concentration 10 mg/ ml).  Gently agitate the dish until the entire surface is covered, ensure 
no air bubbles form around the sutures and pins. Quickly, add 200 µl of 20 mg/ml 
fibrinogen (Sigma Aldrich, St Louis, MO) to each dish and gently mix.  Allow the gel to 
polymerise for 1 hour. Seed the cells into each of the dishes (100,000 cell per dish) in growth 
medium to a final volume of 2 ml. Allow the cells 24 hours to attach prior to changing the 
growth medium every other day. Myoblasts will migrate through the fibrin gel to proliferate 
both within and on top of the gel. After 2 days the gel should begin to contract and the 
myotube will begin to realign themselves between the points of force between the 2 sutures. 
This process should complete around day 7. The myotubes are then differentiated for 2 days 
in reduced serum differentiation medium (2% horse serum). Continue to maintain the 
forming myooids in growth medium containing 7% foetal bovine serum until construct 
formation is completed.  
 
Fig. 3. Formation of three-dimensional C2C12 tissue constructs at different time points after 
initial seeding of the cells. Note the progressive contraction of the gel and subsequent 
alignment of the construct between the two sutures resulting in the formation of a densely 
packed three-dimensional tissue construct. At day 16 the dimensions of the construct were 
determined as approximately 25 mm length and 1 mm in width and the myooid was 





Once construct formation is complete the myooids can be stimulated to contract using 
platinum wire electrodes positioned either side of the constructs using a force transducer. 
Electrical stimulation of constructs has been successfully demonstrated using clonal C2C12 
myotubes in a number of studies (Khodabukus & Baar, 2009; Langelaan et al., 2010; Park et 
al., 2008). However, in our experience the process of electrically stimulating constructs of 
human primary myotubes has proven difficult. Whilst we have previously been able to 
culture the human primary myotubes to form bioengineered skeletal muscle constructs, 
these myooids have been unresponsive to electrical stimulation (McAinch, Unpublished 
observations). As primary cells have limited myogenic capacity, this may reflect changes in 
the electrical potential of the membrane as the cells age in culture. It may be possible to form 
contractile myooids from human primary myotubes which have been isolated from the 
muscle sample immediately prior to culturing in this manner, as opposed to being passaged 
in monolayers initially. However, it remains unclear whether contractile ability is retained.  
Despite the lack of contractile ability, culturing the myotubes in three-dimensional 
arrangements provides an interesting model providing a more physiologically relevant 
arrangement of cells (that is, in vivo cells are rarely arranged in monolayers). When cultured 
in this manner it enables investigations into the importance of cell-cell interactions and 
spatial arrangements on the maturation and metabolic processes of skeletal muscle 
myotubes.   
7. Conclusion 
This chapter has highlighted the diverse nature of research applications associated with the 
use of human primary myotubes for studies investigating muscle physiology and the 
implications of this for systemic health. We have identified significant benefits of using 
human primary myotubes over the use of immortalised cell lines such as the C2C12 and L6 
cell lines due to the fact that these cells retain donor phenotypic traits. This increases the 
physiological relevance of results obtained in studies utilising such primary myotubes. 
Moreover, the relative ease at which samples of sufficient size can be obtain through simple, 
relatively non-invasive biopsy techniques heightens the practicality associated with their 
use. Whilst we have outlined the practices within our research group of isolating myogenic 
satellite cells, growing and maintaining myoblasts and the differentiation of myoblasts into 
myotubes for experimentation, it is apparent that significant variations in methodology do 
prevail. Therefore, the methods described in this chapter may need optimising by the end 
user depending on the outcomes and clinical measures of the specific study. Accordingly, 
we recommend these methods as a highly appropriate starting point for this procedure. We 
have also provided an indication of methods for a number of experimental techniques 
associated with the use of human primary myotubes for developing bioengineered skeletal 
muscle constructs and their application for the treatment of various of myopathies. This list 
of applications is by no means exhaustive which furthers demonstrates the versatile nature 
of this experimental model. 
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1. Introduction 
Membrane transport in human skeletal muscle can be studied with different techniques 
ranging from whole body exercise experiments to in vitro experiments with membranes 
obtained from human skeletal muscle. The membranes for these experiments are usually 
obtained with the biopsy technique. 
2. Muscle biopsy 
A muscle biopsy is a small sample of muscle. Theoretically this sample could be obtained by 
surgery. However, in muscle physiology the established method is the needle-biopsy 
method, usually called the Bergström technique (Bergström 1962). With this technique it is 
possible to obtain 10-100 mg wet weight of tissue or even more if suction is applied.  
2.1 Use of muscle biopsies 
In exercise physiology biopsies obtained before and after exercise have been used to obtain 
snapshoots of the muscle content of ions and metabolites. For instance, the changes in 
muscle glycogen and glucose in association with muscle activity have been quantified. 
Changes in ion composition, for instance accumulation of lactic acid in muscle, the 
associated changes in pH, and changes in Na+ and K+ distribution have also been of interest. 
By repeated biopsies it has been possible to describe the recovery processes after exercise. 
Such measurements are usually combined with blood analysis of the same ions or 
metabolites (see exercise experiments below). 
Muscle biopsies have also been used to obtain snapshoots of the active genes. Measurements 
of transcriptional activity in human skeletal muscle have been difficult because of the large 
amount of muscle tissue needed to isolate nuclei. A new technique involving RT-PCR for 
performing nuclear “run-on” analysis made it possible to determine transcriptional activity 
in the small amount of tissue available from a needle biopsy. This opened the possibility to 
measure transcriptional activity before and in the recovery period in association with 
muscle activity (Pilegaard et al. 2000, Hildebrand & Neufer, 2000). 
2.2 Scope of the paper 
The present review focuses on the use of biopsy material in studies of membrane transport 
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1. Introduction 
Membrane transport in human skeletal muscle can be studied with different techniques 
ranging from whole body exercise experiments to in vitro experiments with membranes 
obtained from human skeletal muscle. The membranes for these experiments are usually 
obtained with the biopsy technique. 
2. Muscle biopsy 
A muscle biopsy is a small sample of muscle. Theoretically this sample could be obtained by 
surgery. However, in muscle physiology the established method is the needle-biopsy 
method, usually called the Bergström technique (Bergström 1962). With this technique it is 
possible to obtain 10-100 mg wet weight of tissue or even more if suction is applied.  
2.1 Use of muscle biopsies 
In exercise physiology biopsies obtained before and after exercise have been used to obtain 
snapshoots of the muscle content of ions and metabolites. For instance, the changes in 
muscle glycogen and glucose in association with muscle activity have been quantified. 
Changes in ion composition, for instance accumulation of lactic acid in muscle, the 
associated changes in pH, and changes in Na+ and K+ distribution have also been of interest. 
By repeated biopsies it has been possible to describe the recovery processes after exercise. 
Such measurements are usually combined with blood analysis of the same ions or 
metabolites (see exercise experiments below). 
Muscle biopsies have also been used to obtain snapshoots of the active genes. Measurements 
of transcriptional activity in human skeletal muscle have been difficult because of the large 
amount of muscle tissue needed to isolate nuclei. A new technique involving RT-PCR for 
performing nuclear “run-on” analysis made it possible to determine transcriptional activity 
in the small amount of tissue available from a needle biopsy. This opened the possibility to 
measure transcriptional activity before and in the recovery period in association with 
muscle activity (Pilegaard et al. 2000, Hildebrand & Neufer, 2000). 
2.2 Scope of the paper 
The present review focuses on the use of biopsy material in studies of membrane transport 





biopsies will be reviewed. It will be described that information obtained with this technique 
can be combined with information obtained from whole body experiments. 
3. Membrane transport in general 
3.1 Specific transport systems 
Membrane transport involves all types of protein-mediated transport systems, including 
channels, carriers, exchangers and pumps. 
3.1.1 Vesicle studies 
In animal studies it is possible to use isolated muscle for transport studies. If a muscle is 
incubated with a radiolabeled compound it is possible to show uptake, and if specific 
inhibiters are known, it is possible to demonstrate that the uptake is mediated by specific 
membrane transport systems. However, a muscle consists of a high number of cells, it is 
therefore not possible to incubate all cells at the same time point, to control the gradient and 
to measure initial rate of uptake. It is therefore not possible based on intact muscle to 
determine the transport kinetic parameters Km and Vmax, the Michaelis- Menten parameters. 
In addition, this type of measurements can not be done in humans. 
The use of vesicles made from human biopsies has solved these problems. 
It has been known for long time that if tissue is homogenized, the membranes usually 
form small closed structures, called vesicles. The diameter of these vesicles is usually less 
than 0.5 μm. Such vesicles have been used for transport studies, but they are difficult to 
use because of the fast uptake/release of compounds due to the large surface/volume 
ration. 
Sarcolemmal giant vesicles are produced with a different method (Burton & Hutter, 1990). 
Muscles are cut in pieces (but are not homogenized), the pieces are treated with 
collagenase and a high K+ concentration (Juel 1991). The exact mechanism is not known. 
The effect of high potassium could be due to an osmotic gradient, bud this is difficult to 
accept because the cells are not intact. Anyway, the outer membranes but out and form 
large vesicles, which can be purified using a step density gradient and slow 
centrifugation. The purified vesicles are from 1-50 μm, with a median of 6 μm (Figure 1). 
This is the size of a red blood cell. Experiments with labeling of the extracellular part of 
the Na,K-ATPase with ouabain have shown no additional labeling if the vesicles were 
opened, which implies that the original outside is still facing outwards, this is usually 
called right side out. These vesicles are much better suited for transport studies because of 
the lower surface-volume ration. In the next sections this type of vesicles will be called 
sarcolemmal giant vesicles. 
It must be noted that this type of vesicles can only be produced from fresh muscle material; 
vesicles can not be produced from frozen material. 
Other types of vesicles have been called giant vesicles; in the present paper the name 
sarcolemmal giant vesicles is restricted to vesicles made with collagenase and K+ treatment 
of muscle. 
 




Fig. 1. Vesicles viewed in the light microscope. These vesicles were produced from human 
biopsy material. Grid: 200μm. 
3.1.2 Lactate transport studies 
Lactate transport was first described in red blood cells. Later it was shown with isolated 
muscle that the lactate uptake in incubated muscle can be inhibited by unspecific transport 
inhibitors (SH-group binding or cinnamate). But this method could not be used to obtain the 
Michealis-Menten parameters. The first study of lactate transport with sarcolemmal giant 
vesicles was carried out with vesicles produced from rat muscle. With this technique it was 
possible to demonstrate saturation, the effects of inhibitors, trans-acceleration, and to 
determine the Michaelis-Menten parameters in different experimental situation: zero-trans 
efflux and equilibrium exchange (Figure 2, right).  
The Michaelis-Menten parameters for lactate/H+ co-transport in human skeletal muscle 
were obtained with vesicles made from needle biopsies (Juel et al. 1994). This is one of the 
first membrane transport studies in humans.  The use of vesicles made this possible. Lactate 
transport (quantified as tracer fluxes) was determined with different lactate concentrations 
in the vesicles and outside the vesicles. This setup and the use of inhibitors to quantify 
simple diffusion made it possible to calculate the Michaelin-Menten parameters Km and Vmax 
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Fig. 2. Lactate transport measures in giant vesicles produced from human skeletal muscle 
biopsies. Data from zero-trans experiments (lactate initially present on one side of the 
membrane) and equilibrium exchange experiments (identical lactate concentration at both 
sides of the membrane, but initially with radio-labeled lactate only at one side). Km was 
found to be 24 and 30 mM lactate, respectively. The lines represent Michaelis-Menten fits to 
the data. Adapted from Juel et al. 1994. Analysis of the pH changes in the same experiments 
revealed that lactate and H+ were transported with a 1:1 ratio; lactate/H+ co-transport is 
therefore the correct name for this type of transport. 
3.1.3 Lactate transport and training in humans  
The proteins responsible for lactate/H+ co-transport were cloned in 1994, but antibodies for 
studies of the two isoforms MCT1 and MCT4 were first available in 1998 (Wilson et al. 1998). 
However, with the use of biopsy material and giant vesicles it was possible to investigate 
the effect of training before the proteins were identified. Biopsies were obtained from 
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subjects with different training status and the rate of lactate transport was quantified from 
tracer fluxes across vesicular membranes (Figure 3). 
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Fig. 3. Lactate transport in vesicles produced from human biopsy material. Lactate transport 
was quantified as tracer flux in vesicles incubated with radio-labeled lactate. Maximal O2 
uptake was used as an index of training status. It can be seen that some individuals with 
high training status had an improved lactate transport capacity (Data from Pilegaard et al. 
1994). 
It was concluded that some well trained sprinters had an increased lactate transport 
capacity. Later it was confirmed with antibodies and biopsy material that training can 
increase the protein density of the proteins involved (Pilegaard et al. 1999). Lactate/H+ co-
transport is mediated by two isoforms called MCT1 and MCT4 (for monocarboxylate 
transporter 1 and 4). 
3.2 Exercise induced changes in transport proteins studied with muscle biopsies 
3.2.1 Exercise 
Muscle biopsies have also been an exceptional tool to investigate the effects of exercise 
training. In combination with the western blotting technique it has been possible to quantify 
the changes at the protein level of many transport proteins, for instance the glucose 
transporter, the lactate H+ co-transporter, the Na+/H+ exchanger and the Na,K-pump. For a 
review on exercise-induced changes in muscle membrane transport systems see (Juel 2006) 
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subjects with different training status and the rate of lactate transport was quantified from 
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Fig. 4. Changes in membrane proteins involved in membrane transport; effect of training. 
All data were obtained with human muscle biopsies taken before and after a training period 
of various durations (weeks) and intensities. Mean ± SD if more than one study. Please note 
that these data are collected from training studies with different training intensities and 
durations. Modified from Juel 2006. 
It can be concluded from Figure 4 that all membrane transport proteins studied in humans 
can undergo changes with training. Although this is a well known phenomenon, the exact 
signaling pathways from physical activity to gene transcription are only partly known.  
3.2.2 Biopsies in exercise and training physiology with special focus on membrane 
transport in humans 
The use of biopsies as snapshots of the ion and metabolite content in muscle is used in 
training and exercise physiology. In addition, biopsies can be used to monitor changes in 
proteins of importance for function. The combined used of other measurements (typically 
blood analysis) and biopsies in training and exercise physiology is demonstrated in the 
example below. 
Human subjects trained with one leg for 8 weeks. The daily training consisted of fifteen 1-
min high intensity bouts (150 % VO2 max) separated by 3 min rest. After the training periods 
an exercise test was carried out both with the trained and the untrained leg. The test 
consisted of incremental exercise to exhaustion. Blood samples were obtained before, during 
the experiment, and in the recovery period. The releases of lactate and H+ were calculated 
from the blood concentrations and blood flow. The effect of training on lactate release is 
illustrated in Figure 5. 
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Fig. 5. Lactate release from exercising leg muscle, the effect of training. Values were 
calculated from arterial and venous blood lactate concentration, and blood flow. Exh: value 
at exhaustion. The exercise intensity (in Watts) is indicated in the diagram below. Adapted 
from Juel et al. 2004.  
It can be concluded that lactate release was nearly doubled in the trained leg compared to 
the untrained leg (Juel et al. 2004). The question is now, what is the underlying mechanism? 
Changes in lactate release could be due to changes in the amount of lactate accumulated in 
the active muscle. Biopsy samples were therefore analyzed for total lactate content. It was 
found that the lactate concentration at exhaustion was higher in untrained muscle compared 
to trained muscle; therefore, the increased release in trained muscle can not be explained by 
a higher gradient, on the contrary the gradient from muscle to plasma was lower in trained 
muscle. 
The improved release of lactate could also bee due to an increased content of lactate/H+ co-
transporter proteins called MCT1 and MCT4. To investigate this possibility, biopsy material 
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Fig. 6. Effects of 2, 4, and 8 weeks of high intensity training on muscle contents of the 
lactate/H+ co-transporter proteins MCT4 and MCT1. Adapted from Juel et al. 2004) 
Indeed, analyses of MCT content in biopsies obtained before, during and after the training 
period, demonstrated an increase in MCT content. However, the increase was moderate, 
and can only partly explain the dramatic increase in lactate release in the test experiments 
comparing trained and untrained leg (Figure 5). Could other mechanisms be involved? 
Again biopsy material was used. The improved lactate release could be due to a higher 
blood flow in the trained compared to untrained muscle, which could be the underlying 
mechanism for a better wash-away of lactate, which maintains the gradient and facilitates a 
higher release. Biopsies were analyzed for number of capillaries per fiber (Jensen et al. 2004). 
The analysis demonstrated a considerable increase in the number of capillaries in the trained 
leg compared to untrained leg (Figure 7). 
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Fig. 7. Effect of training on number of capillaries per muscle fiber. Values determined in 
human biopsy material (data from Jensen et al. 2004). 
Thus, the improvement in lactate release was partly due to a higher number of transporter 
molecules, and partly due to an improved blood flow. The improvement in blood flow was 
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mainly mediated by an increased number of capillaries. In conclusion, analysis of biopsy 
material contributed with information about the underlying mechanisms. 
3.2.3 Biopsies from patients 
It is obvious that muscle biopsies are used for diagnostic purposes. Analyses of biopsy 
material can give information about cellular changes including metabolic changes. Analysis 
of pathological changes is outside the scope of the present review. 
But biopsies have also been used for comparing patients and healthy control groups. One 
example is given below. 
Diabetic patients and normal healthy control subjects differ in their insulin sensitivity and 
glucose handling. The use of biopsies has revealed other differences. 
In a training study comparing diabetic patients and healthy control subjects it was found 
that type 2 diabetic patients had a lover muscle content of Na,K-pump subunits. For both 
groups strength training resulted in an increased density of pumps, but the diabetic patients 
still had a lover level of pump proteins (Dela et al. 2004). Likewise, studies of biopsy 
material from these groups demonstrated that type 2 diabetes is associated with a lower 
capacity for lactate and H+ transport, and that the transport capacity could de increased 
with training in both groups (Juel et al. 2004a). In conclusion, type 2 diabetes is not only 
associated with reduced insulin sensitivity/reduced glucose transport, other membrane 
transport systems are also affected.  
3.3 pH regulation in muscle 
3.3.1 pH regulation in general 
The concentration of H+, which determines pH, is regulated by a number of mechanisms 
including several membrane transport system. The sum of all these mechanism is called pH 
regulation. The main problem in all living cells is that the negative membrane potential 
influences the distribution of H+ across the outer membrane. The internal concentration of 
H+ therefore tends to increase, and as a consequence there is a tendency towards a low 
intracellular pH (cellular acidification). The pH regulating system therefore has to remove 
free H+ from the cell; this is either done by intracellular buffering or by transporting H+ out 
(or OH- in). For a review about pH regulation in human skeletal muscle see Juel (2008). The 
main components in pH regulation are outlined below. 
3.3.2 Kinetics of pH regulation 
Information about the kinetics of skeletal muscle pH regulation has been obtained both from 
whole body experiments and from experiments involving membrane vesicles. 
3.3.3 Whole body experiments 
Interstitial pH in human skeletal muscle can be measured with the microdialysis technique 
combined wit the use of pH sensitive dies (Street et al 2001). With this technique it has been 
possible to measure the time course of the pH changes associated with leg exercise with 
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Fig. 8. Membrane transport proteins involved in pH regulation in skeletal muscle. Adapted 






Interstitial pH in human skeletal muscle, effect of 
30, 50, and 70 Watts exercise with one leg.
 
Fig. 9. Interstitial pH in human skeletal muscle during leg exercise with three different work 
intensities 30, 50 and 70 Watts. It can be seen that pH is reduced during exercise 
(acidification), and that recovery of pH takes place with a half-time of approximately 5 min. 
Data from Street et al. 2001. 
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3.3.4 Vesicle studies 
Regulation of muscle pH has also been studied with sarcolemmal giant vesicles. 
Changes in Na+ concentration
associated with pH regulation
 
Fig. 10. pH regulation studied with vesicles obtained from rat skeletal muscle. At time zero 
external pH is changes 0.5 unit. Vesicular Na+ concentration is measured with an ion 
sensitive dye. The changes in vesicular Na+ concentration reveal that Na+ fluxes across the 
membrane takes place during pH regulation. By the use of a specific inhibitor, amiloride, 
(lower trace) it was demonstrated that part of pH recovery is mediated by Na+/H+ exchange 
(Juel 2000). 
3.3.5 The use of biopsy material to study other components of pH regulation 
The sections below focus on the components involved in pH regulation.  
3.3.6 Sodium/bicarbonate transport 
Only a few studies have investigated the functional significance of sodium/bicarbonate co-
transport in skeletal muscle in general and especially in human muscle. However, two 
isoforms of the Na+/bicarbonate co-transporters NBCs have been identified in rat muscle 
and human muscle. For humans the experiments were based on biopsy material. Studies 
with vesicles made from rat have demonstrated that the NBCs contribution is approximately 
half of the total capacity for pH regulation in resting muscle (Kristensen et al. 2004). 
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Fig. 8. Membrane transport proteins involved in pH regulation in skeletal muscle. Adapted 






Interstitial pH in human skeletal muscle, effect of 
30, 50, and 70 Watts exercise with one leg.
 
Fig. 9. Interstitial pH in human skeletal muscle during leg exercise with three different work 
intensities 30, 50 and 70 Watts. It can be seen that pH is reduced during exercise 
(acidification), and that recovery of pH takes place with a half-time of approximately 5 min. 
Data from Street et al. 2001. 
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3.3.4 Vesicle studies 
Regulation of muscle pH has also been studied with sarcolemmal giant vesicles. 
Changes in Na+ concentration
associated with pH regulation
 
Fig. 10. pH regulation studied with vesicles obtained from rat skeletal muscle. At time zero 
external pH is changes 0.5 unit. Vesicular Na+ concentration is measured with an ion 
sensitive dye. The changes in vesicular Na+ concentration reveal that Na+ fluxes across the 
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2000). The effect of high-intensity training on human Na+/H+ exchange protein NHE1 has 
been studied with biopsy material obtained from trained and untrained muscle (Juel et al. 
2004).  Data from an animal study of Na+/H+ exchange in pH regulation is shown above, 
figure 10. 
3.4 Ion homeostasis 
Activation of skeletal muscle is associated with small displacements of ions; each action 
potential give rise to a small Na+ influx and a small K+ efflux due to opening if specific 
channel. During repeated activation Na+ is accumulated in the muscle cell and K+ is 
accumulated outside the cell. Analysis of blood samples obtained in association with muscle 
activity show an increased plasma K+ concentration during muscle activity and in the first 
minute of the recovery period. The activity of the Na+-K+-pump counteracts these 
concentration changes, but it is obvious that the Na+,K+-pump can not keep pace with the K+ 
efflux during muscle activity, which is the underlying mechanism for the extracellular 
accumulation of K+ (Figure 11). 
Plasma K+ during muscle exercise
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120 min low intensity exercise
3 min exhaustive exercise
 
Fig. 11. Accumulation of K+ in blood plasma during short intense muscle activity and during 
long lasting low intensity exercise. Potassium release was calculated from the arterial and 
venous blood K+ concentration and blood flow. Data From Juel et al. 1990 and Sjøgaard 
1986.   
It can be concluded from Figure 11 that both short and long-lasting exercise is associated 
with a continuous potassium loss from muscle. It has been confirmed with muscle biopsies 
that the extracellular accumulation of K+ is paralleled by a similar decrease in intracellular 
K+ concentration. 
The intracellular Na+ increase and the extracellular K+ concentration increase have been 
associated with muscle fatigue. The underlying mechanism is impaired muscle excitability, 
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which results in reduced force; muscle fatigue. The Na+,K+-pump is the main membrane 
transport system responsible for ion homeostasis. The pump counteracts the ion 
displacements. Regulation of the pump is therefore important for development of fatigue. 
Stimulation of the pump by hormones and other mechanisms delays the development of 
fatigue. 
3.4.1 Membrane purification, Western blotting 
Analysis of sarcolemmal giant vesicle material with the use of specific membrane marker 
antibodies, has revealed that vesicular membranes exclusively consist of outer membranes 
with no contribution from T-tubuli and endoplasmatic reticulum membranes. This fact has 
been used in studies of protein distribution. The use of vesicles as a method to purify the 
outer membrane seems to be more efficient that the traditional methods, which include 
several spinning steps. This fact has been used to determine the cellular localization of 
membrane transport proteins, an example is given below. 
3.4.2 Translocation of pumps 
It was suggested before 2000, that the cell-surface Na,K-ATPase protein density in rat could 
be increased by insulin and exercise. But it was not known whether this mechanism is also 
present in human muscle. This was probably due to the large amount of muscle tissue 
needed for membrane purification. However, the development of the sarcolemmal giant 
vesicle technique and the optimization for the small amount of vesicles obtained from 
human muscle biopsies, made it possible to study the distribution of the Na,K-ATPase 
(Na,K-pump) in human skeletal muscle. In the first study to use this technique 6 human 
subjects performed one legged exercise until fatigue, and needle biopsies were obtained 
before exercise and immediately after fatigue. The amounts of Na,K-ATPase isoforms in the 
sarcolemmal membrane were measured with antibodies. It was demonstrated that exercise 
significantly increased the amount of α2, total α, and β subunit proteins by 70, 35 and 26 %, 
respectively (Juel et al. 2000). These values clearly indicated that pump subunits can be 
translocated from one store to the outer membrane during exercise. However, the 
underlying nature of this translocation remained unknown. It was later demonstrated with 
sarcolemmal material from rat muscle that the translocation of pump subunits to the outer 
membrane is reversible with a half-time of approximately 20 minutes (Juel et al. 2001). 
The translocation mechanism has later been studied with other techniques including biotin 
labeling of surface membrane proteins in combination with sarcolemmal giant vesicles used 
as a membrane purification method (Kristensen et al. 2008). These studies confirmed that 
Na,K-ATPase subunits can translocate to the outer membrane. In addition it was 
demonstrated that changes in caveolae pump content could be part of the mechanism. This 
is another example of the use of biopsy material; these experiments clearly brought new 
knowledge. 
3.4.3 Glucose transport 
The use of sarcolemmal giant vesicles produced from biopsy material was a success in 
studies of lactate transport.  It was therefore logic to use the same method for the study of 
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was possible to demonstrate that glycose transport across the vesicular membranes was 
affected by insulin and muscle contractions (Ploug et al. 1993). Furthermore, the effect of pH 
and glucose-6-phosophate was studied (Kristiansen et al. 1994).  
Studies of glucose transport using vesicles from human biopsies have also been published. 
Since vesicles exclusively consist of material from the outer membrane it is possible to 
investigate if the glucose transporters GLUT4 are translocated to the outer membrane 
during exercise. Changes in glucose transport and translocation of GLUT4 with endurance 
training have been investigated with vesicles produced from biopsies from human muscle 
(Richter et al. 1998) However, in spite of the first promising experiments with vesicles; this 
technique has not been used in newer experiments. The reason is that regulation of glucose 
transport is dependent on internal signaling pathways, which are lost during the 
preparation of vesicles. 
3.4.4 Fri fatty acid transport 
Long-chain fatty acids, LCFA, are important as an energy source in many tissues including 
skeletal muscle. It was originally believed that long chain-fatty acids can freely diffuse 
across the plasma membrane. It was early recognized that LCFA can bind to the outer 
membrane; the binding proteins were simply called fatty acid binding proteins. The details 
could only be studied in a model system; again vesicles were used. The early studies of fatty 
acid membrane transport were carried out with sarcolemmal giant vesicles produced from 
rat muscle (Bonen et al, 1999; Luiken et al., 2001; Turcotte at al., 2000; Bonen et al., 1998; 
Bonen et al., 2000). It was demonstrated that the transport showed saturation and could be 
inhibited with specific antibodies, which clearly indicates that a transport system is involved 
(Turcotte et al. 2000).  
These studies in combination with the use of antibodies and western blotting revealed three 
groups of transport systems: fatty acid binding proteins (FABPm), fatty acid translocase 
(FAT), and fatty acid transporter proteins (FATP)(Bonen et al. 1998a). These early transport 
studies were not based on human membrane material. But human biopsy material was later 
used to identify the transporter proteins in human skeletal muscle (Roepstorff et al. 2004). In 
addition, biopsies taken before and after training were used to characterize the effect of 
endurance training on the FABPm protein density, which was increased by 49 % after three 
weeks of training (Kiens et al. 1997).  
4. Conclusion 
Whole body experiments in humans have given much information about membrane 
transport. These data have been combined with information obtained by the use of biopsies. 
Biopsies from human skeletal muscle have been used to give a snapshot of metabolite 
content and ion composition in connection with muscle activity and training. It is also 
possible to study dynamic aspects of gene regulation in human biopsy material. 
The present review has focused on studies of membrane transport based on biopsy material. 
It has been shown that muscle treated with collagenase and high K+ concentrations induce 
formation of membrane vesicles. Single vesicles were originally used for microelectrode 
recordings of ion currents (Burton et al. 1990). A method to purification vesicles made from 
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animal muscle was later developed (Juel 1990), and the method was further developed 
allowing vesicles to be produced from human skeletal muscle biopsies (Juel et al. 1994). 
These vesicles were demonstrated to be a new and unique method to investigate membrane 
transport processes in human skeletal muscle. In combination with the use of radio-labeled 
tracers these vesicles allowed quantification of the transport kinetic parameters Km and Vmax 
(per square cm of membrane). 
The first membrane transport system to be investigated in humans with the biopsy based 
vesicle technique was the lactate/proton co-transport system. This transport system was 
characterized first in rat skeletal muscle membranes later in membranes from human 
skeletal muscle (Juel 1991, Pilegaard et al. 1993, Juel et al. 1994). With this technique it was 
possible to measure lactate/proton co-transport in muscle fiber types and to show that this 
transport system could be up-regulated with training and decreased with inactivity. It must 
be noted that the first discovered adaptive changes was quantified before the transport 
protein was cloned and before antibodies were available. Later studies have used vesicles as 
a method to purify muscle membranes. These studies were combined with information 
obtained by whole body experiments. 
Sarcolemmal giant vesicles have later been used to study: 
 glucose transport (Kristiansen et al. 1994) 
 pH regulation (Juel 1995) 
 translocation of Na,K-pump subunits (Juel et al. 2001) 
 Na+/H+ exchange 
 K+ displacement during exercise  
 membrane transport of free fatty acids (Bonen et al. 1998) 
Data from biopsies were also used in exercise and training experiments. These studies 
gained from the fact that a biopsy represents a snapshoot of the metabolic and ionic content 
of an active muscle. 
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Within the past decade, the list of publications involving mitochondrial dysfunction in the 
etiology of metabolic disorders in obesity, insulin resistance and type 2 diabetes, has been 
growing steadily. Today, large controversies still exist and it is clear that the understanding 
of the causes and consequences of impairments in mitochondrial functioning are far from 
being accomplished. In this context, our purpose is to review techniques used in human 
samples to highlight defects in mitochondrial activity, with a particular focus on skeletal 
muscle. Several tools are described to assess a large array of mitochondrial functions. In 
order to facilitate the reading of the review, several details related to methodological 
concerns are provided in supplementary materials and remain available upon request to the 
authors. 
2. Basic knowledge on mitochondrial functioning 
Mitochondria are found in nearly all eukaryotes. They are forming a complex network 
which shape and functioning is determined by the interaction with the cytoskeleton and by 
the balance between fusion and fission reactions (Zorzano et al., 2009). They vary in number 
and location according to cell type. Within skeletal muscle fibers, mitochondrial density and 
activity mainly varies according to fiber types and physical training (Howald et al., 1985) 
although type 2 diabetes and genetic inheritance have been also proposed as potential 
modulators (Petersen et al., 2004; Morio et al., 2005; Befroy et al., 2007). Mitochondria are 
located either around the nuclei, this subgroup is called subsarcolemmal mitochondria, or 
nestled between myofibrils. These mitochondria are named intermyofibrillar and have 
distinct activity from subsarcolemmal ones (Koves et al., 2005; Mollica et al., 2006). 
Intermyofibrillar mitochondria are mainly dedicated to energy production for muscle fiber 
contraction. By contrast, subsarcolemmal mitochondria may play a key role in signal 
transduction and substrate transport. Deficiency in the latter pool has been proposed to 
contribute to the pathogenesis of muscle insulin resistance in type 2 diabetes (Ritov et al., 
2005; Benton et al., 2008). 
 5 
Evaluation of Mitochondrial Functions and 
Dysfunctions in Muscle Biopsy Samples 
Frédéric Capel1,2, Valentin Barquissau1,2, 
Ruddy Richard1,2 and Béatrice Morio1,2 
1INRA, UMR1019 Nutrition Humaine, CRNH Auvergne, 
F-63120 Saint-Genès-Champanelle 




Within the past decade, the list of publications involving mitochondrial dysfunction in the 
etiology of metabolic disorders in obesity, insulin resistance and type 2 diabetes, has been 
growing steadily. Today, large controversies still exist and it is clear that the understanding 
of the causes and consequences of impairments in mitochondrial functioning are far from 
being accomplished. In this context, our purpose is to review techniques used in human 
samples to highlight defects in mitochondrial activity, with a particular focus on skeletal 
muscle. Several tools are described to assess a large array of mitochondrial functions. In 
order to facilitate the reading of the review, several details related to methodological 
concerns are provided in supplementary materials and remain available upon request to the 
authors. 
2. Basic knowledge on mitochondrial functioning 
Mitochondria are found in nearly all eukaryotes. They are forming a complex network 
which shape and functioning is determined by the interaction with the cytoskeleton and by 
the balance between fusion and fission reactions (Zorzano et al., 2009). They vary in number 
and location according to cell type. Within skeletal muscle fibers, mitochondrial density and 
activity mainly varies according to fiber types and physical training (Howald et al., 1985) 
although type 2 diabetes and genetic inheritance have been also proposed as potential 
modulators (Petersen et al., 2004; Morio et al., 2005; Befroy et al., 2007). Mitochondria are 
located either around the nuclei, this subgroup is called subsarcolemmal mitochondria, or 
nestled between myofibrils. These mitochondria are named intermyofibrillar and have 
distinct activity from subsarcolemmal ones (Koves et al., 2005; Mollica et al., 2006). 
Intermyofibrillar mitochondria are mainly dedicated to energy production for muscle fiber 
contraction. By contrast, subsarcolemmal mitochondria may play a key role in signal 
transduction and substrate transport. Deficiency in the latter pool has been proposed to 
contribute to the pathogenesis of muscle insulin resistance in type 2 diabetes (Ritov et al., 





The most prominent role of mitochondria is to produce the “energy carrier” adenosine 
triphosphate (ATP) mainly from glucose and fatty acid oxidation, and to a lesser extend 
from amino acid oxidation. Nutrient oxidation within the cytosol and/or the mitochondrial 
matrix results in acetyl-CoA production, the main substrate of the tricarboxylic acid (TCA) 
cycle which takes place in the mitochondrial matrix. The β-oxidation pathway is specific to 
fatty acid oxidation and results in acetyl-CoA production which feeds TCA cycle. These 
oxidative pathways are coupled to the mitochondrial electron transport chain (ETC), whose 
enzyme content and activity together define the mitochondrial oxidative capacity. The latter 
factor combined with mitochondrial density determines the tissue oxidative capacity. The 
main rate-limiting oxidative enzymes are citrate synthase and isocitrate dehydrogenase 
(TCA cycle), -hydroxyacyl-CoA dehydrogenase (β-oxidation) and cytochrome c oxidase 
(ETC). Mitochondria are also key organelles for regulation of cell metabolism. Mitochondrial 
functioning has been proven to control cellular metabolism, redox and calcium signalling, 
apoptosis-programmed cell death and cellular proliferation. This shows that a perpetual 
cross talk exists between cell and mitochondria, the result being the cell adaptation to 














Fig. 1. Involvement of the cross-talk between nucleus and mitochondria in the regulation of 
cell adaptations. 
2.1 Mitochondrial respiratory chain, membrane potential and energy production, and  
main alterations observed in metabolic disorders 
Nutrient oxidation consists in a series of enzyme-catalysed oxidative reactions which aims 
at transferring energy-rich electrons to the cofactors nicotinamide adenine dinucleotide 
[NAD+] and flavin mononucleotide [FAD], forming respectively NADH, H+ and FADH2. 
The latter reduced carriers provide thereafter the ETC with these energy-rich electrons. The 
ETC is situated into the mitochondrial inner membrane and consists of four large enzyme 
complexes (Complex I, NADH-CoQ oxidoreductase; II, succinate dehydrogenase; III, CoQ-
cytochrome c oxidoreductase; and IV, cytochrome c oxidase). Mobile electron carriers (e.g. 
coenzyme Q or ubiquinone, and cytochrome c) transport the electrons from one complex to 
the next with oxygen acting as the final electron acceptor within cytochrome c oxidase. The 
transfer of the high-energy electrons along the electron transport chain results in the 
pumping of H+ ions across the inner membrane, creating an electrochemical gradient (also 
named membrane potential, m) that provides the energy required to drive the synthesis 
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of ATP thanks to a fifth complex called F0F1 ATP synthase. The latter consists of a H+ ion 
channel (F0) connected to a catalytic subunit (F1). The energy provided by the flux of H+ ions 
through F0 is used to drive ATP synthesis from ADP and Pi by F1 (Figure 2). The 
electrochemical gradient determines the coupling between the oxidative and the 
phosphorylative reactions. It is named oxidative phosphorylation (OXPHOS). 
 
Fig. 2. Main organization of mitochondrial oxidative and phosphorylative pathways. 
TCA cycle, tricarboxylic cycle; Complex I, NADH-CoQ oxidoreductase; Complex II, 
succinate dehydrogenase; Complex III, CoQ-cytochrome c oxidoreductase; Complex IV, 
cytochrome c oxidase; Q, coenzyme Q or ubiquinone; Cyt c, cytochrome c; ANT, adenine 
nucleotide translocase, ANT; mtCK, creatine kinase. This figure is derived from Wikipedia. 
Mitochondrial membrane potential is a key indicator of cellular viability. As demonstrated 
by Peter Mitchell (1961), it is the driving force behind ATP production. It also governs ROS 
production, mitochondrial calcium storage, opening of mitochondrial permeability 
transition pores (mPTP) and mitochondrial-apoptotic programmed cell death (reviews in 
Casteilla et al., 2001; Hand & Menze, 2008). Mitochondrial ATP production has to strictly 
match cellular needs. It is tightly controlled by different factors. The ATP/ADP-Pi ratio, 
through a mitochondrial ADP sensing which is still not fully understood (Wilson et al., 
1977), the NAD+/NADH-H+ ratio and local oxygen pressure chance. The transfers of ATP, 
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(adenine nucleotide translocase, ANT). The high-energy phosphate group of ATP may be 
also transferred to creatine to yield phosphocreatine. This reaction is catalyzed by the 
mitochondrial isoform of creatine kinase (mtCK), which is located in the mitochondrial 
intermembrane space. The dynamic of the phosphate group transfer between ATP and 
creatine and the transport of these metabolites between cytosol and mitochondrial 
intermembrane space, differs between contractile fiber types. This is due to differential 
coupling between mtCK, ANT and porin (voltage-dependent anion channel, VDAC) which 
determines the flux of ADP entrance within the mitochondrial matrix (Saks et al., 1994). 
Unlike glycolytic fibers (type IIb) for which mitochondrial respiration is regulated by 
cytosolic ADP, mitochondrial respiration of oxidative fibers (type I) is more controlled by 
the ratio between creatine and phosphocreatine than by ADP (Zoll et al., 2003). The oxydo-
glycolytic fibers (type IIa) present an intermediate situation. 
Except in Asian Indians, consistent decrease in muscle mitochondrial ATP production has 
been reported in insulin resistance in obesity and type 2 diabetes (Petersen et al., 2004, 2005; 
Szendroedi et al., 2007; Chanseaume et al., 2010). By contrast, the theory linking insulin 
resistance to decreased mitochondrial oxidative capacity is more challenged. It has been 
supported by several cross-sectional studies in obese insulin-resistant and type 2 diabetic 
patients compared to healthy individuals (Howald et al., 1985; Kelley et al., 2002; Pertersen 
et al., 2004; Ritov et al., 2005, 2010). These observational studies are reviewed in table 1. By 
contrast, recent studies (Petersen et al., 2005; Chanseaume et al., 2010) and clinical trials that 
involve interventions (weight loss, physical activity) altering insulin sensitivity (Brons et al., 
2008; Toledo et al., 2008) demonstrated a dissociation between insulin resistance and 
mitochondrial functioning in skeletal muscle. Part of the discrepancy may be due to bias 
induced by confounding factors, such as physical activity. Indeed when the latter factor is 
rigorously taken into account, mitochondrial oxidative capacity is similar between lean and 
obese-insulin resistant volunteers (Chanseaume et al., 2010). However, genetic and/or 
epigenetic predisposition have also to be taken into account (Petersen et al., 2004, 2005; 
Morino et al., 2005; Befroy et al., 2007; Nair et al., 2008). 
2.2 Mitochondrial fatty acid oxidation and cellular meanings 
Mitochondria are the principal site of long-chain fatty acid (LCFA) oxidation for cellular 
energy production. A defect in this process may trigger the accumulation of toxic lipid 
metabolites in skeletal muscle. Mitochondrial LCFA oxidation is tightly regulated by the 
enzyme carnitine palmitoyltransferase 1 (CPT1), which is situated in the outer 
mitochondrial membrane and regulates the entry of acyl-CoAs into mitochondria. Malonyl-
CoA, the first metabolic intermediate of lipogenesis produced by the enzyme acetyl-CoA 
carboxylase, is the physiological allosteric inhibitor of CPT1 (McGarry & Brown, 1997). This 
malonyl-CoA/CPT1 partnership is considered as a “fuel sensor” whose role is to regulate 
the rate of LCFA oxidation according to the relative disposal of LCFA and glucose within 
the cell. When circulating lipids increase, whereas glucose availability decreases (such as 
during starvation), lipids are oxidized in mitochondria at the expense of glucose 
(Rasmussen & Wolfe, 1999). When mitochondrial LCFA oxidative capacity becomes limited, 
excess LCFAs taken up by the cell are initially redirected towards storage in the form of 
triacylglycerols (TAG). For these reasons, new concept has emerged pointing out muscle 
mitochondrial dysfunction as the leading cause for TAG accumulation in obesity and insulin 
resistance (Petersen & Shulman, 2006). 
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Abdul-Ghani et al., 2009? in obese, = in type-2 diabeticObese and type-2 diabetic
Chanseaume et al., 2010?Obese and insulin resistant*
ROS production
Schrauwen-Hinderling
et al., 2007?Type-2 diabetic
Brons et al., 2008=Insulin resistant with predisposition
P-creatine synthesis
Nair et al., 2008=Type-2 diabetic
Szendroedi et al., 2007?Type-2 diabetic
Abdul-Ghani et al., 2009?Obese and type-2 diabetic
Chanseaume et al., 2010?Obese and insulin resistant*
Petersen et al., 2005?Insulin resistant with family predisposition
Petersen et al., 2004?Insulin resistant with family predisposition
ATP synthesis
Nair et al., 2008= Citrate synthaseType-2 diabetic
Ortenblad et al., 2005? Citrate synthaseType-2 diabetic
Boushel et al., 2007? Citrate synthaseType-2 diabetic
Kelley et al., 2002? Citrate synthase, complexe 1Obese and type-2 diabetic
He et al., 2001? Complexe 2Obese and type-2 diabetic
Ritov et al., 2005? Complexe 2Obese and type-2 diabetic
Chanseaume et al., 2010= Citrate synthase, COXObese and insulin resistant*
Holloway et al., 2007? CPT1, ßHAD, COXObese
Kim et al., 2000? CPT1, ßHAD, citrate synthaseObese
Heilbronn et al., 2007? Citrate synthaseInsulin resistant
Maximal enzyme activity
Befroy et al., 2007? acetyl-CoA oxidationInsulin resistant with family predisposition
Kim et al., 2000? LCFA oxidationObese
Substrates oxidation
Nair et al., 2008= PGC-1a/ß, NRF1, OXPHOSType-2 diabetic
Debard et al., 2004? PGC-1aType-2 diabetic
Mootha et al., 2003? PGC-1a/ß, OXPHOSType-2 diabetic
Patti et al., 2003? PGC-1a/ß, NRF1, OXPHOSType-2 diabetic and insulin resistant with predisposition
Chanseaume et al., 2010= PGC-1a/ß, NRF1, OXPHOSObese and insulin resistant*
Brons et al., 2008= PGC-1a , OXPHOSInsulin resistant with family predisposition
Heilbronn et al., 2007? PGC-1a , complexes 1-3-4Insulin resistant with family predisposition
Biogenesis signalling pathway
Ritov et al., 2005? sizeType-2 diabetic
Kelley et al., 2002? size, areaObese and type-2 diabetic
Morphology
Ashmann et al., 2006=Type-2 diabetic
Nair et al., 2008=Type-2 diabetic
Boushel et al., 2007?Type-2 diabetic
Ritov et al., 2005?Obese and type-2 diabetic
Chanseaume et al., 2010=Obese and insulin resistant*
Holloway et al., 2007?Obese




Table 1. Alterations in mitochondrial structure, content and functioning reported in skeletal 
muscle of insulin resistant, obese and/or type-2 diabetic patients. * all volunteers were 
similarly sedentary 
Cellular TAG buffering capacity in lean tissues such as skeletal muscle, is limited and 
rapidly flooded, especially for saturated LCFAs such as palmitate which are poorly 
incorporated into TAG (garcia-Martinez et al., 2005). In these conditions, excess LCFAs may 
enter alternative non-oxidative pathways that result in the production and accumulation of 
toxic lipid metabolites, such as diacylglycerols (DAG), acyl-CoAs or ceramides. These LCFA 
derivatives have been demonstrated to be deleterious for cell functioning since they are able 
to modulate activity of protein kinases (Shulman, 2000; Hegarty et al., 2003) which 
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involve interventions (weight loss, physical activity) altering insulin sensitivity (Brons et al., 
2008; Toledo et al., 2008) demonstrated a dissociation between insulin resistance and 
mitochondrial functioning in skeletal muscle. Part of the discrepancy may be due to bias 
induced by confounding factors, such as physical activity. Indeed when the latter factor is 
rigorously taken into account, mitochondrial oxidative capacity is similar between lean and 
obese-insulin resistant volunteers (Chanseaume et al., 2010). However, genetic and/or 
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Morino et al., 2005; Befroy et al., 2007; Nair et al., 2008). 
2.2 Mitochondrial fatty acid oxidation and cellular meanings 
Mitochondria are the principal site of long-chain fatty acid (LCFA) oxidation for cellular 
energy production. A defect in this process may trigger the accumulation of toxic lipid 
metabolites in skeletal muscle. Mitochondrial LCFA oxidation is tightly regulated by the 
enzyme carnitine palmitoyltransferase 1 (CPT1), which is situated in the outer 
mitochondrial membrane and regulates the entry of acyl-CoAs into mitochondria. Malonyl-
CoA, the first metabolic intermediate of lipogenesis produced by the enzyme acetyl-CoA 
carboxylase, is the physiological allosteric inhibitor of CPT1 (McGarry & Brown, 1997). This 
malonyl-CoA/CPT1 partnership is considered as a “fuel sensor” whose role is to regulate 
the rate of LCFA oxidation according to the relative disposal of LCFA and glucose within 
the cell. When circulating lipids increase, whereas glucose availability decreases (such as 
during starvation), lipids are oxidized in mitochondria at the expense of glucose 
(Rasmussen & Wolfe, 1999). When mitochondrial LCFA oxidative capacity becomes limited, 
excess LCFAs taken up by the cell are initially redirected towards storage in the form of 
triacylglycerols (TAG). For these reasons, new concept has emerged pointing out muscle 
mitochondrial dysfunction as the leading cause for TAG accumulation in obesity and insulin 
resistance (Petersen & Shulman, 2006). 
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Abdul-Ghani et al., 2009? in obese, = in type-2 diabeticObese and type-2 diabetic
Chanseaume et al., 2010?Obese and insulin resistant*
ROS production
Schrauwen-Hinderling
et al., 2007?Type-2 diabetic
Brons et al., 2008=Insulin resistant with predisposition
P-creatine synthesis
Nair et al., 2008=Type-2 diabetic
Szendroedi et al., 2007?Type-2 diabetic
Abdul-Ghani et al., 2009?Obese and type-2 diabetic
Chanseaume et al., 2010?Obese and insulin resistant*
Petersen et al., 2005?Insulin resistant with family predisposition
Petersen et al., 2004?Insulin resistant with family predisposition
ATP synthesis
Nair et al., 2008= Citrate synthaseType-2 diabetic
Ortenblad et al., 2005? Citrate synthaseType-2 diabetic
Boushel et al., 2007? Citrate synthaseType-2 diabetic
Kelley et al., 2002? Citrate synthase, complexe 1Obese and type-2 diabetic
He et al., 2001? Complexe 2Obese and type-2 diabetic
Ritov et al., 2005? Complexe 2Obese and type-2 diabetic
Chanseaume et al., 2010= Citrate synthase, COXObese and insulin resistant*
Holloway et al., 2007? CPT1, ßHAD, COXObese
Kim et al., 2000? CPT1, ßHAD, citrate synthaseObese
Heilbronn et al., 2007? Citrate synthaseInsulin resistant
Maximal enzyme activity
Befroy et al., 2007? acetyl-CoA oxidationInsulin resistant with family predisposition
Kim et al., 2000? LCFA oxidationObese
Substrates oxidation
Nair et al., 2008= PGC-1a/ß, NRF1, OXPHOSType-2 diabetic
Debard et al., 2004? PGC-1aType-2 diabetic
Mootha et al., 2003? PGC-1a/ß, OXPHOSType-2 diabetic
Patti et al., 2003? PGC-1a/ß, NRF1, OXPHOSType-2 diabetic and insulin resistant with predisposition
Chanseaume et al., 2010= PGC-1a/ß, NRF1, OXPHOSObese and insulin resistant*
Brons et al., 2008= PGC-1a , OXPHOSInsulin resistant with family predisposition
Heilbronn et al., 2007? PGC-1a , complexes 1-3-4Insulin resistant with family predisposition
Biogenesis signalling pathway
Ritov et al., 2005? sizeType-2 diabetic
Kelley et al., 2002? size, areaObese and type-2 diabetic
Morphology
Ashmann et al., 2006=Type-2 diabetic
Nair et al., 2008=Type-2 diabetic
Boushel et al., 2007?Type-2 diabetic
Ritov et al., 2005?Obese and type-2 diabetic
Chanseaume et al., 2010=Obese and insulin resistant*
Holloway et al., 2007?Obese




Table 1. Alterations in mitochondrial structure, content and functioning reported in skeletal 
muscle of insulin resistant, obese and/or type-2 diabetic patients. * all volunteers were 
similarly sedentary 
Cellular TAG buffering capacity in lean tissues such as skeletal muscle, is limited and 
rapidly flooded, especially for saturated LCFAs such as palmitate which are poorly 
incorporated into TAG (garcia-Martinez et al., 2005). In these conditions, excess LCFAs may 
enter alternative non-oxidative pathways that result in the production and accumulation of 
toxic lipid metabolites, such as diacylglycerols (DAG), acyl-CoAs or ceramides. These LCFA 
derivatives have been demonstrated to be deleterious for cell functioning since they are able 
to modulate activity of protein kinases (Shulman, 2000; Hegarty et al., 2003) which 





dysfunction (Coll et al., 2006), oxidative stress (Montuschi et al., 2004) and apoptosis (Slawik 
& Vidal-Puig, 2006). Whereas mechanisms linking those LCFA metabolites to insulin 
resistance have raised large consensus, the involvement of mitochondrial LCFA oxidative 
capacity in the regulation of their synthesis rates is still controversial (Rimbert et al., 2004, 
2009). These arguments suggest that more complex interactions exist between LCFA 
availability and cell metabolism, and determine the intracellular fates of LCFAs (for review 
Kewalramani et al., 2010). 
2.3 Mitochondrial production of reactive oxygen species and cell consequences 
During the electron transfer through the respiratory chain, a small percentage of electrons 
may prematurely reduce oxygen, forming reactive oxygen species (ROS) such as superoxide 
anion radicals (O2-).  It was demonstrated that the main sites of ROS production are located 
at complexes I and III, the iron-sulphur centers of complex I being potentially the most 
important ROS generators (Barja, 1999). ROS are generated either from “normal” electron 
transfer after oxidation of substrates of complex I and complex II, but also from “reversed” 
electron transfer from complex II towards complex I (Liu et al., 2002). The latter situation is 
suggested to be the most physiologically relevant ROS production in mammals (Miwa & 
Brand, 2003). Recent work from Seifert et al. (2010) showed that LCFA β-oxidation is 
associated with enhanced ROS production, through a mechanism involving complex III, the 
electron transfer flavoprotein (ETF) and ETF-oxidoreductase.  
As reviewed by Murphy (2009), the rate of ROS production is mainly determined by the 
membrane potential, the ratio between NADH and NAD+, the ratio between CoQH2 and 
CoQ and the local O2 concentration. It is well established that there is a strong positive 
correlation between membrane potential and ROS production. Small increase in membrane 
potential has been associated to a large stimulation of ROS production (Korshunov et al., 
1997). Similarly, a small decrease in membrane potential deeply reduces ROS production 
(Votyakova & Reynolds, 2001). Therefore mild uncoupling resulting from a small decrease 
in membrane potential is considered as a natural antioxidant process (Seifert et al., 2010; 
Skulachev, 1997). However, not all sites of ROS production are sensitive to membrane 
potential. Indeed, Seifert et al. (2010) found that the ROS produced during LCFA β-
oxidation and involving complex III, ETF and ETF-oxidoreductase, was relatively 
insensitive to membrane potential changes. In addition, Miwa and Brand reported that the 
ROS produced at the cytosolic side of complex I through glycerol-3-phosphate 
dehydrogenase, which donates electrons to the electron carrier Q, is insensitive to 
membrane potential (2003). By contrast, ROS production from complex I following reverse 
electron flow is highly sensitive to membrane potential. Mild uncoupling is based on a 
proton leak across the inner membrane. It is mediated by thyroid hormones, LCFAs, 
complex IV slipping but most importantly by the activity of the uncoupling proteins UCP2 
and UCP3, although molecular mechanism are still not well understood (for review see 
Murphy, 2009; Schrauwen & Hesselink, 2002; Bezaire et al., 2007). Whereas overexpression 
of UCP in skeletal muscle has been shown to prevent diet-induced obesity and insulin 
resistance in mice (Li et al., 2000), their specific involvement in mitochondrial functioning 
and muscle metabolism in obesity and type 2 diabetes is still under debate in humans 
(Krook et al., 1998; Bao et al., 1998; Samec et al., 1999). 
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Spontaneously or by the action of superoxide dismutase (SOD), O2- dismutates into 
hydrogen peroxide H2O2, which is more stable and can diffuse through biological 
membranes. H2O2 has been shown to inhibit TCA cycle oxidative enzymes (alpha-
ketoglutarate dehydrogenase, succinate dehydrogenase, aconitase) and complex II (Moser et 
al., 2009; Nulton-Persson & Szweda, 2001). It is an important signal molecule, regulating 
major redox signalling pathways (for review see Leloup et al., 2011). It can also react to form 
hydroxyl radical or peroxynitrite, which are both highly damaging. In that context, 
oxidative stress can occur due to the accumulation of oxidative damages within DNA, 
protein and lipid components of the organelle. This may contribute to the decline in 
mitochondrial function and lead in turn to enhanced ROS generation. This vicious circle has 
been involved in many pathologies and the aging process. It is however questioned in the 
aetiology of insulin resistance in obesity and type 2 diabetes because reduced mitochondrial 
ROS production has been reported in those latter situations (Abdul-Ghani et al., 2009; 
Chanseaume & Morio, 2009). Because mitochondrial dysfunction in type 2 diabetes has been 
related to oxidative stress (Bonnard et al., 2008), other cellular sites of ROS production are 
potentially involved. 
2.4 Mitochondrial calcium storage and cellular consequences 
Mitochondrial calcium uptake has been first described in the early 1960s (Deluca & 
Engstrom, 1961; Vasington & Murphy, 1962). Since then it has been recognized that 
mitochondria are able to store amount of calcium bound to phosphate within their matrix 
large (review in Nicholls & Chalmers, 2004). Differential regulation of mitochondrial Ca2+ 
uptake and release are presented by Hoppe (2010). Calcium taken up by the mitochondria 
regulates mitochondrial functioning in response to a variety of extracellular stimuli 
(Jouaville et al., 1999; Territo et al., 2000). It activates three dehydrogenases of the TCA 
cycle, pyruvate dehydrogenase, isocitrate dehydrogenase, and -keto glutarate 
dehydrogenase (63). It may also regulate the ETC, the F0F1ATP synthase and ANT 
(McCormack et al., 1990). This induces an increased substrate uptake by mitochondria, 
enhanced mitochondrial NADH/NAD+ ratio and increased ATP production. The high 
capacity to accumulate calcium confer to mitochondria a key role in the regulation of 
intracellular calcium signalling (Gunter KK & Gunter TE, 1994; Rizzuto et al., 1998), which 
includes regulation of gene expression (including those involved in mitochondrial 
biogenesis and glucose uptake), cell functioning, control of protein trafficking between 
compartments, and processes linked to the suffering and eventual demise of cells (for 
review see Lukyanenko et al., 2009). 
2.5 Mitochondrial involvement in cell apoptosis  
Mitochondria are closely involved in the induction of apoptosis. Indeed, the intermembrane 
space contains several pro-apoptotic proteins which can lead to cell death upon release into 
the cytosol. Mitochondrial dysfunctions precede and are required for the initiation of the 
mitochondrial apoptosis pathway (for review see Marzetti et al., 2010). As previously 
mentioned, subsarcolemmal and intermyofibrillar mitochondria display different 
susceptibility towards apoptotic stimuli (Adhihetty et al., 2005). Mitochondria may therefore 





dysfunction (Coll et al., 2006), oxidative stress (Montuschi et al., 2004) and apoptosis (Slawik 
& Vidal-Puig, 2006). Whereas mechanisms linking those LCFA metabolites to insulin 
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capacity in the regulation of their synthesis rates is still controversial (Rimbert et al., 2004, 
2009). These arguments suggest that more complex interactions exist between LCFA 
availability and cell metabolism, and determine the intracellular fates of LCFAs (for review 
Kewalramani et al., 2010). 
2.3 Mitochondrial production of reactive oxygen species and cell consequences 
During the electron transfer through the respiratory chain, a small percentage of electrons 
may prematurely reduce oxygen, forming reactive oxygen species (ROS) such as superoxide 
anion radicals (O2-).  It was demonstrated that the main sites of ROS production are located 
at complexes I and III, the iron-sulphur centers of complex I being potentially the most 
important ROS generators (Barja, 1999). ROS are generated either from “normal” electron 
transfer after oxidation of substrates of complex I and complex II, but also from “reversed” 
electron transfer from complex II towards complex I (Liu et al., 2002). The latter situation is 
suggested to be the most physiologically relevant ROS production in mammals (Miwa & 
Brand, 2003). Recent work from Seifert et al. (2010) showed that LCFA β-oxidation is 
associated with enhanced ROS production, through a mechanism involving complex III, the 
electron transfer flavoprotein (ETF) and ETF-oxidoreductase.  
As reviewed by Murphy (2009), the rate of ROS production is mainly determined by the 
membrane potential, the ratio between NADH and NAD+, the ratio between CoQH2 and 
CoQ and the local O2 concentration. It is well established that there is a strong positive 
correlation between membrane potential and ROS production. Small increase in membrane 
potential has been associated to a large stimulation of ROS production (Korshunov et al., 
1997). Similarly, a small decrease in membrane potential deeply reduces ROS production 
(Votyakova & Reynolds, 2001). Therefore mild uncoupling resulting from a small decrease 
in membrane potential is considered as a natural antioxidant process (Seifert et al., 2010; 
Skulachev, 1997). However, not all sites of ROS production are sensitive to membrane 
potential. Indeed, Seifert et al. (2010) found that the ROS produced during LCFA β-
oxidation and involving complex III, ETF and ETF-oxidoreductase, was relatively 
insensitive to membrane potential changes. In addition, Miwa and Brand reported that the 
ROS produced at the cytosolic side of complex I through glycerol-3-phosphate 
dehydrogenase, which donates electrons to the electron carrier Q, is insensitive to 
membrane potential (2003). By contrast, ROS production from complex I following reverse 
electron flow is highly sensitive to membrane potential. Mild uncoupling is based on a 
proton leak across the inner membrane. It is mediated by thyroid hormones, LCFAs, 
complex IV slipping but most importantly by the activity of the uncoupling proteins UCP2 
and UCP3, although molecular mechanism are still not well understood (for review see 
Murphy, 2009; Schrauwen & Hesselink, 2002; Bezaire et al., 2007). Whereas overexpression 
of UCP in skeletal muscle has been shown to prevent diet-induced obesity and insulin 
resistance in mice (Li et al., 2000), their specific involvement in mitochondrial functioning 
and muscle metabolism in obesity and type 2 diabetes is still under debate in humans 
(Krook et al., 1998; Bao et al., 1998; Samec et al., 1999). 
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Spontaneously or by the action of superoxide dismutase (SOD), O2- dismutates into 
hydrogen peroxide H2O2, which is more stable and can diffuse through biological 
membranes. H2O2 has been shown to inhibit TCA cycle oxidative enzymes (alpha-
ketoglutarate dehydrogenase, succinate dehydrogenase, aconitase) and complex II (Moser et 
al., 2009; Nulton-Persson & Szweda, 2001). It is an important signal molecule, regulating 
major redox signalling pathways (for review see Leloup et al., 2011). It can also react to form 
hydroxyl radical or peroxynitrite, which are both highly damaging. In that context, 
oxidative stress can occur due to the accumulation of oxidative damages within DNA, 
protein and lipid components of the organelle. This may contribute to the decline in 
mitochondrial function and lead in turn to enhanced ROS generation. This vicious circle has 
been involved in many pathologies and the aging process. It is however questioned in the 
aetiology of insulin resistance in obesity and type 2 diabetes because reduced mitochondrial 
ROS production has been reported in those latter situations (Abdul-Ghani et al., 2009; 
Chanseaume & Morio, 2009). Because mitochondrial dysfunction in type 2 diabetes has been 
related to oxidative stress (Bonnard et al., 2008), other cellular sites of ROS production are 
potentially involved. 
2.4 Mitochondrial calcium storage and cellular consequences 
Mitochondrial calcium uptake has been first described in the early 1960s (Deluca & 
Engstrom, 1961; Vasington & Murphy, 1962). Since then it has been recognized that 
mitochondria are able to store amount of calcium bound to phosphate within their matrix 
large (review in Nicholls & Chalmers, 2004). Differential regulation of mitochondrial Ca2+ 
uptake and release are presented by Hoppe (2010). Calcium taken up by the mitochondria 
regulates mitochondrial functioning in response to a variety of extracellular stimuli 
(Jouaville et al., 1999; Territo et al., 2000). It activates three dehydrogenases of the TCA 
cycle, pyruvate dehydrogenase, isocitrate dehydrogenase, and -keto glutarate 
dehydrogenase (63). It may also regulate the ETC, the F0F1ATP synthase and ANT 
(McCormack et al., 1990). This induces an increased substrate uptake by mitochondria, 
enhanced mitochondrial NADH/NAD+ ratio and increased ATP production. The high 
capacity to accumulate calcium confer to mitochondria a key role in the regulation of 
intracellular calcium signalling (Gunter KK & Gunter TE, 1994; Rizzuto et al., 1998), which 
includes regulation of gene expression (including those involved in mitochondrial 
biogenesis and glucose uptake), cell functioning, control of protein trafficking between 
compartments, and processes linked to the suffering and eventual demise of cells (for 
review see Lukyanenko et al., 2009). 
2.5 Mitochondrial involvement in cell apoptosis  
Mitochondria are closely involved in the induction of apoptosis. Indeed, the intermembrane 
space contains several pro-apoptotic proteins which can lead to cell death upon release into 
the cytosol. Mitochondrial dysfunctions precede and are required for the initiation of the 
mitochondrial apoptosis pathway (for review see Marzetti et al., 2010). As previously 
mentioned, subsarcolemmal and intermyofibrillar mitochondria display different 
susceptibility towards apoptotic stimuli (Adhihetty et al., 2005). Mitochondria may therefore 





response to short-term immobilisation in ageing individuals (Kim  et al., 2010; Magne et al., 
2011). 
3. Transcriptional regulation of mitochondrial oxidative capacity – interaction 
with fusion-fission dynamics 
A number of transcriptional modulators have been implicated in the regulation of muscle 
mitochondrial biogenesis and OXPHOS activity (figure 3, see also for review Puigserver & 
Spiegelman, 2003; Chanseaume & Morio, 2009). They include PPAR gamma coactivator 1 
alpha (PGC-1), in cooperation with several factors such as PGC-1β, the peroxisome 
proliferator-activated receptors (PPAR), the estrogen-related receptor- (ERR), the nuclear 
respiratory factors 1 and 2 (NRF-1 and NRF-2) (Fredenrich & Grimaldi, 2004; Patti et al., 
2003; Sparks et al., 2005; Tanaka et al., 2003), or the specificity protein 1 (Sp1), an ubiquitous 
transcription factor known to regulate the constitutive expression of oxidative OXPHOS 
genes (Zaid et al., 1999). Sp1 can function as both a positive (e.g. cytochrome c1 and 
mitochondrial transcription factor A, TFAM) and a negative (e.g. ANT2 and F1-ATPase beta 
subunit) regulator of transcription (Yang et al., 2001). 
PPAR and PPAR are involved in the regulation of mitochondrial LCFA oxidative 
capacity. When bound to their ligands (e.g. LCFA), PPARs form a heterodimeric complex 
with the retinoid X receptor (RXR) to regulate gene transcription involved in LCFA 
metabolism. Muscle-specific overexpression of PPAR in mice was shown to increase 
oxidative enzyme activities such as citrate synthase or -hydroxyacyl-CoA dehydrogenase, 
and to enhance expression of genes implicated in fatty acid catabolism (Luquet et al., 2003). 
PGC-1 and PGC-1β, but most importantly PGC-1, are master modulators of gene 
expression in skeletal muscle (Moyes, 2003). PGC-1β has been shown to drive the formation 
of highly oxidative fibers containing type IIX myosin heavy chain (Arany et al., 2007). By 
contrast, PGC-1 was found to drive the formation of oxidative type I fibres (Lin et al., 
2002). In muscle cells, overexpression of PGC-1 was shown to induce the gene expression 
of NRF-1, NRF-2, TFAM and to activate the expression of genes involved in mitochondrial 
oxidative capacity (Chabi et al., 2005). PGC-1 gene expression is potently regulated by 
CREB (cAMP response element-binding protein) binding protein (TORC) 1, a coactivator of 
CREB (Wu et al., 2006), and by the sirtuin SIRT1 (Amat et al., 2009). Its activity is increased 
when phosphorylated by p38 stress-activated MAPK (Puigserver et al., 2001) and when 
deacylated by SIRT1 (Lagouge et al., 2006). Coactivation of ERR and PPARs by PGC-1 
and PGC-1β has been proposed as the major regulatory pathway involved in the control of 
mitochondrial oxidative capacity (Puigserver & Spiegelman, 2003; Arany et al., 2007; 
Soriano et al., 2006). For these reasons, alterations in PGC-1, and to a lesser extent PGC-1β, 
activity are considered the primary contributors to decreased mitochondrial oxidative 
capacity in metabolic disorders. Potential intrinsic mechanisms responsible of alterations in 
mitochondrial biogenesis are reviewed in Chanseaume et al. (2009). 
Finally and complementary to mitochondrial biogenesis, recent evidences have 
demonstrated that the dynamics of mitochondrial network is strongly involved in the 
control of mitochondrial functioning. It is determined by the balance between fusion and 
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fission events which are govern by mitochondrial proteins such as mitofusin 1 and 2 (Mnf1, 
Mnf2) and OPA1 for fusion, and dynamin-related protein (DRP1) for fission. Importantly, 
Mfn2, which gene expression is regulated by PGC-1 and PGC-1β (Pich et al., 2005; Soriano 
et al., 2006), stimulates respiration, substrate oxidation and OXPHOS subunits expression 
(Pich et al., 2005). Zorzano et al. (2009) therefore hypothesized that these mitochondrial 
dynamics proteins play a key role in mitochondrial dysfunction in obesity or in type 2 
diabetes and may participate in the development of insulin resistance. This concept is 
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Fig. 3. Major coactivators and transcription factors involved in the regulation of muscle 
mitochondrial oxidative and phosphorylation (OXPHOS) activity. Non exhaustive key 
genes, whose expression is regulated by the transcription factors, are given for example. 
4. Measurement of muscle mitochondrial OXPHOS activity on muscle biopsy 
samples 
Changes in mitochondrial functioning can be assessed using a battery of biochemical 
analyses that can often be applied to whole tissue, cells or isolated organelles. These 
techniques are essential for elucidating intrinsic mechanisms responsible for mitochondrial 
dysfunctions. However most frequently, they inform about the maximal activity of key 
enzymes or pathways. In addition, they are limited to the conditions used for the 
measurements, for example the substrates used to feed the ETC. Therefore, care should be 
always taken in extrapolating ex vivo observations to the in vivo situations and 
generalization should be avoided. 
4.1 Samples preparation 
Because unfreezing muscle samples brakes mitochondrial structure and alters their 
functionality, most measurements have to be performed on fresh samples. It is possible to 
maintain the tissue intact during several hours by using a preservation solution at 4°C  until 
mitochondrial isolation or skinned fiber preparation. Depending on the information 
required, mitochondrial functioning can be assessed either on isolated organelles or on 
whole tissue. The latter solution means that one works on tissue homogenates or using the 





response to short-term immobilisation in ageing individuals (Kim  et al., 2010; Magne et al., 
2011). 
3. Transcriptional regulation of mitochondrial oxidative capacity – interaction 
with fusion-fission dynamics 
A number of transcriptional modulators have been implicated in the regulation of muscle 
mitochondrial biogenesis and OXPHOS activity (figure 3, see also for review Puigserver & 
Spiegelman, 2003; Chanseaume & Morio, 2009). They include PPAR gamma coactivator 1 
alpha (PGC-1), in cooperation with several factors such as PGC-1β, the peroxisome 
proliferator-activated receptors (PPAR), the estrogen-related receptor- (ERR), the nuclear 
respiratory factors 1 and 2 (NRF-1 and NRF-2) (Fredenrich & Grimaldi, 2004; Patti et al., 
2003; Sparks et al., 2005; Tanaka et al., 2003), or the specificity protein 1 (Sp1), an ubiquitous 
transcription factor known to regulate the constitutive expression of oxidative OXPHOS 
genes (Zaid et al., 1999). Sp1 can function as both a positive (e.g. cytochrome c1 and 
mitochondrial transcription factor A, TFAM) and a negative (e.g. ANT2 and F1-ATPase beta 
subunit) regulator of transcription (Yang et al., 2001). 
PPAR and PPAR are involved in the regulation of mitochondrial LCFA oxidative 
capacity. When bound to their ligands (e.g. LCFA), PPARs form a heterodimeric complex 
with the retinoid X receptor (RXR) to regulate gene transcription involved in LCFA 
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expression in skeletal muscle (Moyes, 2003). PGC-1β has been shown to drive the formation 
of highly oxidative fibers containing type IIX myosin heavy chain (Arany et al., 2007). By 
contrast, PGC-1 was found to drive the formation of oxidative type I fibres (Lin et al., 
2002). In muscle cells, overexpression of PGC-1 was shown to induce the gene expression 
of NRF-1, NRF-2, TFAM and to activate the expression of genes involved in mitochondrial 
oxidative capacity (Chabi et al., 2005). PGC-1 gene expression is potently regulated by 
CREB (cAMP response element-binding protein) binding protein (TORC) 1, a coactivator of 
CREB (Wu et al., 2006), and by the sirtuin SIRT1 (Amat et al., 2009). Its activity is increased 
when phosphorylated by p38 stress-activated MAPK (Puigserver et al., 2001) and when 
deacylated by SIRT1 (Lagouge et al., 2006). Coactivation of ERR and PPARs by PGC-1 
and PGC-1β has been proposed as the major regulatory pathway involved in the control of 
mitochondrial oxidative capacity (Puigserver & Spiegelman, 2003; Arany et al., 2007; 
Soriano et al., 2006). For these reasons, alterations in PGC-1, and to a lesser extent PGC-1β, 
activity are considered the primary contributors to decreased mitochondrial oxidative 
capacity in metabolic disorders. Potential intrinsic mechanisms responsible of alterations in 
mitochondrial biogenesis are reviewed in Chanseaume et al. (2009). 
Finally and complementary to mitochondrial biogenesis, recent evidences have 
demonstrated that the dynamics of mitochondrial network is strongly involved in the 
control of mitochondrial functioning. It is determined by the balance between fusion and 
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fission events which are govern by mitochondrial proteins such as mitofusin 1 and 2 (Mnf1, 
Mnf2) and OPA1 for fusion, and dynamin-related protein (DRP1) for fission. Importantly, 
Mfn2, which gene expression is regulated by PGC-1 and PGC-1β (Pich et al., 2005; Soriano 
et al., 2006), stimulates respiration, substrate oxidation and OXPHOS subunits expression 
(Pich et al., 2005). Zorzano et al. (2009) therefore hypothesized that these mitochondrial 
dynamics proteins play a key role in mitochondrial dysfunction in obesity or in type 2 
diabetes and may participate in the development of insulin resistance. This concept is 
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Fig. 3. Major coactivators and transcription factors involved in the regulation of muscle 
mitochondrial oxidative and phosphorylation (OXPHOS) activity. Non exhaustive key 
genes, whose expression is regulated by the transcription factors, are given for example. 
4. Measurement of muscle mitochondrial OXPHOS activity on muscle biopsy 
samples 
Changes in mitochondrial functioning can be assessed using a battery of biochemical 
analyses that can often be applied to whole tissue, cells or isolated organelles. These 
techniques are essential for elucidating intrinsic mechanisms responsible for mitochondrial 
dysfunctions. However most frequently, they inform about the maximal activity of key 
enzymes or pathways. In addition, they are limited to the conditions used for the 
measurements, for example the substrates used to feed the ETC. Therefore, care should be 
always taken in extrapolating ex vivo observations to the in vivo situations and 
generalization should be avoided. 
4.1 Samples preparation 
Because unfreezing muscle samples brakes mitochondrial structure and alters their 
functionality, most measurements have to be performed on fresh samples. It is possible to 
maintain the tissue intact during several hours by using a preservation solution at 4°C  until 
mitochondrial isolation or skinned fiber preparation. Depending on the information 
required, mitochondrial functioning can be assessed either on isolated organelles or on 
whole tissue. The latter solution means that one works on tissue homogenates or using the 





from at least 80mg of homogenized muscles (Palmer et al., 1977; Capel et al., 2004; 
supplementary material). This approach is dedicated to the exploration of the organelle 
intrinsic functioning. Although contaminated by lysosomes, peroxisomes, tubular Golgi 
membranes, and small amounts of endoplasmic reticulum, the obtained fraction is suitable 
for respiratory studies (96). Further purification is possible, for example, with Percoll 
gradients as described by Mickelson et al. (1980) and Graham (2001). Mitochondrial integrity 
can be monitored by measuring citrate synthase activity before and after freeze–thaw 
membrane disruption and Triton X-100 addition (Stump et al., 2003). Similarly, 
mitochondrial purity can be assessed by assessing marker enzymes for lysosomes (β-
galactosidase) and peroxisomes (catalase) as discussed by Graham (2001). 
By contrast, although evaluated ex-vivo, permeabilized fibers take into account both the 
intrinsic functioning of mitochondria and the cellular content in mitochondria. Of note, 
skinned fibers require less muscle sample than the isolation procedure. Fifteen to 20 mg of 
fresh muscle sample is sufficient for one preparation of saponin-skinned muscle fibers. 
Briefly as described by Saks et al. (1998), fiber bundles are mechanically separated with 
tongs and permeabilized with saponin on ice. Bundles are then washed to remove ADP, 
phosphocreatine, soluble enzymes and metabolites. All steps are critical for obtaining clean 
skinned fibers for accurately measuring mitochondrial OXPHOS activity and coupling. The 
time of incubation with saponin depends on the cell type and the animal model. This 
technique requires therefore a well-trained investigator to assure accurate and repeatable 
measurements. Novices should follow at the beginning the association between the degree 
of mechanical separation, time of incubation with saponin and percentage of cells 
permeabilized and/or respirometric responses. Overpermeabilization should be avoided. 
The degree of permeabilization can be checked using toluidine blue under optic microscopy. 
Mitochondrial outer membrane integrity can be also verified during respirometry 
measurements by checking that addition of cytochrome c had no effect on oxygen 
consumption.  
4.2 Evaluation of mitochondrial density 
Mitochondrial density, as well as location, shape and structural integrity, can be reliably 
assessed using transmission electron microscopy. For that purpose, muscle samples are 
dissected free of adipose and connective tissue, cut into small pieces (1x1x2mm) and fixed.  
Transverse sections of 8µm are cut using a cryostat and mounted on slides. Images of 10 
random and independent transverse sections of muscle fibers at 36,000 X must be 
considered. Mitochondrial cross-sectional area (size) and mitochondrial volume density (the 
fraction of cell volume occupied by mitochondria) are measured by digital imaging 
morphometry and stereological principles of point sampling, in a blind fashion (Weibel, 
1979; Gundersen et al., 1988).  
Maximal activity of citrate synthase has been often used as an index of mitochondrial 
density. This measure is performed on whole tissue homogenates. However, citrate 
synthase activity can be altered in some physiological situations independently of changes 
in mitochondrial density. For example, it is well known that aging is associated to a decrease 
in citrate synthase activity whereas other mitochondrial oxidative enzyme activities are 
unaltered (Rimbert et al., 2004). 
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Recently the number of mitochondrial DNA (mtDNA) copy has been considered to reflect 
mitochondrial content (Wiesner et al., 1992; Barrientos, 2002), the ratio between mtDNA and 
nuclear DNA has been proposed as a reliable index of mitochondrial density. For that 
purpose, mitochondrial and nuclear DNAs are extracted during the standard procedure of 
RNA extraction as described in Chanseaume et al. (2010) and in supplementary material. 
Purified DNA is ready for  quantitative real-time PCR analysis of nuclear and mitochondrial 
DNA content using primer pairs specific for nuclear (β-actin or myogenin promoter) and 
mitochondrial (NADH dehydrogenase 1 (ND1), ND2, cytochrome B or cytochrome c 
oxidase 1 (COX1)) genes (Stump et al., 2003; Petersen et al., 2005; Chanseaume et al., 2010). 
4.3 Assessment of maximal activity of key oxidative enzymes 
This technique allows the use of frozen samples, either whole tissues, homogenates or 
isolated organelles. Frozen samples should be kept at -80°C for better preservation of the 
enzymes integrity. It assesses the maximal activity of the enzyme catalytic site. For that 
purpose, optimal concentrations in substrates are used to stimulate the enzyme activity. 
Catalytic activity is determined mostly using spectrophotometry on sample homogenates 
prepared in sucrose, EDTA Tris-HCl buffer (supplementary material)). For example, complex I 
activity is assessed measuring NADH oxidation at 340nm. Similarly, complex IV activity is 
performed at 550nm following the oxidation of reduced cytochrome c. Enzyme activities are 
often expressed per mg of mitochondrial protein but a most relevant normalisation should be 
citrate synthase activity or, because of the reason exposed in the previous paragraph, mtDNA 
content. Methods for measuring the separate activity of all ETC complexes as well as citrate 
synthase activity are extensively described by Barrientos (2002). 
Finally, one can also consider the maximal activity of β-hydroxyacyl-CoA dehydrogenase as 
a fair index of the beta-oxidation pathway. The assay has been established by Bass et al. 
(1969). Its principle is based on the disappearance of NADH following reduction of 
acetoacetyl-CoA to ß-Hydroxybutyryl-CoA (supplementary material). 
4.4 Measurement of fatty acid oxidative capacity 
Whole muscle LCFA oxidative capacity can be easily determined on fresh muscle 
homogenates. This technique described by Veerkamp et al. (1983), informs on the maximal 
ability of muscle tissue to oxidize a specific LCFA. Using two distinct preparations, one can 
separate peroxisomal from mitochondrial beta-oxidation activities. Of note, our personnal 
data repeatedly showed that the peroxisomal contribution to whole tissue LCFA oxidative 
capacity averages 10-14%, in humans as well as in rodents. 
This technique uses a radiolabelled [1 or U-14C] fatty acid (such as oleate or palmitate for the 
most commons) bound to albumin at the ratio 4.5:1 (Morio et al., 2001; Rimbert et al., 2004; 
Tardy et al., 2008). A detailed procedure is provided in supplementary materials. Briefly, total 
LCFA oxidation is measured using sealed vials containing an aliquot of muscle homogenate in 
the presence of ATP, NAD+, coenzyme A, L-carnitine, L-malate and cytochrome c. 
Peroxisomal LCFA oxidation is determined in the presence of mitochondrial oxidation 
inhibitors (rotenone and antimycin A), but in the absence of  L-carnitine and L-malate . 
CPT-1 is the key enzyme regulating muscle fatty acid oxidative capacity. It is allosterically 
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palmitoyl-carnitine produced from palmitoyl-CoA and carnitine as described by Kim et al. 
(2000) and is presented in supplementary materials. CPT-1 activity is measured on freshly 
isolated mitochondria. It allows assessment of maximal CPT-1 activity as well as its 
sensitivity to malonyl-CoA inhibition (IC50). Although rarely used, CPT-1 maximal activity 
can be also assessed from fresh whole muscle homogenates using modification of the above 
mentioned method ( Rimbert et al., 2004). Alternatively, the affinity of mitochondria for 
palmitoylcarnitine could be assessed using isolated muscle fibers (Ponsot et al., 2005). 
4.5 Measurement of mitochondrial respiration 
Table 2 summarizes the main substrates used to assess mitochondrial oxidative capacity on 
isolated organelles or skinned fibers. It also presents the inhibitors required for additional 
investigation of mitochondrial intrinsic functioning and for measuring state 4 respiration 
rate. Isolated mitochondria or skinned fiber respiration rates are usually measured at 25°C 
using an oxygraph system. Higher temperatures, e.g. 30 or 37°C, can be used. This enhances 
the respiratory rate. Respiration is assayed on 0.25 mg/mL of mitochondrial proteins or 0.5-





































Table 2. Substrates, inhibitors and uncouplers used in the polarographic experiments. 
Concentrations within brackets are indicative. * used in the presence of rotenone (2 µM); DPI, 
diphenyliodonium chloride; TTFA, Thenoyltrifluoacetone; TMPD, N,N,N’,N’-tetramethyl-p-
phenylenediamine; KCN, potassium cyanide; FCCP, carbonyl cyanide p-
(trifluoromethoxyl)phenylhydrazone. 
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State 2 (non-phosphorylating) respiration is measured in the presence of respiratory 
substrates without ADP. State 3 (phosphorylated) respiration is measured after the addition 
of of ADP, saturating concentration leading to maximal ADP-stimulated respiration being 1 
mM (Gueguen et al., 2005). A replicate experiment can be done to evaluate uncoupled 
respiratory rate in the presence of an uncoupler such as carbonylcyanide p-
(trifluoromethoxy)phenylhydrazone (FCCP). State 4 respiration is assayed after addition of 
oligomycin B, an inhibitor of ATP synthase, or after addition of atractyloside, a potent 
inhibitor of ANT. This measure validates the quality of fiber preparation (notably complete 
removal of free ADP during washing) if respiration returns to state 2. However, inhibiting 
ANT may improve the OXPHOS coupling since ANT may be responsible for basal and 
LCFA-induced uncoupling ( Di Paola & Lorusso, 2006). Respiratory control rate is evaluated 
by dividing state 3 by state 4 rates. Respiration rates are expressed as natom (nat) 
O/min/µg protein for isolated mitochondria or natom (nat) O/min/mg dried (24 h at 
110°C) fibers  for skinned fibers. 
When differential regulation of respiration by ADP and mitochondrial kinases (creatine 
kinase, AK2) is of interest, titration protocols with increasing concentration in ADP (from 0.1 
to 1 mM) should be performed in the presence or not of 20 mM creatine (creatine kinase 
activation), or 10 mM glucose (hexokinase activation), 1 mM AMP (AK2 activation), 10 µM 
Ap5A (AK2 inhibition) (Gueguen et al., 2005). The functional coupling of miCK to energy 
production could be determined, calculating the affinity for ADP using a combined protocol 
on permeabilized fibers (N'Guessan et al., 2004). 
4.6 Measurement of mitochondrial ATP production 
ATP synthase (ATPase) activity is assayed on freshly isolated mitochondria. Maximal activity 
is measured spectrophotometrically by monitoring the increase in absorbance at 340 nm 
using a NADP-linked ADP-regenerating system. Mitochondria are added to the reaction 
buffer in the presence of glucose, AMP, NADP, ADP, hexokinase, and glucose-6-P 
dehydrogenase (see supplementary materials) and the reaction is followed at room 
temperature (Rustin et al., 1994). Similarly, it can also be assessed using a coupled assay 
between lactate dehydrogenase and pyruvate kinase, NADH reduction being checked at 340 
nm (Rustin et al., 1994). 
ATP production can be directly measured using bioluminescence kit assay by incubating 
isolated mitochondria with various substrates of the ETC (Table 2). Blank tubes are used for 
measuring background and all reactions for a given sample are monitored simultaneously 
and calibrated with addition of an ATP standard. Mitochondrial ATP production is 
calculated from the area under the curve (Wibom & Hultman, 1990). 
Finally, mitochondrial ATP production can be measured kinetically in parallel with 
respiration (on isolated mitochondria or permeabilized fibers) as described by Ouhabi et al. 
(1998). After ADP is added, five 10µl samples are taken every 15 sec in the oxygraph 
chamber, and frozen in 100µl DMSO before ATP is assayed using a bioluminescence assay 
kit. ATP production rate is expressed as nmol/min/mg dried fibers. ATP/O is calculated to 
evaluate coupling of ATP production to ADP-stimulated oxygen consumption (state 3 in 





palmitoyl-carnitine produced from palmitoyl-CoA and carnitine as described by Kim et al. 
(2000) and is presented in supplementary materials. CPT-1 activity is measured on freshly 
isolated mitochondria. It allows assessment of maximal CPT-1 activity as well as its 
sensitivity to malonyl-CoA inhibition (IC50). Although rarely used, CPT-1 maximal activity 
can be also assessed from fresh whole muscle homogenates using modification of the above 
mentioned method ( Rimbert et al., 2004). Alternatively, the affinity of mitochondria for 
palmitoylcarnitine could be assessed using isolated muscle fibers (Ponsot et al., 2005). 
4.5 Measurement of mitochondrial respiration 
Table 2 summarizes the main substrates used to assess mitochondrial oxidative capacity on 
isolated organelles or skinned fibers. It also presents the inhibitors required for additional 
investigation of mitochondrial intrinsic functioning and for measuring state 4 respiration 
rate. Isolated mitochondria or skinned fiber respiration rates are usually measured at 25°C 
using an oxygraph system. Higher temperatures, e.g. 30 or 37°C, can be used. This enhances 
the respiratory rate. Respiration is assayed on 0.25 mg/mL of mitochondrial proteins or 0.5-





































Table 2. Substrates, inhibitors and uncouplers used in the polarographic experiments. 
Concentrations within brackets are indicative. * used in the presence of rotenone (2 µM); DPI, 
diphenyliodonium chloride; TTFA, Thenoyltrifluoacetone; TMPD, N,N,N’,N’-tetramethyl-p-
phenylenediamine; KCN, potassium cyanide; FCCP, carbonyl cyanide p-
(trifluoromethoxyl)phenylhydrazone. 
 
Evaluation of Mitochondrial Functions and Dysfunctions in Muscle Biopsy Samples 
 
97 
State 2 (non-phosphorylating) respiration is measured in the presence of respiratory 
substrates without ADP. State 3 (phosphorylated) respiration is measured after the addition 
of of ADP, saturating concentration leading to maximal ADP-stimulated respiration being 1 
mM (Gueguen et al., 2005). A replicate experiment can be done to evaluate uncoupled 
respiratory rate in the presence of an uncoupler such as carbonylcyanide p-
(trifluoromethoxy)phenylhydrazone (FCCP). State 4 respiration is assayed after addition of 
oligomycin B, an inhibitor of ATP synthase, or after addition of atractyloside, a potent 
inhibitor of ANT. This measure validates the quality of fiber preparation (notably complete 
removal of free ADP during washing) if respiration returns to state 2. However, inhibiting 
ANT may improve the OXPHOS coupling since ANT may be responsible for basal and 
LCFA-induced uncoupling ( Di Paola & Lorusso, 2006). Respiratory control rate is evaluated 
by dividing state 3 by state 4 rates. Respiration rates are expressed as natom (nat) 
O/min/µg protein for isolated mitochondria or natom (nat) O/min/mg dried (24 h at 
110°C) fibers  for skinned fibers. 
When differential regulation of respiration by ADP and mitochondrial kinases (creatine 
kinase, AK2) is of interest, titration protocols with increasing concentration in ADP (from 0.1 
to 1 mM) should be performed in the presence or not of 20 mM creatine (creatine kinase 
activation), or 10 mM glucose (hexokinase activation), 1 mM AMP (AK2 activation), 10 µM 
Ap5A (AK2 inhibition) (Gueguen et al., 2005). The functional coupling of miCK to energy 
production could be determined, calculating the affinity for ADP using a combined protocol 
on permeabilized fibers (N'Guessan et al., 2004). 
4.6 Measurement of mitochondrial ATP production 
ATP synthase (ATPase) activity is assayed on freshly isolated mitochondria. Maximal activity 
is measured spectrophotometrically by monitoring the increase in absorbance at 340 nm 
using a NADP-linked ADP-regenerating system. Mitochondria are added to the reaction 
buffer in the presence of glucose, AMP, NADP, ADP, hexokinase, and glucose-6-P 
dehydrogenase (see supplementary materials) and the reaction is followed at room 
temperature (Rustin et al., 1994). Similarly, it can also be assessed using a coupled assay 
between lactate dehydrogenase and pyruvate kinase, NADH reduction being checked at 340 
nm (Rustin et al., 1994). 
ATP production can be directly measured using bioluminescence kit assay by incubating 
isolated mitochondria with various substrates of the ETC (Table 2). Blank tubes are used for 
measuring background and all reactions for a given sample are monitored simultaneously 
and calibrated with addition of an ATP standard. Mitochondrial ATP production is 
calculated from the area under the curve (Wibom & Hultman, 1990). 
Finally, mitochondrial ATP production can be measured kinetically in parallel with 
respiration (on isolated mitochondria or permeabilized fibers) as described by Ouhabi et al. 
(1998). After ADP is added, five 10µl samples are taken every 15 sec in the oxygraph 
chamber, and frozen in 100µl DMSO before ATP is assayed using a bioluminescence assay 
kit. ATP production rate is expressed as nmol/min/mg dried fibers. ATP/O is calculated to 
evaluate coupling of ATP production to ADP-stimulated oxygen consumption (state 3 in 





4.7 Measurement of mitochondrial ROS production 
Using similar incubation conditions than described for respiration or ATP assays, 
superoxide anion (O2-) can be assessed on isolated mitochondria using the 
chemiluminescent probes 2-methyl-6-p methoxyphenylethynylimidazopyazinone (MPEC) 
(Nakai et al., 2004) or lucigenin (Bis-N-methylacridinium) (Li et al., 1999). Fluorescent 
sensitive probes such as hydroethidine, especially MitoSOXTM Red which targets the 
mitochondrial matrix, can also be used. Isolated permeabilized fibers were recently used for 
O2- generation measurement using the triphenylphosphonium Hydroethidine (TTP-HE) 
reporter (Xu et al., 2010). Signals were analyzed by micellar electrokinetic capillary 
chromatography coupled to fluorescence detection. 
O2- rapidly dismutates into H2O2 in the presence of mitochondrial SOD which considerably 
reduce its matrix level. Then the quantification of the more stable H2O2 can be assessed using 
luminol chemiluminescence (Li et al., 1999). H2O2 can be also measured using non-fluorescent 
dyes that become fluorescent upon enzymatic oxidation by H2O2 in the presence of 
horseradish peroxidase. The most commonly used dyes are homovanilic acid (Ruch et al., 
1983), 2',7'-dichlorfluorescein-diacetate (DCFH-DA) or Amplex® Red (Chen et al., 2003). 
Kinetic or global approaches are both adequate for calculating the rate of mitochondrial ROS 
production. Standard curve is obtained by adding known amounts of H2O2 to assay medium 
in the presence of the reactants. It is critical to quantify background fluorescence, in the 
absence of mitochondria. Net fluorescence is then calculated minus background and H2O2 
production is expressed in pmol/mg of protein/min. The heterogeneity of mitochondrial 
alteration during metabolic disorders could be studied on permeabilized fibers, characterizing 
the specificity of H2O2 production depending on myofiber type (Anderson et al., 2006). If 
oxygen consumption and ROS production were determined in similar experimental conditions 
on isolated mitochondria or permeabilized fibers, the free radical leak can be calculated as an 
indicator of the fraction of electron reducing oxygen to O2- (Sanz et al., 2005). It has been 
shown that this leakage was higher in glycolytic compared to oxidative fibers (Anderson et al., 
2006). More recently, new methods were developed to analyze local change in ROS generation 
on individual isolated fibers. Hence, ROS production could be analyzed by confocal imaging 
(Shkryl et al., 2009) or real time fluorescence microscopy (Palomero et al., 2008). Although 
more reliable than O2- quantification, the detection of H2O2 as an index of O2- production has 
also its limits, i.e., the reaction of O2- with other molecules (such as NO), the removal by 
matrix peroxidase and contamination by H2O2 produce within the intermembrane space (see 
(Murphy, 2009) as a more detailed review on this topic). 
4.8 Additional measurement of mitochondrial functionality 
Mitochondrial membrane potential can be determined simultaneously with oxygen consumption 
using the potential-dependent triphenylmethylphosphonium cation (TPMP+) probe as 
described by Kamo et al. (1979). Development of fluorescent probes sensitive to mitochondrial 
membrane potential has facilitated the investigation on isolated organelles as well as cells. The 
most commonly used dyes are rhodamine 123, its derivatives tetramethylrhodamine methyl 
and ethyl esters (TMRM and TMRE), 3,3'-dihexyloxacarbocyanine,iodide (DiOC6(3)) and 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolcarbocyanine iodide (JC-1). The latter has 
been proposed as the most reliable probe (Salvioli et al., 1997). Results are usually compared 
with those obtained in the presence of a mitochondrial uncoupler, such as FCCP, to attain 
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maximum depolarization. Membrane potential could also be determined using isolated 
permeabilized fibers in a multiwell plate (Xu et al., 2010). 
Calcium retention capacity of mitochondria and sensitivity of the permeability transition pore is 
evaluated on isolated mitochondria using the same incubation buffer and substrates than for 
respiration, except that 1 µM Calcium GreenTM-5N is added (Fontaine et al., 1998). Pulses of 
10 µM Ca2+ are added every minute until pore opening. Specificity of mitochondrial pore 
opening is assessed by adding cyclosporin A. Comparison between fiber types could be 
done in a similar approach using permeabilized fibers (Picard et al., 2008). 
4.9 Evaluation of mitochondrial biogenesis and fusion-fission dynamics 
Supported by steadily increasing literature data, changes in mitochondrial biogenesis and 
dynamics are relevant mechanisms potentially responsible for mitochondrial dysfunctions. 
PCR and western blotting analyses are pertinent techniques to investigate these pathways in 
human samples with limited size (20 to 30 mg). Major proteins potentially involved in these 
pathways have been described in the previous chapter “Transcriptional regulation of 
mitochondrial oxidative capacity – interaction with fusion-fission dynamics” and can be 
targeted using molecular tools. 
4.10 Investigation of the mitoproteome 
The recent development of genomic tools has considerably improved or knowledge of 
metabolic disorders within key metabolic tissues. Recently, a proteomic study of 
mitochondrial proteins (mitoproteome) reported that more than 80% of ETC proteins can be 
identified (Lefort et al., 2009). The authors were able to reliably detect proteins implicated in 
ROS generation, scavenging, FA oxidation and apoptosis. One hundred micrograms of 
human biopsie are required and allow a more than 7 fold enrichment in mitochondrial 
proteins with a classical isolation procedure as described for respirometry assay. Of note, 
30% of identified proteins from the whole tissue proteome are assigned to mitochondria (Yi 
et al., 2008). Further studies should aim to relate the metabolic disorders and modification of 
the mitoproteome in insulin sensitive and resistant subjects. This tool combined to 
transcriptomic analysis should provide key elements to distinguish between mitochondrial 
functioning defect and mitochondrial density variation during insulin resistance. 
5. Conclusions 
Exploring mitochondrial functioning in muscle samples, especially from human muscle 
biopsies, can be achieved using combination of strategies which require a minimal amount 
of 20mg of tissue for permeabilized fibers for one experimental condition (e.g. respirometry 
with one substrate), 30mg for molecular exploration and 30mg for an enzyme activity. The 
most tissue-consuming techniques are those based on isolated mitochondria, which 
necessitate at least 80mg of tissue for the extraction procedure. Once mitochondrial pellets 
are obtained, if further purification is not performed, combined and miniaturized methods 
allow assessing several parameters characterizing mitochondrial functioning (for example 
respiration, ATP and ROS production and enzyme activities). Hence, 150 to 200mg of tissue 
sample could be considered as a sufficient condition to build a complete investigation as 
presented in figure 4. These explorations are however limited in the number of substrates 





4.7 Measurement of mitochondrial ROS production 
Using similar incubation conditions than described for respiration or ATP assays, 
superoxide anion (O2-) can be assessed on isolated mitochondria using the 
chemiluminescent probes 2-methyl-6-p methoxyphenylethynylimidazopyazinone (MPEC) 
(Nakai et al., 2004) or lucigenin (Bis-N-methylacridinium) (Li et al., 1999). Fluorescent 
sensitive probes such as hydroethidine, especially MitoSOXTM Red which targets the 
mitochondrial matrix, can also be used. Isolated permeabilized fibers were recently used for 
O2- generation measurement using the triphenylphosphonium Hydroethidine (TTP-HE) 
reporter (Xu et al., 2010). Signals were analyzed by micellar electrokinetic capillary 
chromatography coupled to fluorescence detection. 
O2- rapidly dismutates into H2O2 in the presence of mitochondrial SOD which considerably 
reduce its matrix level. Then the quantification of the more stable H2O2 can be assessed using 
luminol chemiluminescence (Li et al., 1999). H2O2 can be also measured using non-fluorescent 
dyes that become fluorescent upon enzymatic oxidation by H2O2 in the presence of 
horseradish peroxidase. The most commonly used dyes are homovanilic acid (Ruch et al., 
1983), 2',7'-dichlorfluorescein-diacetate (DCFH-DA) or Amplex® Red (Chen et al., 2003). 
Kinetic or global approaches are both adequate for calculating the rate of mitochondrial ROS 
production. Standard curve is obtained by adding known amounts of H2O2 to assay medium 
in the presence of the reactants. It is critical to quantify background fluorescence, in the 
absence of mitochondria. Net fluorescence is then calculated minus background and H2O2 
production is expressed in pmol/mg of protein/min. The heterogeneity of mitochondrial 
alteration during metabolic disorders could be studied on permeabilized fibers, characterizing 
the specificity of H2O2 production depending on myofiber type (Anderson et al., 2006). If 
oxygen consumption and ROS production were determined in similar experimental conditions 
on isolated mitochondria or permeabilized fibers, the free radical leak can be calculated as an 
indicator of the fraction of electron reducing oxygen to O2- (Sanz et al., 2005). It has been 
shown that this leakage was higher in glycolytic compared to oxidative fibers (Anderson et al., 
2006). More recently, new methods were developed to analyze local change in ROS generation 
on individual isolated fibers. Hence, ROS production could be analyzed by confocal imaging 
(Shkryl et al., 2009) or real time fluorescence microscopy (Palomero et al., 2008). Although 
more reliable than O2- quantification, the detection of H2O2 as an index of O2- production has 
also its limits, i.e., the reaction of O2- with other molecules (such as NO), the removal by 
matrix peroxidase and contamination by H2O2 produce within the intermembrane space (see 
(Murphy, 2009) as a more detailed review on this topic). 
4.8 Additional measurement of mitochondrial functionality 
Mitochondrial membrane potential can be determined simultaneously with oxygen consumption 
using the potential-dependent triphenylmethylphosphonium cation (TPMP+) probe as 
described by Kamo et al. (1979). Development of fluorescent probes sensitive to mitochondrial 
membrane potential has facilitated the investigation on isolated organelles as well as cells. The 
most commonly used dyes are rhodamine 123, its derivatives tetramethylrhodamine methyl 
and ethyl esters (TMRM and TMRE), 3,3'-dihexyloxacarbocyanine,iodide (DiOC6(3)) and 
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolcarbocyanine iodide (JC-1). The latter has 
been proposed as the most reliable probe (Salvioli et al., 1997). Results are usually compared 
with those obtained in the presence of a mitochondrial uncoupler, such as FCCP, to attain 
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maximum depolarization. Membrane potential could also be determined using isolated 
permeabilized fibers in a multiwell plate (Xu et al., 2010). 
Calcium retention capacity of mitochondria and sensitivity of the permeability transition pore is 
evaluated on isolated mitochondria using the same incubation buffer and substrates than for 
respiration, except that 1 µM Calcium GreenTM-5N is added (Fontaine et al., 1998). Pulses of 
10 µM Ca2+ are added every minute until pore opening. Specificity of mitochondrial pore 
opening is assessed by adding cyclosporin A. Comparison between fiber types could be 
done in a similar approach using permeabilized fibers (Picard et al., 2008). 
4.9 Evaluation of mitochondrial biogenesis and fusion-fission dynamics 
Supported by steadily increasing literature data, changes in mitochondrial biogenesis and 
dynamics are relevant mechanisms potentially responsible for mitochondrial dysfunctions. 
PCR and western blotting analyses are pertinent techniques to investigate these pathways in 
human samples with limited size (20 to 30 mg). Major proteins potentially involved in these 
pathways have been described in the previous chapter “Transcriptional regulation of 
mitochondrial oxidative capacity – interaction with fusion-fission dynamics” and can be 
targeted using molecular tools. 
4.10 Investigation of the mitoproteome 
The recent development of genomic tools has considerably improved or knowledge of 
metabolic disorders within key metabolic tissues. Recently, a proteomic study of 
mitochondrial proteins (mitoproteome) reported that more than 80% of ETC proteins can be 
identified (Lefort et al., 2009). The authors were able to reliably detect proteins implicated in 
ROS generation, scavenging, FA oxidation and apoptosis. One hundred micrograms of 
human biopsie are required and allow a more than 7 fold enrichment in mitochondrial 
proteins with a classical isolation procedure as described for respirometry assay. Of note, 
30% of identified proteins from the whole tissue proteome are assigned to mitochondria (Yi 
et al., 2008). Further studies should aim to relate the metabolic disorders and modification of 
the mitoproteome in insulin sensitive and resistant subjects. This tool combined to 
transcriptomic analysis should provide key elements to distinguish between mitochondrial 
functioning defect and mitochondrial density variation during insulin resistance. 
5. Conclusions 
Exploring mitochondrial functioning in muscle samples, especially from human muscle 
biopsies, can be achieved using combination of strategies which require a minimal amount 
of 20mg of tissue for permeabilized fibers for one experimental condition (e.g. respirometry 
with one substrate), 30mg for molecular exploration and 30mg for an enzyme activity. The 
most tissue-consuming techniques are those based on isolated mitochondria, which 
necessitate at least 80mg of tissue for the extraction procedure. Once mitochondrial pellets 
are obtained, if further purification is not performed, combined and miniaturized methods 
allow assessing several parameters characterizing mitochondrial functioning (for example 
respiration, ATP and ROS production and enzyme activities). Hence, 150 to 200mg of tissue 
sample could be considered as a sufficient condition to build a complete investigation as 
presented in figure 4. These explorations are however limited in the number of substrates 


















Fig. 4. Main guidelines for exploring mitochondrial functioning in human muscle biopsies. 
6. Supplementary materials: buffers composition and protocols 
6.1 Preservative solution for isolated fibers 
CaK2EGTA 1.9mM, K2EGTA 8.1mM, imidazole 20mM, DTT 0.5mM, MgCl2 9.5mM, MES 
53.3mM, taurine 20mM, ATP 2.5mM, phosphocreatine 19mM, pH 7.1. 
6.2 Mitochondria isolation buffers and procedure 
Tissue grinding: 100mM KCl, 50mM Tris, 5mM MgSO4, 2mM EDTA, 1mM ATP, 0.2% BSA, 
pH 7.4.  To improve the extraction rate of intermyofibrillar mitochondria, treatment with 




To obtain mix of subsarcollemmal and intermyofibrillar mitochondria :
Incubation with protease in ATP buffer, 2 min on ice
Rinse with ATP buffer
polytron homogenate
surpernatant
To discriminate intermyofibrillar mitochondria :
Resuspend in ATP buffer and Polytron






Centrifuge 1000g, 10 min, 4°C
Centrifuge 4400g, 10 min, 4°C
Resuspend in KCl Buffer




Fig. 5. Procedure for isolating subcellular fractions enriched in mitochondria using 
differential centrifugation. 
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KCl buffer: KCl 100mM, Tris 50mM, MgSO45mM, EDTA 2mM, pH 7.4. 
ATP buffer: KCl buffer with ATP 1mM and BSA 0.2%, pH 7.4. 
Protease buffer: ATP buffer with subtilisine type VIII (1.5 mg/ml, 5 ml/g tissue). 
Sucrose medium: sucrose 0.25M, EGTA 0.1mM, Tris-HCl 10mM, pH 7.4. 
6.3 Respiration buffer 
CaK2EGTA 1.9mM, K2EGTA 8.1mM, imidazole 20mM, DTT 0.5mM, KH2PO4 3mM, MgCl2 
4mM, MES 100mM, taurine 20mM, EDTA 20μM and 0.2% BSA. 
6.4 Measurement of mitochondrial ATP production 
Add freshly isolated mitochondria to the reaction medium containing glucose 400 mM, 
MgCl2100 mM, KPO4 100mM, potassium succinate 200mM, AMP 110mM, Hepes 10mM, 
NADP 7.5mM, ADP 50mM, hexokinase 10μg, and glucose-6-P dehydrogenase 10mg. The 
total volume in the cuvette is 1 ml. The increase in absorbance at 340nm is followed at room 
temperature for 3 min (Rustin et al., 1994). 
ATP production can also be assessed using a coupled assay between lactate dehydrogenase 
and pyruvate kinase, NADH reduction being checked at 340 nm. Aliquots of mitochondria 
(20-40 µg protein) are added to a medium (Tris 50mM, BSA 5mg/ml, MgCl2 20mM, KCl 
50mM, carbonyl cyanide m-chlorophenylhydrazone 15µM, antimycin A 5µM, 
phosphoenolpyruvate10mM, ATP 2.5mM, 4 units of lactate dehydrogenase and pyruvate 
kinase, NADH 1mM, pH 8.0) pre-incubated for 5 min at 37°C. The reaction is followed for 3 
min before and after  oligomycin 3µM is added in order to distinguish the ATPase activity 
coupled to the ETC (Short et al., 2001). 
6.5 DNA purification for mtDNA quantification 
Remove the aqueous phase with RNA. Isolate and spun the interphase/organic phase at 
12000×g for 5min at 4°C. Remove the remaining aqueous phase to limit contamination with 
RNA. Add back extraction buffer (4M Guanidine Thiocyanate, 50mM Sodium citrate, 1M 
Tris; 0.5mL per 1mL of Trizol used for RNA extraction) to each tube and mix for 10 min. 
Centrifuge at 12000×g for 30min at room temperature. Incubate the upper phase with 
isopropanol (0.4mL per 1mL of Trizol used for RNA extraction) 5min at room temperature 
and spun at 12000×g for 15 min at 4°C. Pellets which contain DNA are washed twice with 
ethanol 70% and spun at 12000×g for 15min at 4°C. Final dissolution is done with sterile 
water after ethanol removal. DNA concentration is determined spectrophotometrically at 
260nm. Total DNA solutions could be stored at -20°C. 
6.6 Maximal activity of key oxidative enzymes 
Homogeneization buffer for muscle samples: sucrose 0.25mM, EDTA 2mM and Tris-HCl 
10mM, pH 7.4. 
Buffer for assessing β-hydroxyacyl-CoA dehydrogenase activity: Na2HPO4 0.1M, EDTA 
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KCl buffer: KCl 100mM, Tris 50mM, MgSO45mM, EDTA 2mM, pH 7.4. 
ATP buffer: KCl buffer with ATP 1mM and BSA 0.2%, pH 7.4. 
Protease buffer: ATP buffer with subtilisine type VIII (1.5 mg/ml, 5 ml/g tissue). 
Sucrose medium: sucrose 0.25M, EGTA 0.1mM, Tris-HCl 10mM, pH 7.4. 
6.3 Respiration buffer 
CaK2EGTA 1.9mM, K2EGTA 8.1mM, imidazole 20mM, DTT 0.5mM, KH2PO4 3mM, MgCl2 
4mM, MES 100mM, taurine 20mM, EDTA 20μM and 0.2% BSA. 
6.4 Measurement of mitochondrial ATP production 
Add freshly isolated mitochondria to the reaction medium containing glucose 400 mM, 
MgCl2100 mM, KPO4 100mM, potassium succinate 200mM, AMP 110mM, Hepes 10mM, 
NADP 7.5mM, ADP 50mM, hexokinase 10μg, and glucose-6-P dehydrogenase 10mg. The 
total volume in the cuvette is 1 ml. The increase in absorbance at 340nm is followed at room 
temperature for 3 min (Rustin et al., 1994). 
ATP production can also be assessed using a coupled assay between lactate dehydrogenase 
and pyruvate kinase, NADH reduction being checked at 340 nm. Aliquots of mitochondria 
(20-40 µg protein) are added to a medium (Tris 50mM, BSA 5mg/ml, MgCl2 20mM, KCl 
50mM, carbonyl cyanide m-chlorophenylhydrazone 15µM, antimycin A 5µM, 
phosphoenolpyruvate10mM, ATP 2.5mM, 4 units of lactate dehydrogenase and pyruvate 
kinase, NADH 1mM, pH 8.0) pre-incubated for 5 min at 37°C. The reaction is followed for 3 
min before and after  oligomycin 3µM is added in order to distinguish the ATPase activity 
coupled to the ETC (Short et al., 2001). 
6.5 DNA purification for mtDNA quantification 
Remove the aqueous phase with RNA. Isolate and spun the interphase/organic phase at 
12000×g for 5min at 4°C. Remove the remaining aqueous phase to limit contamination with 
RNA. Add back extraction buffer (4M Guanidine Thiocyanate, 50mM Sodium citrate, 1M 
Tris; 0.5mL per 1mL of Trizol used for RNA extraction) to each tube and mix for 10 min. 
Centrifuge at 12000×g for 30min at room temperature. Incubate the upper phase with 
isopropanol (0.4mL per 1mL of Trizol used for RNA extraction) 5min at room temperature 
and spun at 12000×g for 15 min at 4°C. Pellets which contain DNA are washed twice with 
ethanol 70% and spun at 12000×g for 15min at 4°C. Final dissolution is done with sterile 
water after ethanol removal. DNA concentration is determined spectrophotometrically at 
260nm. Total DNA solutions could be stored at -20°C. 
6.6 Maximal activity of key oxidative enzymes 
Homogeneization buffer for muscle samples: sucrose 0.25mM, EDTA 2mM and Tris-HCl 
10mM, pH 7.4. 
Buffer for assessing β-hydroxyacyl-CoA dehydrogenase activity: Na2HPO4 0.1M, EDTA 





(Na2HPO4 0.1M, EDTA 2mM, pH 7.5 adjusted with NaH2PO4 0.1M, EDTA 2mM). 75µl of 
homogenate is added to 925µl of medium (triethanolamine 100mM, EDTA 5mM, 
acetoacetyl-CoA 0.1mM, β-NADH 0.45mM, pH 7) and incubated at 30°C during 2 min 
whilst absorbance is measured at 340nm (Morio et al., 2001). 
6.7 Measurement of fatty acid oxidative capacity 
At least 50mg of fresh muscle sample is cut into small pieces and crushed in the ice-cold 
homogeneization buffer (cf 6.6). Total LCFA oxidation is measured using sealed vials in a 
total volume of 0.5mL containing 75μL of muscle homogenate in a medium (sucrose 25mM, 
Tris-HCl 75mM, KH2PO4 10mM, MgCl2 5mM, EDTA 1mM, pH 7.4) supplemented with ATP 
5mM, NAD+ 1mM, coenzyme A 0.1mM, L-carnitine 0.5mM, L-malate 0.5mM and 
cytochrome c 25μM. Peroxisomal LCFA oxidation is determined in the presence of 
mitochondrial oxidation inhibitors (rotenone and antimycin A) in a medium lacking L-
carnitine and L-malate. Blanks are produced by replacing the muscle homogenate with 
homogeneization buffer. 
After 5 min of pre-incubation at 37°C under shaking, the reaction is started by injecting 
0.1mL of 600μM of the radiolabelled [14C] fatty acid. Incubation is carried out at 37°C for 30 
min and stopped by the addition of 0.2mL of 3M perchloric acid. After 90 min at 4°C, the 
acid incubation mixture is centrifuged for 5 min at 10,000 g, and the 0.5mL supernatant 
containing 14C-labelled perchloric acid-soluble products is assayed for radioactivity by 
liquid scintillation. LCFA oxidation rate is calculated from 14C-labelled perchloric acid-
soluble products and expressed in nmoles of fatty acids oxidized per minute per gram wet 
tissue weight. Mitochondrial oxidation rate is calculated by subtracting the peroxisomal rate 
from the total oxidation rate. Of note, 14CO2 production can be trapped in 0.3mL 
ethanolamine/ethylene glycol (1:2, v/v) and measured by liquid scintillation. 
6.8 Measurement of CPT-1 activity 
CPT-1 activity is measured from freshly isolated mitochondria (0.1mg of protein/ml) at 
30°C from palmitoyl-L-[methyl-3H]carnitine formed from L-[methyl-3H]carnitine (200µM; 
10Ci/mol) and palmitoyl-CoA (80µM) in the presence of 1% (w/v) BSA. Increasing 
concentration of malonyl-CoA (from 0.01 to 600µM) are used for the estimation of the IC50 
value (concentration of malonyl-CoA required to achieve 50% inhibition if CPT-1 activity). 
This method measures the amount of palmitoyl-carnitine produced from palmitoyl-CoA 
and carnitine and is originately described by Kim et al. (2000). 
CPT-1 maximal activity on fresh whole muscle homogenates: 50mg of muscle is 
homogenized in ice-cold incubation buffer containing KCl 75mM, Hepes 5mM, KCN 2mM, 
EGTA 0.2mM, DTT 1mM, ATP 5mM, pH 7.3. Fifty microliters of a 5-fold diluted muscle 
homogenate are preincubated for 5 min at 30°C with 350µl of incubation buffer and 100µl of 
80µM palmitoyl-CoA. Reactions are initiated when 50µl of 10mM L-[3H]carnitine (1µCi) are 
added at 30°C for 15 min. The reaction is terminated with 1ml of isobutanol. The formed 
[3H]palmitoyl-carnitine is extracted with saturated SO4(NH4)2 and counted by liquid 
scintillation. CPT I activity is expressed in nanomoles [3H]palmitoyl-carnitine per gram of 
wet tissue per minute corrected for malonyl-CoA (0.3mM)-insensitive [3H]palmitoyl-
carnitine synthesis (Rimbert et al., 2004). 
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1. Introduction 
It has been well established that in several chronic diseases such as in chronic obstructive 
pulmonary disease (COPD), diabetes, cancer or congestive heart failure patients, next to 
central dysfunctions, the patients develop some systemic consequences that can lead to 
peripheral muscle dysfunction. Some important clinical implications such as reduced 
exercise capacity, reduced quality of life and lower survival in these patients are related to 
changes in muscle structure (mass) and function (power and endurance) (Maltais et al., 
1996; 1999; Mettauer et al., 2006). In chronic disease, peripheral perturbations generally 
include neurohormonal and inflammatory changes, microvascular dysfunction, endothelial 
abnormalities, tissue wasting, apoptosis and energetic imbalance in skeletal muscle cells, 
causing reduced exercise capacity. These multisystem abnormalities contribute to the 
progressive worsening of the disease, and ultimately, lead to premature death. Among the 
numerous skeletal muscle cell changes that occur in chronic disease, energetic dysfunction 
has received renewed attention in the last decade and is increasingly considered to be a 
possible unifying mechanism in the development of muscle failure (Mettauer et al., 2006).  
The mitochondrial impairments seem to be central in the development of energy dysfunction. 
Indeed, morphometric analysis of vastus lateralis from chronic heart failure patients revealed a 
decreased volume density of the mitochondria and decreased surface of the cristae in 
proportion with the decrease in VO2peak (Drexler, 1992). The percentage of the mitochondria 
stained for cytochrome oxidase (COX) is also reduced but improves with training (Hambrecht 
et al., 1995). Muscle enzymatic analysis as citrate synthase activity was decreased (De Sousa et 
al., 2000; Mettauer et al., 2001; Williams et al., 2004). Mitochondrial dysfunction has also been 
implicated in the pathology of chronic metabolic disease characterized by insulin resistance 
such as obesity, type 2 diabetes mellitus, and aging (Johannsen & Ravussin, 2009). In some 
chronic diseases as heart failure, skeletal muscle abnormalities resemble those induced by 
physical deconditioning, but some features argue for a generalized metabolic myopathy. 
These observations shown in several studies were obtained using various experimental 
techniques such as nuclear magnetic resonance (NMR) spectroscopy, measurement of 
mitochondrial function in situ or in vitro by oxygraphy, proteomics and genomics in human 
or animal models, which have all revealed muscular energetic perturbations. Indeed, 
mitochondria play a central role in hereditary mitochondrial diseases, ischemia reperfusion 
injury, heart failure, metabolic syndrome, neurodegenerative diseases and cancer. Thus, 
comprehension of mitochondrial function regulation is fundamental in order to enlarge the 
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1. Introduction 
It has been well established that in several chronic diseases such as in chronic obstructive 
pulmonary disease (COPD), diabetes, cancer or congestive heart failure patients, next to 
central dysfunctions, the patients develop some systemic consequences that can lead to 
peripheral muscle dysfunction. Some important clinical implications such as reduced 
exercise capacity, reduced quality of life and lower survival in these patients are related to 
changes in muscle structure (mass) and function (power and endurance) (Maltais et al., 
1996; 1999; Mettauer et al., 2006). In chronic disease, peripheral perturbations generally 
include neurohormonal and inflammatory changes, microvascular dysfunction, endothelial 
abnormalities, tissue wasting, apoptosis and energetic imbalance in skeletal muscle cells, 
causing reduced exercise capacity. These multisystem abnormalities contribute to the 
progressive worsening of the disease, and ultimately, lead to premature death. Among the 
numerous skeletal muscle cell changes that occur in chronic disease, energetic dysfunction 
has received renewed attention in the last decade and is increasingly considered to be a 
possible unifying mechanism in the development of muscle failure (Mettauer et al., 2006).  
The mitochondrial impairments seem to be central in the development of energy dysfunction. 
Indeed, morphometric analysis of vastus lateralis from chronic heart failure patients revealed a 
decreased volume density of the mitochondria and decreased surface of the cristae in 
proportion with the decrease in VO2peak (Drexler, 1992). The percentage of the mitochondria 
stained for cytochrome oxidase (COX) is also reduced but improves with training (Hambrecht 
et al., 1995). Muscle enzymatic analysis as citrate synthase activity was decreased (De Sousa et 
al., 2000; Mettauer et al., 2001; Williams et al., 2004). Mitochondrial dysfunction has also been 
implicated in the pathology of chronic metabolic disease characterized by insulin resistance 
such as obesity, type 2 diabetes mellitus, and aging (Johannsen & Ravussin, 2009). In some 
chronic diseases as heart failure, skeletal muscle abnormalities resemble those induced by 
physical deconditioning, but some features argue for a generalized metabolic myopathy. 
These observations shown in several studies were obtained using various experimental 
techniques such as nuclear magnetic resonance (NMR) spectroscopy, measurement of 
mitochondrial function in situ or in vitro by oxygraphy, proteomics and genomics in human 
or animal models, which have all revealed muscular energetic perturbations. Indeed, 
mitochondria play a central role in hereditary mitochondrial diseases, ischemia reperfusion 
injury, heart failure, metabolic syndrome, neurodegenerative diseases and cancer. Thus, 
comprehension of mitochondrial function regulation is fundamental in order to enlarge the 
knowledge in the field of mitochondrial physiology, and above all in order to better 
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diagnose the implication of mitochondria in many diseases. Direct assessment of 
mitochondrial function by measuring coupled respiration and ATP synthesis provides more 
full information, and the study of oxidative phosphorylation in skeletal muscles is an 
important initial screening procedure for the potential presence of mitochondrial diseases. 
At the fundamental level, comprehension of the mechanisms governing mitochondrial 
function as well as mitochondrial biogenesis remain to be explored in details with more and 
more molecular and cellular approaches. 
2. Different types of skeletal muscle are available 
2.1 Different muscle types 
In function of pathologies, clinical symptoms, experimental conditions or physical exercise 
type, the choice of skeletal muscle could be different. Deltoid and Vastus Lateralis muscles 
are the skeletal muscles classically explored. But muscular biopsy could also be carried out 
in Tibialis anterior and Gastrocnemius muscles. During chirurgical intervention, some other 
striated muscles such as pectoral, respiratory or backbone muscles could also be explored. 
For that, researchers need to obtain the informed consent from all patients and the study has 
to be approved by the institutional ethical review board. 
2.2 Different muscle fibres 
In function of muscle types, the composition and the properties of muscle fibres will be 
different. Indeed, an abundance of literature shows that human skeletal muscles are made of 
a mixed nature, depending on its function. Muscles are composed of various proportions of 
the three fibre types I, IIa and IIx (or IIb depending on the species), each having specific 
contractile and metabolic characteristics. Fibre type composition exhibits great plasticity that 
depends on activity, mechanical load, hormonal status and age (Baldwin et al., 1975; 
Schiaffino & Reggiani, 1996; Fluck & Hoppeler, 2003). Moreover, quantitative differences 
between muscles in terms of mitochondrial and capillary density, enzymatic profile and 
content of high-energy phosphates have been widely reported (Table 1, figure1).  
 
Table 1. The different characteristics of muscle fibres. For the sake of simplicity fibre types 
have been separated in slow oxidative type I, fast oxidative type IIa and fast glycolytic type 
IIb. miCK: mitochondrial isoenzyme of creatine kinase. (Mettauer et al., 2006) 
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Fig. 1. Representative photographies to compare oxidative fibres to glycolytic fibres. On the 
left, there is a representative electron photomicrographs. On the right, muscles are stained 
with Haematoxylin-eosin (source: Pearson education, Inc., publishing as Benjamin Cummings).  
Oxidative capacity of a given muscle can be linked to quantitative characteristics, especially 
mitochondrial and enzymatic contents. According to the relative importance of glycolysis 
and mitochondria, preferred substrate utilization can also vary from mainly carbohydrate to 
high-lipid utilization in highly oxidative muscles (Jackman & Willis, 1996; Ponsot et al., 
2005). 
Two families of muscles have been described in function of their metabolic activities. In 
oxidative muscles, composed essentially with slow oxidative fibres, the energy supplied 
continuously by mitochondria can sustain contractile activity for long periods of time 
without fatigue. By contrast, the glycolytic muscle composed with fast glycolytic fibres, has 
high levels of phosphocreatine and a high sensitivity to cytosolic ADP, which is, thus, the 
likely metabolic signal driving mitochondrial respiration (Mettauer et al., 2006).  
Among these systems, there is the family of creatine kinase (CK) that catalyzes the reversible 
transfer of a phosphate moiety between creatine and adenosine diphosphate (ADP) 
(Mettauer et al., 2006). Four different isoforms of CK are expressed in a tissue specific and 
developmentally regulated manner. Among these isoforms, there is the mitochondrial 
isoenzyme (mi-CK), which is functionally coupled to oxidative phosphorylation and 
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Fig. 2. The mechanisms of energy production in oxidative muscles, from. (Mettauer et al., 
2006) 
In glycolytic muscle fibres (type IIX/B), the mitochondria, together with glycolytic 
complexes, are concerned with replenishing intracellular phosphocreatine (PCr) stores 
which are immediately available for the ATPases-bound creatine kinases. This can be 
described as a “twitch now pay later” mode of operation (Kaasik et al., 2003; Ventura-
Clapier et al., 2004; Mettauer et al., 2006)(figure 3).  
 
Fig. 3. The mechanisms of energy production in glycolytic muscles described before. 
(Mettauer et al., 2006) 
 




Fig. 4. Representative electron photomicrographs of mitochondrial ultrastructure in muscle 
fibres control (Mariappan et al., 2007). The second photo represents a muscle fibre with 
myofibrils and mitochondria (source: David R. Caprette,  Rice University)  
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3. Mitochondrial analysis of muscle biopsy 
3.1 Methods 
Techniques and protocols of assessment of mitochondrial properties are of important 
physiological and physiopathological significance. 31P NMR spectroscopy has given the 
opportunity to study in vivo the intracellular metabolism under various conditions, 
including exercise in normal subjects and patients. However this approach did not reveal 
the intrinsic mitochondrial properties but rather the mitochondrial function under an 
uncontrolled intracellular medium. In the past, muscle mitochondrial properties were more 
closely explored either: 
- By morphometric methods that give access to the mitochondria volume density and 
surface of cristae. The technique used the transmission electronic microscopy (figure 4) 
(Veksler et al., 1987),  
- By biochemical methods determining the activity of intramitochondrial enzymes like 
citrate synthase (CS) and cytochrome oxidase (Cox). Actually, we can measure, directly 
the enzymatic activity of citrate synthase, which can be a good marker for quantifying 
mitochondria. Moreover, there are more and more different enzyme immunoassays to 
detect the consequence of the activities of metabolic enzymes. In addition, the different 
complexes implicated in the mitochondrial respiration can be explored (Birch-Machin & 
Turnbull, 2001). 
- By polarographic methods, measuring O2 uptake of isolated mitochondria. These 
studies, on isolated mitochondria, required large amounts of tissue (approximately 500 
mg), above the yield of routine human biopsy technique (10–50 mg), although efforts 
have been made to improve their sensitivity. More than two decades ago, Veksler et al. 
(Veksler et al., 1987) reported a method to assess the mitochondrial function of animal 
as well as human muscles. This new technique was based on the selective 
permeabilization of the sarcolemma by a low concentration of saponin (Kuznetsov et 
al., 2008). This approach allows the analysis of mitochondria within an integrated 
cellular system, preserving essential interactions with the cytoskeleton (Saks et al., 1998; 
Milner et al., 2000), nucleus (Dzeja et al., 2002) and endoplasmic reticulum (Rizzuto et 
al., 1998; Csordas et al., 2006). 
3.2 Mitochondrial respiration 
Oxidative phosphorylation has to be studied in intact mitochondria, which can be achieved 
by measuring the oxygen consumption of isolated mitochondria or muscle fibres from a 
tissue. 
The skinned muscle fibre technique is adapted by Veksler and Saks for cardiac muscle fibres 
and also for skeletal muscle fibres (Veksler et al., 1987; Kuznetsov et al., 2008). This 
approach applies the ability of several chemical agents to specifically interact with the 
cholesterol in plasma membranes of cells or muscle fibres. These agents, for example 
saponin, have a high affinity to cholesterol and thus preferentially interact with cholesterol 
from membranes. Since, plasma membranes contain more cholesterol than the membrane of 
endoplasmic reticulum (ER) as well as the mitochondrial outer and inner membranes 
(Comte et al., 1976; Kuznetsov et al., 2008), there are no lesions on the intracellular 
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membrane structures (mitochondria and ER) (Saks et al., 1998). Importantly, functionally 
intact mitochondria, myofilaments or sarcoplasmic reticulum (SR) of permeabilized muscle 
fibres respond quickly to changes in concentrations of ions, adenine nucleotides, substrates, 
inhibitors (Kuznetsov et al., 2008). So the intracellular space of permeabilized muscle fibres 
is equilibrated with the external medium (figure 5) (Veksler et al., 1987; Kunz et al., 1993; 
Kuznetsov et al., 1997; Kuznetsov et al., 1998; Kuznetsov et al., 2004), and mitochondria are 
able to use substrates added in the extracellular medium. 
 
Fig. 5. Scheme explaining the effect of saponin on muscle fibres. Panel A represents the 
intracellular compartiment, with mitochondria, sarcoplasmic reticulum, nucleus (N). Panel 
B, when saponin acted; It appears a loss of plasmic membrane integrity. The mitochondrial 
sarcoplasmic membranes stayed intact.  (Kuznetsov et al., 2008) 
The addition of substrates allows us to analyze separately the different complexes I, II, III 
and IV of the mitochondrial respiratory chain. The measure consists in measuring the 
oxygen consumption polarographically with a Clark-type electrode. The substrates used are 
in function of the complex activity observed. The experiment started, all the time, by a 
measure of the basal respiration in non-phosphorylated condition but in the presence of 
glutamate-malate substrate, and is named V0. Then, for observing the maximal 
mitochondrial respiration by activating complexes I, III and IV, the addition of ADP (in 
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saturating concentration) is sufficient, and the respiration rate is named Vmax. The next step 
is to activate the complex II in adding amytal or rotenone, (specific inhibitors of complex I), 
followed by the addition of succinate, this respiration rate is named Vsucc. The complex III 
can be inhibited by the addition of antimycin A. Finally, to measure the specific activity of 
complex IV, N, N, N′, N′-tetramethyl-p-phenylenediamine dihydrochloride (TMPD) and 
ascorbate were added as an artificial electron donor to complex IV, the mitochondrial rate is 
named VTMPD/asc ( Charles et al., 2011.; Kuznetsov et al., 2008)(figure 6).  
 
Fig. 6. Mitochondrial respiratory chain complexes activities using saponin skinned fibres. 
GM : glutamate/ malate. CI: complex I; CII: complex II; CIII: complex III ; CIV: complex IV ; 
ATP Synt : ATP synthase ; cytC : cytochrome c; CoQ : coenzyme Q.  
It is important to indicate that substrate utilization differ among muscle types (Baldwin et 
al., 1972; Holloszy & Booth, 1976; Jackman & Willis, 1996; Dyck et al., 1997). This means that 
muscle tissue has developed specific adaptations in terms of respiration control and 
intracellular energy distribution depending on its specific needs (Saks et al., 2001). 
The Glycerol-3-Phosphate (G3-P) has a key role in the transfer of reducing equivalents from 
the cytosol to the mitochondrial matrix. This substrate is more used by the glycolytic 
muscles (Jackman & Willis, 1996). 
Pyruvate is the substrate preferentially oxidized by all the different muscles (Ponsot et al., 
2005). While the fatty acids like palmitoyl-carnitin are predominantly used by the cardiac 
and more generally by the oxidative skeletal muscles (Ponsot et al., 2005). The mechanisms 
of these different substrates are summarized in the figure 7. 
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Fig. 7. The intervention of different substrates depending on their transport mechanism 
(Ponsot et al., 2005).  
(1) pyruvate (Pyr), which activates the pyruvate dehydrogenase complex (PDH) localized in 
the mitochondrial matrix; (2) palmitoyl-carnitine (Palm-C), which is transferred into the 
matrix by the inner membrane-localized carnitine translocase (CT) and carnitine palmitoyl 
transferase II (CPTII), and activates the b-oxidation (b-ox); (3) G3-P, which diffuses to the 
intermembrane space and activates the mitochondrial G3-P dehydrogenase; (4) lactate 
(Lact), which could be converted into Pyr by mitochondrial LDH if it is present and 
functional. dicarboxylate translocase (DcT); dihydroxiacetone- phosphate (DHP); glutamate 
aspartate translocase (GAT); glycerol-3-phosphate (G3P); mitochondrial aspartate 
transaminase (m-AT); mitochondrial glycerol-3-phosphate dehydrogenase (m-G3PDH); 
mitochondrial malate dehydrogenase (m-MDH); pyruvate dehydrogenase complex (PDH). 
3.3 Adenosine-5'-triphosphate (ATP) production 
3.3.1 Definition 
Adenosine-5'-triphosphate (ATP) is a multifunctional nucleotide used in cells as a 
coenzyme. ATP transports chemical energy within cells for metabolism. It is produced from 
Adenosine-5'-triphosphate (ADP) during glycolysis and the oxidative phosphorylation via 
the mitochondrial electron transport chain, which is the principal source of ATP in aerobic 
condition in mammals. ATP is used by enzymes and structural proteins in many cellular 
processes. It is used as a substrate in signal transduction pathways by kinases that 
phosphorylate proteins and lipids, as well as by Adenylate cyclase, which uses ATP to 
produce the second messenger molecule cyclic AMP. Apart from its roles in energy 
metabolism and signaling, ATP is also incorporated into nucleic acids by polymerases in the 
processes of DNA replication and transcription.  
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In muscle, it plays a crucial role for the contraction. Indeed, ATP is the direct energy source 
for muscle contraction (Rayment et al., 1993).  
3.3.2 The interest of ATP measurement 
In living cells, the distribution of ATP is ubiquitous, and is lost rapidly in dead cells. It is an 
appropriate marker for cell viability (Petty et al., 1995). Moreover ATP is extracted and 
measured easily.  
3.3.3 Methods 
Several methods exist allowing to quantify ATP concentration in myocytes: 
- High-performance liquid chromatography (HPLC) with phosphate buffer as the mobile 
phase and UV detection (Lazzarino et al., 2003),  
- Ion exchange chromatography, also with UV detection (Ally & Park, 1992; Maguire et 
al., 1992). 
- However, the firefly luciferin-luciferase bioluminescence method is the most rapid, 
sensitive, and reproducible assay. 
The bioluminescence assay is based on the reaction of ATP with recombinant firefly 
luciferase and its substrate luciferin. The stabilities of the reaction mixture as well as 
relevant ATP standards were quantified (Wibom & Hultman, 1990; Wibom et al., 1990).  
It is a reagent based upon firefly luciferase, which emits light proportional to the ATP 
concentration. 
The production of light is caused by the reaction of ATP with added luciferase and D-
luciferin. This is illustrated in the following reaction scheme: 
 
So, the ATP measurement permits to explain the importance of understanding the energy 
capacity of mitochondria in biology, physiology, cellular dysfunction, and ultimately, 
disease pathologies and aging (Drew & Leeuwenburgh, 2003; Aas et al., 2010). 
3.4 Uncoupling of mitochondria 
To phosphorylate ADP into ATP, the mitochondrion uses a coupling of oxidative 
phosphorylation across the mitochondrial inner membrane. But there is a phenomenon 
called mild uncoupling which allows the return of protons into the matrix without ATP 
production. This proton leak lowers the membrane potential across the inner membrane and 
increases the mitochondrial respiration rate (Brand, 1990). This leak goes by the uncoupling 
proteins (UCP). Discovered in 1978 (Nicholls et al., 1978), the first one, UCP1, localized in 
brown adipose tissue, is involved in cold-induced thermogenesis. The role of the other UCP, 
principally UCP2 (expressed ubiquitously) and UCP3 (expressed almost exclusively in 
skeletal muscle), is more controversial. As they are activated in extreme conditions (fasting, 
intensive exercise, high fat diet…) they could be a protective mechanism against oxidative 
ATP + D-Luciferin + O2 
LUCIFERASE
Mg2+
Oxyluciferin + AMP + PPi + CO2 + Light
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stress. Indeed, when uncoupling is activated, mitochondrial respiration has to increase in 
order to maintain the membrane potential and ATP production. It seems that this 
mechanism reduces mitochondrial ROS production (Starkov, 1997). 
Visualization of this phenomenon is indirect in vivo (calorimetric approaches), and only 
observed in vitro in specific conditions. The proton leak is shown from the measurement of 
the membrane potential together with the respiration rate (in non-phosphorylating state) 
(Brand, 1995; Cadenas et al., 2002). 
3.5 ROS production 
Reactive oxygen species (ROS) are involved in the regulation of many physiological processes. 
However, overproduction of ROS under various cellular stresses results in cell death and 
organ injury and thus contributes to a broad spectrum of diseases and pathological conditions. 
ROS are formed preferentially in mitochondria also under normal conditions and may 
participate in many signaling and regulation pathways. However, under various cell stresses, 
such as ischemia–reperfusion, hypoxia–reoxygenation, and treatment with toxic agents, 
mitochondrial ROS are produced in excess and are rapidly released into cytoplasm, where 
they may have damaging effects, leading to oxidative stress and cell injury. Different methods 
exist allowing to characterise ROS formation at the level of muscle tissue (see the chapter from 
Lejay et al. for much more explanations and the description of the methods). 
3.6 Mitochondrial biogenesis and genes expression 
Gene expression profiling is considered as a key technology for understanding the biology of 
tissue plasticity as well as pathological disorders. A growing body of evidence is accumulating 
that implies muscular gene expressional alterations to be involved to a significant extent in the 
unique response of cells and tissues to external stressors. Transcriptional profiling evolves as a 
powerful tool to explore the molecular mechanisms underlying such adaptation. Real time RT-
PCR (reverse transcription-polymerase chain reation) is the basic but efficient technique 
allowing to explore mitochondrial gene expression in muscle. 
Advances in molecular biology have started to elucidate the transcriptional events 
governing mitochondrial biogenesis. Peroxisome proliferator-activated receptor gamma co-
activator (PGC-1) is considered to be the major regulator of mitochondrial biogenesis 
(Ventura-Clapier et al., 2008). Mitochondrial biogenesis can be defined as the growth and 
division of pre-existing mitochondria. According to the accepted endosymbiotic theory, 
mitochondria are the direct descendants of a-proteobacteria endosymbiont that became 
established in a host cell. Due to their ancient bacterial origin, mitochondria have their own 
genome and a capacity for auto-replication. Mitochondrial proteins are encoded by the 
nuclear and the mitochondrial genomes. The double-strand circular mitochondrial DNA 
(mtDNA) is 16.5 kb in vertebrates and contains 37 genes encoding 13 subunits of the 
electron transport chain (ETC) complexes I, III, IV, and V, 22 transfer RNAs, and 2 ribosomal 
RNAs necessary for the translation. Correct mitochondrial biogenesis relies on the 
spatiotemporally coordinated synthesis and import of 1000 proteins encoded by the 
nuclear genome, of which some are assembled with proteins encoded by mitochondrial 
DNA within newly synthesized phospholipid membranes of the inner and outer 
mitochondrial membranes. All of these processes have to be tightly regulated in order to 
meet the tissue requirements. Mitochondrial biogenesis is triggered by environmental 
stresses such as exercise, cold exposure, caloric restriction, oxidative stress, cell division and 
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renewal, and differentiation. The biogenesis of mitochondria is accompanied by variations 
in mitochondrial size, number, and mass. The discovery that alterations in mitochondrial 
biogenesis contribute to some chronic pathologies have increased the interest of the 
scientific community in this process and its regulation (Ventura-Clapier et al., 2008). 
Mitochondrial biogenesis is induced as followed: Peroxisome proliferator-activated receptor 
gamma co-activator (PGC-1a) activates nuclear transcription factors (NTFs) leading to 
transcription of nuclear-encoded proteins and of the mitochondrial transcription factor 
Tfam. Tfam activates transcription and replication of the mitochondrial genome. Nuclear-
encoded proteins are imported into mitochondria through the outer- (TOM) or inner (TIM) 
membrane transport machinery. Nuclear- and mitochondria-encoded subunits of the 
respiratory chain are then assembled. Mitochondria in the cells of most tissues are tubular, 
and dynamic changes in morphology are driven by fission, fusion, and translocation 
(Bereiter-Hahn, 1990). The ability to undergo fission/fusion enables mitochondria to divide 
and helps ensure proper organization of the mitochondrial network during biogenesis. 
Mitochondrial fission is driven by dynamin-related proteins (DRP1 and OPA1), while 
mitochondrial fusion is controlled by mitofusins (Mfn1 and 2) (figure 8). 
 
Fig. 8. Schematic representation of mitochondrial biogenesis. Peroxisome proliferator-
activated receptor gamma co-activator (PGC-1α) activates nuclear transcription factors 
(NTFs) leading to transcription of nuclear- encoded proteins and of the mitochondrial 
transcription factor Tfam. Tfam activates transcription and replication of the mitochondrial 
genome. Nuclear-encoded proteins are imported into mitochondria through the outer- 
(TOM) or inner (TIM) membrane transport machinery. Nuclear- and mitochondria-encoded 
subunits of the respiratory chain are then assembled. Mitochondrial fission through the 
dynamin-related protein 1 (DRP1) for the outer membrane and OPA1 for the inner 
membrane of mitochondria allow mitochondrial division while mitofusins (Mfn) control 
mitochondrial fusion. Processes of fusion/fission lead to proper organization of the 
mitochondrial network. OXPHOS: oxidative phosphorylation (Ventura-Clapier et al., 2008). 
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Measurement of mRNA expression of all theses proteins by RT-PCR technique could be a 
good means in order to show activation or deactivation of the mechanisms of mitochondrial 
biogenesis as well as mitochondrial fission/fusion. For details see the review of Ventura-
Clapier et al (Ventura-Clapier et al., 2008). 
In skeletal muscles, the consequences of a dysregulation of the mitochondrial biogenesis 
mechanisms could induce some important energetic changes including: 
- a reduction of oxidative capacity and energy production; 
- a decrease of energy transfer by the phosphotransfer kinases, 
- a reduction of antioxidant buffering capacity; 
- a global decrease of energy consumption efficiency. On the other hand, the signalling 
and molecular origins of these defects are unknown. 
4. Analysis of muscle biopsy for detection of mitochondrial defects 
Metabolic myopathies are inborn errors of metabolism that result in impaired energy 
production due to defects in glycogen, lipid, mitochondria, and possibly adenine nucleotide 
metabolism. Mitochondrial myopathies, fatty acid oxidation defects, and glycogen storage 
disease represent the three main groups of disorders (Burr et al., 2008; van Adel & 
Tarnopolsky, 2009). The mitochondrial myopathies manifest predominantly during 
endurance-type activity, under fasted or other metabolically stressful conditions. The 
clinical examination is often normal, and testing requires various combinations of exercise 
stress testing, serum creatine kinase activity and lactate concentration determination, urine 
organic acids, muscle biopsy, neuroimaging, and specific genetic testing for the diagnosis of 
a specific metabolic myopathy. Mitochondrial diseases are often disorders caused by an 
impairment of the mitochondrial respiratory chain function. They are usually progressive, 
isolated or multi-system diseases and have variable times of onset. Because mitochondria 
have their own DNA (mtDNA), mitochondrial diseases can be caused by mutations in both 
mtDNA and nuclear DNA (nDNA). The complexity of genetic control of mitochondrial 
function is in part responsible for the intra- and inter-familiar clinical heterogeneity of this 
class of diseases (Scarpelli et al., 2010).  
Many forms of mitochondrial defects require a muscle biopsy to determine if any 
impairment exists. Unfortunately, not all mitochondrial defects are fully known, and so 
cannot be tested. Therefore, the detection of ragged red fibres by histological technique is 
looked for indications of a mitochondrial defect. A high lactic acid level is also often an 
indication. Moreover if a patient has three or more body systems affected, (for example 
circulatory, respiratory, and digestive systems), there is a suspicion of mitochondrial defect. 
5. Skeletal muscle responses to metabolic and mechanical stimulations (i.e. 
physical exercise) 
The introduction of the skeletal muscle biopsy procedure in the 1860's (Duchennes, 1864) 
has led to a tremendous step forward in our understanding of skeletal muscle physiology in 
humans. One of the fields that has most benefited from this new technique is the area of 
exercise physiology. There are major advances in the cellular and molecular mechanisms 
underlying the skeletal muscle responses to acute and chronic exercise, either with or 
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without the combined effect of additional environmental stressors such as altitude or 
hypo/hyperthermia. Then, the skeletal muscle biopsy is considered as a masterpiece in the 
ongoing development of the integrative approach of exercise physiology. This links the 
molecular and cellular events occurring in individual skeletal muscle fibres to cellular, tissue 
and whole body structures and functions. Thanks to the insights provided by skeletal 
muscle biopsies, skeletal muscle plasticity to exercise training is currently believed to be 
driven by metabolic (i.e increased energy demand) or mechanical (i.e increased muscle 
tension) stimuli generated during the training sessions (Coyle, 2000; Dufour et al., 2007). The 
paragraphs below present some examples of scientific advances obtained through the use of 
skeletal muscle biopsies in the area of exercise physiology. 
5.1 Skeletal muscle responses to metabolic stimulation 
One way to selectively increase the metabolic stimulation on skeletal muscle is to compare 
normoxic vs hypoxic exercise training (Dufour, 2005). The lowered partial pressure for 
oxygen (PO2) in the inspired air translates into lowered muscle intracellular PO2 
(Richardson et al., 1995), thereby triggering skeletal muscle adaptations to cope with the 
enhanced metabolic load. After 6 weeks of intermittent hypoxic vs normoxic treadmill 
training, our laboratory has shown specific and significant improvement in whole body 
aerobic performance capacity in endurance athletes (VO2max, time to exhaustion,...) 
(Dufour et al., 2006). Using biopsies of the vastus lateralis, we observed that the enhanced 
performance capacity was concomitant to an improved skeletal muscle mitochondrial 
function (Ponsot et al., 2006) and an up-regulated transcription of selected genes involved in 
oxygen sensing, mitochondrial biogenesis, mitochondrial metabolism, carbohydrate 
metabolism, pH regulation and oxidative stress (Zoll et al., 2006a). In this series of studies, 
muscle biopsies proved useful in highlighting the role of metabolic stimulations in the 
regulation of the metabolic component of skeletal muscle plasticity to exercise training. 
5.2 Skeletal muscle responses to mechanical stimulation 
Similarly to the metabolic stimuli, it is also possible to selectively increase the mechanical 
stimuli generated during the training sessions using concentric vs eccentric cycle ergometry 
(Dufour, 2005). Eccentric muscle actions are characterized by high forces and low energy 
expenditure emphasizing muscle mechanical tension with very little energy demand 
(Lastayo et al., 1999; Lastayo et al., 2000; Lindstedt et al., 2001; LaStayo et al., 2003b). 
Currently taken as a promising tool to develop skeletal muscle force in order to improve 
performance in athletes (Gross et al., 2010), eccentric cycle ergometry is also increasingly 
considered as a valuable method to counteract the impairment of skeletal muscle function 
observed in various populations including elderly (Lastayo et al., 2002; LaStayo et al., 2003a; 
LaStayo et al., 2007), chronic obstructive pulmonary disease (Rooyackers et al., 2003), 
coronary artery disease (Steiner et al., 2004), type 2 diabetes mellitus (Marcus et al., 2008; 
Marcus et al., 2009), Parkinson disease (Dibble et al., 2006a; Dibble et al., 2006b; Dibble et al., 
2009), multiple sclerosis patients (Hayes et al., 2011) and cancer survivors (Hansen et al., 
2009; Lastayo et al., 2010; LaStayo et al., 2011). After 8 weeks of eccentric vs concentric cycle 
ergometry with coronary patients, significant improvement in knee extensor muscle force 
has been observed (Steiner et al., 2004). Biopsies of vastus lateralis demonstrated an 
increased volume of myofibrils, an increased proportion of type IIa muscle fibres and an 
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enhanced transcription of IGF-1 in the eccentric group (Zoll et al., 2006b). For the elderly 
patients (mean age = 80 yr old), eccentric cycle ergometry induced a greater gain in 
isometric strength of the knee extensors (Mueller et al., 2009), as compared with a 
conventional resistance training program. In this study, biopsies of vastus lateralis showed 
an enhanced expression of transcripts encoding factors involved in muscle growth, repair 
and remodeling (i.e. IGF-1, HGF, MYOG, MYH3) (Mueller et al., 2011). Of note, eccentric 
cycle ergometry was observed to depress genes encoding mitochondrial and metabolic 
transcripts. Taken together, the above experiments using muscle biopsies in human subjects 
show that mechanical stimulation of skeletal muscle trigger beneficial responses of the 
mechanical but not the metabolic component of skeletal muscle plasticity to exercise 
training. 
5.3 Future developments in the muscle biopsy procedure 
In human subjects, the withdrawal of muscle samples to perform biochemical, histochemical 
and histomorphometric muscle analyses has evolved from open air to semi open procedures 
(Henriksson, 1979), including "forceps" and the nowadays "gold standard" percutaneous 
Bergstrom needle procedure (Bergstrom, 1962). A suction system through the cutting 
trocard was introduced in 1982 in order to augment the size of the muscle tissue withdrawn 
at each insertion of the needle. These techniques do all need skin, subcutaneous and deep 
fascia anesthesia as well as a 5-10mm incision to access the muscle tissue with a 4 to 6 mm 
diameter Bergstrom needle (Hennessey et al., 1997). With these techniques, muscle samples 
of 77-170 mg can be obtained for each sample and doubling the sampling by rotating the 
needle 90° clockwise increased the size of the muscle sample to 172-271 mg in one pass 
(Hennessey et al., 1997). However, limitations exist for these procedures as their invasive 
character makes difficult the realization of serial sampling for studies examining the time 
course of intracellular physiological events (Hayot et al., 2005). Moreover, the procedure is 
sometimes difficult to get accepted by local ethics committee when applied to healthy 
normal subjects or athletes. Finally, some reservations should be made about the 
sterilization process and particularly the risk associated to Prion-contaminated medical 
instruments (sterilization of a hollow needle) (Weber & Rutala, 2002). As a less invasive 
alternative, microbiopsy procedures have been developed using fine disposable needles to 
obtain muscle samples in human subjects (Cote et al., 1992; Hayot et al., 2005). Although 
local anaesthesia is still required, skin incision is not always necessary. The skin is directly 
punctured with an insertion cannula perpendicular to the muscle until the fascia is pierced. 
The biopsy needle is subsequently inserted through the cannula and the muscle sample is 
obtained by the activation of a trigger button, which unloads the spring of the microbiopsy 
system and activates the needle to collect the muscle sample. Given the smaller size of the 
cannula and biopsy needles ranging from 11 to 18 gauges (i.e. 3.2 to 1.2 mm), the muscle 
samples obtained with microbiopsy procedures are much smaller. Despite the reduced 
muscle volumes, these developing microbiopsy procedures greatly facilitate serial muscle 
sampling either to increase the total size of the biopsy sample and/or to investigate the time 
course of intracellular physiological process of interest. An additional strength of the 
microbiopsy is that the procedure has been reported to be much more comfortable for the 
subjects and easier to perform compared to open air or percutaneous Bergstrom needle 
procedure (Cote et al., 1992; Hayot et al., 2005), allowing its wider use in the future of many 
areas of skeletal muscle physiology, including exercise physiology. 
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6. Conclusion 
Exploration of energetic metabolism with skeletal muscle biopsy is central in order to 
characterise and to better understand the mitochondrial function and the mechanisms of cell 
death and pathophysiology of a variety of human diseases, including myopathies, 
neurodegenerative diseases, heart failure, diabetes and cancer. Indeed, clinical implications 
such as reduced exercise capacity, reduced quality of life are related to changes in muscle 
mitochondrial function. In the last decade, new experimental approaches with new 
biological techniques were applied to human biopsies allowing to help to diagnose several 
metabolic impairments in skeletal muscle. A lot of mitochondrial dysfunctions developed in 
chronic disease may be reversible, and then, improvement of the comprehension of 
mitochondrial physiology and pathophysiology could help to find new therapeutic avenues 
in the future. 
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6. Conclusion 
Exploration of energetic metabolism with skeletal muscle biopsy is central in order to 
characterise and to better understand the mitochondrial function and the mechanisms of cell 
death and pathophysiology of a variety of human diseases, including myopathies, 
neurodegenerative diseases, heart failure, diabetes and cancer. Indeed, clinical implications 
such as reduced exercise capacity, reduced quality of life are related to changes in muscle 
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biological techniques were applied to human biopsies allowing to help to diagnose several 
metabolic impairments in skeletal muscle. A lot of mitochondrial dysfunctions developed in 
chronic disease may be reversible, and then, improvement of the comprehension of 
mitochondrial physiology and pathophysiology could help to find new therapeutic avenues 
in the future. 
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1. Introduction  
1.1 Peripheral arterial disease 
Peripheral arterial disease (PAD) is a manifestation of atherosclerosis which produces 
stenoses and occlusions in lower limbs arteries. PAD was commonly divided in four stages, 
introduced by Rene Fontaine in 1954 (Fontaine et al., 1954): stage 1 defined an asymptomatic 
patient, stage 2 defined a patient presenting with a significant impairment of his ability to 
walk (intermittent claudication). Then claudication worsens and the patient develops rest 
pain in stage 3, and non-healing ulcers or gangrene in stage 4.   
Recently, other criteria have been proposed for the diagnosis of PAD. Stage 2 of Leriche is 
now called « functional ischemia », and stages 3 and 4 are now called « critical ischemia » 
(Norgren et al., 2007). Critical ischemia is called this way because of its poor prognosis. 
With this new classification, the diagnosis of critical limb ischemia requires both clinical 
criteria, but also hemodynamic criteria (ankle-brachial index, toe pressure). Normal 
values of ankle-brachial index are between 0,9 and 1,3. PAD is characterized by ankle-
brachial values under 0,9 (0,4-0,9: functional ischemia, <0,4: critical ischemia). The normal 
value of the toe pressure is 60-65 mm Hg, it can be normal or within the limits of the 
normal in functional ischemia, but it is commonly under 10 mm Hg in critical ischemia. 
These hemodynamic criteria objectify the arterial etiology of the lesions, because it is 
sometimes difficult to define the exact origin of rest pain or tissue loss (diabetes, venous 
insufficiency…). 
Insufficient oxygen supply secondary to reduced blood flow is presumed to be the main 
physiologic cause for the manifestations of peripheral arterial disease, but more recently the 
presence of mitochondriopathy in chronically ischemic skeletal muscle has been proposed. 
Suboptimal energy production from defective mitochondria participates in PAD 
pathogenesis in addition to reduced oxygen supply (Marbini et al., 1986; Lundgren et al., 
1989; Bhat et al., 1999; Brass et al., 2001; Pipinos et al., 2008a)(Figure 1). 
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Fig. 1. Pathogenesis of peripheral arterial disease 
1.2 Mitochondrial function and oxidative stress 
Every action requires energy, and this energy is stored in adenosine triphosphate (ATP) 
molecules that are produced in the mitochondria by the process of oxidative 
phosphorylation. Mitochondria are present in every cell, but there are in high concentrations 
in muscle cells because high energetic requirements of muscles.  
1.2.1 Structure of mitochondria  
Mitochondria are enclosed within two membranes: the outer membrane and the inner 
membrane. The outer membrane is a relatively simple phospholipid bilayer, containing 
protein structures called porins which allow molecules of 10 kilodaltons in weight to pass 
through it. This explains why the outer membrane is completely permeable to nutrient 
molecules, ions, ATP and ADP molecules. The inner membrane is more complex in 
structure than the outer membrane because it contains electron transport chain, ATP 
synthetase, and transport proteins. It is freely permeable only to oxygen, carbon dioxide and 
water. The wrinkles, or folds, are organized into layers called cristae, which increase total 
surface area of the inner membrane (figure2). 
Skeletal Muscle Mitochondrial Function 
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Outer and inner membranes delineate two compartments: the intermembrane space, and the 
cytoplasmic matrix. The intermembrane space is located between the inner and the outer 
membranes. It has an important role in oxidative phosphorylation. The cytoplasmic matrix 
contains the enzymes that are responsible for citric acid cycle reactions. The matrix also 
contains dissolved oxygen, water, and carbon dioxide.  
 
Fig. 2. Mitochondrial structure.  (source: Pearson education, Inc., publishing as Benjamin 
Cummings).  
1.2.2 Functions of mitochondria 
One of the major mitochondrial functions is cellular respiration. It is a chemical process of 
releasing energy stored in glucose. The energy utilized in breaking down glucose is 
supplied by ATP molecules, and ATP molecules are produced by mitochondria. The entire 
process of aerobic cellular respiration is a three step process: 
- Glycolysis: Glucose is a six carbon sugar. The enzymes in the cytoplasmic matrix 
initiate glycolysis in which a glucose molecule is oxidized to two molecules of three 
carbon sugars. Products of glycolysis are two molecules of ATP, two molecules of 
pyruvic acid and two NADH (Nicotinamide Adenine Dinucleotide) molecules (which 
are electron carrying molecules) 
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- Citric Acid Cycle (Krebs cycle): This is the second phase of cellular respiration. The 
three carbon molecules which have been produced as a result of glycolysis are 
converted into acetyl compounds. However, the intermediary reactions of this process 
yield ATP molecules of energy, NAD and FAD molecules too. NAD and FAD 
molecules are further reduced in the Citric Acid Cycle to high energy electrons 
- Electron Transport: The electron transport chain is constituted of a series of electron 
carriers generated in the membrane of the mitochondria from Citric Acid Cycle. The 
ATP molecules are further produced by the chemical reactions of these electron carrier 
molecules. A eukaryotic cell produces about 36 ATP molecules after cellular respiration. 
In fact, mitochondrial function in cellular energy metabolism is concerned with the 
processes of fatty acid and pyruvate oxidation, resulting in the formation of acetyl-CoA, 
which is subsequently oxidized in the Citric Acid Cycle. When combined, these processes 
generate reduced coenzymes, which deliver electrons to oxygen to form water, through the 
respiratory chain of the inner membrane. The whole process of fat and carbohydrate 
oxidation is strongly exergonic and the normal mitochondrion conserves the major part of 
this energy in the form of ADP phosphorylation to ATP. This dependence on oxygen is 
critical in skeletal muscle. Under normal circumstances, skeletal muscle has the capacity to 
increase its energy turnover, and this makes the transition from rest to exercise. Efficient 
oxygen delivery is very important for normal mitochondrial function, and patients suffering 
from peripheral arterial disease have a decreased blood flow to the legs due to 
arteriosclerosis, making less oxygen available to the mitochondria. 
Other main mitochondrial functions are control of cell cycle, management of apoptosis, 
monitoring of cell differentiation, growth and development and reactive oxygen species 
production and clearance. 
1.2.3 Mitochondria and reactive oxygen species  
Mitochondria, main energy sources of the cells, are causes and targets of increased oxidative 
stress. Thus, the role of mitochondria extends far beyond energy production, as they are 
important generators of reactive oxygen species (ROS), which can act either as second 
messengers or as a source of cellular damage, depending on the produced amount. ROS are 
a double-edged sword: they are beneficial by playing an important role in cell signaling 
involved in antioxidant defense network, but could be harmful by inducing excessive 
oxidative stress resulting in protein carboxylation, lipids peroxydation and DNA damage. 
These free radicals have oxidizing properties, and they react in the environment where they 
are produced with a variety of biological substrates: fats, carbohydrates, proteins and DNA. 
There are also environmental factors that generate free radicals: pollution, sun exposure, 
smoking, consumption of alcohol or drugs, physical exercise. These situations induce an 
overproduction of reactive oxygen species. There are also defense systems that can regulate 
the production of theses species: free radicals are neutralized by enzymatic systems 
(superoxide dismutase, catalase and glutathione peroxidase), elements (copper, zinc, iron, 
selenium), as well as antioxidants such as vitamins A, C and E (Figure 3).  
ROS include radical species such as primary superoxide O2•−, and its conjugated acid 
hydroperoxyl radical HO2•. Also included are the hydroxyl (•OH), carbonate (CO3• −), 
peroxyl (RO2•), and alkoxyl (RO•) radical. Also some non-radical species are ascribed to  
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Fig. 3. Reactive oxygen species in peripheral arterial disease. SOD: superoxide dismutase; 
GPX: gluthatione peroxidase 
ROS, namely H2O2, HOCl, fatty acid hydroperoxides (FAOOH), reactive aldehydes, singlet 
oxygen and other compounds (Chance et al., 1979). Superoxide anion O2•− is the most 
important, it is a fairly stable compound, especially in an aqueous environment at neutral 
pH. Its toxicity is principally based on generation of further reactive species, called 
“downstream products” of O2• −, which are then able to attack intracellular biomolecules.  
There are currently seven separate sites of mitochondrial ROS production that have been 
identified (Figure 4) (Brand et al., 2004).  
 
Fig. 4. Sites and topology of mitochondrial superoxide production. PDH: pyruvate 
dehydrogenase ; OGDH: 2-oxoglutarate dehydrogenase ; Site IF: NADH binding site of 
complex I ; Site IQ: uniquinine reduction site of complex I  
ETFQOR: electron transferring flavoprotein ubiquinone oxidoreductase ; GPDH: glycerol 3-
phosphate dehydrogenase  
Site IIIQO: quinone binding site of the Q-cycle in complex III. 
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The relative importance of each site to total superoxide production in isolated mitochondria 
is contentious, partly because of different assays, different substrates and different sources 
of mitochondria. Most assays of superoxide production from defined sites measure maximal 
capacities for superoxide production, and the actual rate from each site in the absence of 
inhibitors is not known. During reverse electron transport from succinate to NAD+, 
complex I can produce superoxide at high rates (Han et al., 2001; Votyakova & Reynolds, 
2001; Kushnareva et al., 2002; Liu et al., 2002; Han et al., 2003; Turrens, 2003; Lambert & 
Brand, 2004), although the physiological relevance is unclear (Votyakova & Reynolds, 2001). 
During forward electron transport from NAD-linked substrates (which may be more 
physiological), most mitochondria produce superoxide at high rates after addition of 
inhibitors such as rotenone (for complex I) (Han et al., 2001; Liu et al., 2002; St-Pierre et al., 
2002; Han et al., 2003; Lambert & Brand, 2004) or antimycin A (for complex III)(Liu et al., 
2002; St-Pierre et al., 2002; Muller et al., 2004). Other physiologically relevant substrates, such 
as fatty acids and glycerol 3-phosphate, may cause superoxide production from sites that are 
less active during pyruvate oxidation, such as ETF-Q oxidoreductase and glycerol 3-
phosphate dehydrogenase. 
O2•− in the matrix is converted to H2O2 by matrix MnSOD, while O2•− released to the 
intramembrane space is partly dismuted by intermembrane space CuZnSOD (Inoue et al., 
2003). Any residual O2•− which diffuses into the cytosol is similarly converted by the 
cytosolic CuZnSOD. If any mitochondrial O2•− can reach the extracellular space, it is then 
detoxified by extracellular CuZnSOD (SOD3) (Brand, 2010). Non-enzymatic 
lipoperoxidation is also a detoxification reaction. It can be considered not only as a 
detoxification reaction, but, due to its self-propagating nature, also as a new radical source 
initiated by the highly reactive radicals. Glutathione-based systems, including glutathione S 
transferase and the thioredoxin system, including peroxiredoxins, constitute the major redox 
buffer in the cytosol. Other detoxification systems (degrading H2O2 and ROS) are proteins of 
thioredoxin family, acting in concert with the thioredoxin-dependent peroxide reductase, 
and a family glutathione-S- transferase. H2O2 can be reduced to water by catalase or 
glutathione peroxidase, or alternatively to the hydroxyl radical in the presence of reduced 
copper or iron (Camello-Almaraz et al., 2006).  
Increased oxidative stress plays a key role in PAD and IR-induced muscular impairments. 
Both increased ROS secondary to mitochondrial dysfunction and decreased ROS catabolism 
are involved (Figures 1 and 3).  
2. Mitochondrial and oxidative stress analysis of muscle biopsies 
2.1 Histological methods 
2.1.1 Histological analysis of skeletal muscle mitochondria 
Mitochondria can be detected in confocal microscopy by conventional fluorescent stains, 
such as rhodamine 123 and tetramethylrosamine. These stains are readily sequestered by 
functioning mitochondria, but they are subsequently washed out of the cells once the 
mitochondrion's membrane potential is lost. This characteristic limits their use in 
experiments in which cells must be treated with aldehyde-based fixatives or other agents 
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that affect the energetic state of the mitochondria. To overcome this limitation, it is possible 
to use a serie of mitochondrion selective stains (MitoTracker probes®) that are concentrated 
by active mitochondria and well retained during cell fixation. Because these mitochondrion 
selective stains are also retained following permeabilization, the sample retains the 
fluorescent staining pattern characteristic of live cells during subsequent processing steps 
for immunocytochemistry, in situ hybridization or electron microscopy. 
MitoSOX® Red mitochondrial superoxide indicator is a fluorogenic dye for highly selective 
detection of superoxide in the mitochondria of live cells. It is live-cell permeant and is 
rapidly and selectively targeted to the mitochondria. Once in the mitochondria, it is 
oxidized by superoxide (but not by other reactive oxygen species) and exhibits red 
fluorescence. Oxidation of the probe is prevented by superoxide dismutase. The oxidation 
product becomes highly fluorescent (excitation/emission maxima of approximately 510/580 
nm) upon binding to nucleic acids. Cells adhering to coverslips have to be covered by 1 or 2 
mL of 5 M of MitoSOX® reagent working solution, and incubated for 10 minutes at 37°C, 
protected from light. They are then washed gently three times with warm buffer, and 












Fig. 5 Assessment of superoxide generation. MitoSOX Red stain (top panel) revealed the 
presence of superoxide anion MitoSOX Red colocalized with MitoTracker Green (middle 
panel) in merged images (bottom panels), indicating that the excess superoxide anion was 
concentrated in mitochondria (Quinzii et al., 2008).  
In transmission electron microscopy, mitochondrial ultrastructure can be studied. The 
material is fixed, embedded, sectioned, and then examined. It is important to note that the 
sections must be less than 0.1 m in thickness, even less than 0.05 m, in order to show the 
structural details described with enough clarity for profitable study of the mitochondria 
(Frey et al., 2002) (figure 6).  
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The relative importance of each site to total superoxide production in isolated mitochondria 
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by active mitochondria and well retained during cell fixation. Because these mitochondrion 
selective stains are also retained following permeabilization, the sample retains the 
fluorescent staining pattern characteristic of live cells during subsequent processing steps 
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Fig. 5 Assessment of superoxide generation. MitoSOX Red stain (top panel) revealed the 
presence of superoxide anion MitoSOX Red colocalized with MitoTracker Green (middle 
panel) in merged images (bottom panels), indicating that the excess superoxide anion was 
concentrated in mitochondria (Quinzii et al., 2008).  
In transmission electron microscopy, mitochondrial ultrastructure can be studied. The 
material is fixed, embedded, sectioned, and then examined. It is important to note that the 
sections must be less than 0.1 m in thickness, even less than 0.05 m, in order to show the 
structural details described with enough clarity for profitable study of the mitochondria 
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Fig. 6. Micrographs of transmission electron microscopy sections of mitochondria, TEM 
×60K. The left photo represent a healthy mitochondrion the arrow indicates the cristae; the 
right photo represents a swelling mitochondrion (Li et al., 2010).  
2.1.2 Microscopy fluorescence: Dihydroethidium staining 
To detect the presence of ROS in skeletal muscles, serial sections (10 μm-thick) are cut on a 
cryostat microtome, mounted into glass slides and incubated with 2.5 μM dihydroethidium 
(DHE). DHE produces red fluorescence when oxidized to ethidium bromide (EtBr), mainly 
by superoxide anion. After staining, sections are examined under an epifluorescence 
microscope (Nikon Eclipse E800) and emission signal are recorded with a Zeiss filter 
(Dikalov et al., 2007) (figure 7). 
 
Fig. 7. A representative photo of Superoxide production by dihydroethidium staining of 
tissue in the acute phase of stress cardiomyopathy (Nef et al., 2008) 
Inhibitors of NADPH oxidase (diphenylene iodonium) and xanthine oxidase are known to 
reduce mitochondrial superoxide production through inhibiting NADH ubiquinone 
oxidoreductase (complex I) (Riganti et al., 2004).  
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2.2 Functional methods 
2.2.1 Mitochondrial respiratory chain complexes activities using saponin skinned 
fibres 
The mitochondrial respiratory chain complexes activities study is described in an other 
chapter. This technique is based on the measure of oxygen consumption in skinned fibres in 
order to determine the functional oxidative capacity of the skeletal muscle in its cellular 
environment (Veksler et al., 1987; Riganti et al., 2004) (see the chapter from Charles et al. for 
much more explanations and the description of the methods).  
2.2.2 H2O2 Production in permeabilized fibres 
H2O2 production is assessed in permeabilized fibres (Kuznetsov et al., 2008) in response to 
sequential addition of substrates and inhibitors (Anderson & Neufer, 2006). H2O2 
production is measured with Amplex Red reagent (Invitrogen), which reacts with H2O2 in a 
1:1 stoichiometry catalyzed by HRP (Horse Radish Peroxidase; Fluka Biochemika) to yield 
the fluorescent compound resorufin and molar equivalent O2. Resorufin has 
excitation/emission characteristics of 563/587 nm and is extremely stable once formed. 
Fluorescence is measured continuously [change in fluorescence (ΔF)/sec] with a 
spectrofluorometer with temperature control and magnetic stirring. After a baseline, ΔF 
(reactants only) is established; the reaction is initiated by addition of a permeabilized fibre 
bundle to 600 µl of buffer Z with glutamate (5µM) and malate (2.5µM) as substrates for 
complex I and succinate (5mM) for complex II. ADP (2mM) is injected in the reaction buffer 
and led to a reduction in H2O2 release, which is expected when electron flow through the 
respiratory chain is stimulated. Finally, addition of the complex I inhibitor amytal (2mM) 
and the complex III inhibitor antimycin (8µM) led to interruption of normal electron flow 
and induced an increase in H2O2 release. 
3. Mitochondrial dysfunctions during peripheral arterial disease 
During PAD, significant muscles ischemia/reperfusion is well known to induce skeletal 
muscles alterations (Figure 1). The pathogenesis of PAD manifestations is lead to the 
development of athero-occlusive disease in the lower limb arteries. Arterial stenoses usually 
do not affect the blood supply at rest, but at the time of walking or other exercise, they make 
the leg ischemic and painful forcing the patient to rest. At rest, perfusion returns again to 
normal levels. These cycles of ischemia and reperfusion launch a cascade of inflammatory 
changes and induce the production of ROS in the skeletal muscle. Multiple daily 
ischemia/reperfusion events initiated by simple activities such as walking result, over time, 
in morphological and ultrastructural changes in both the contractile element of the muscle 
and its mitochondria. Dysfunctional mitochondria then further lower the already decreased 
(by compromised blood supply) energy levels in the pathologic muscle and become sources 
of ever increasing levels of ROS and possibly inducers of apoptosis. A vicious cycle is thus 
initiated gradually leading to deteriorating mitochondrial function and escalating ROS 
production with ongoing damage of every structure in the myocytes. Apoptosis, along with 
cellular necrosis (from ischemia, reactive oxygen species, and low energy levels), may then 
be induced, eventually leading to a severe myopathy that significantly affects the function 
and performance of PAD limbs. In addition, nerves, skin, and subcutaneous tissues 
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and led to a reduction in H2O2 release, which is expected when electron flow through the 
respiratory chain is stimulated. Finally, addition of the complex I inhibitor amytal (2mM) 
and the complex III inhibitor antimycin (8µM) led to interruption of normal electron flow 
and induced an increase in H2O2 release. 
3. Mitochondrial dysfunctions during peripheral arterial disease 
During PAD, significant muscles ischemia/reperfusion is well known to induce skeletal 
muscles alterations (Figure 1). The pathogenesis of PAD manifestations is lead to the 
development of athero-occlusive disease in the lower limb arteries. Arterial stenoses usually 
do not affect the blood supply at rest, but at the time of walking or other exercise, they make 
the leg ischemic and painful forcing the patient to rest. At rest, perfusion returns again to 
normal levels. These cycles of ischemia and reperfusion launch a cascade of inflammatory 
changes and induce the production of ROS in the skeletal muscle. Multiple daily 
ischemia/reperfusion events initiated by simple activities such as walking result, over time, 
in morphological and ultrastructural changes in both the contractile element of the muscle 
and its mitochondria. Dysfunctional mitochondria then further lower the already decreased 
(by compromised blood supply) energy levels in the pathologic muscle and become sources 
of ever increasing levels of ROS and possibly inducers of apoptosis. A vicious cycle is thus 
initiated gradually leading to deteriorating mitochondrial function and escalating ROS 
production with ongoing damage of every structure in the myocytes. Apoptosis, along with 
cellular necrosis (from ischemia, reactive oxygen species, and low energy levels), may then 
be induced, eventually leading to a severe myopathy that significantly affects the function 
and performance of PAD limbs. In addition, nerves, skin, and subcutaneous tissues 
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damages are formed, ultimately leading to the characteristically atrophic legs of patients 
with advanced PAD having thin muscles; brittle, hairless, and thin skin with shiny texture; 
and impaired sensorimotor function. On the basis of these concepts, it is easy to understand 
how claudication, rest pain, and tissue loss find their place in the heart of this continuum of 
events, coming into view as the external manifestations of ongoing tissue injury and 
deterioration (Blaisdell, 2002; Pipinos et al., 2008a). 
3.1 Selected experimental data (Table 1) 
Author Journal Year Histology Oxidative stress Respirometry 
Makris Vascular 2007 
Myopathic 
features 
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Peripheral arterial disease is a consequence of compromised blood supply to the ischemic 
limb (Brass, 1996; Brass & Hiatt, 2000). Experimental data show that skeletal muscle 
responds to inflow arterial occlusion with the development of myopathic histological 
changes, a drop in total protein content, and a trend toward decreased wet weight (Makris, 
et al., 2007 ; Pipinos, et al., 2008b). Peripheral arterial disease is characterized by a significant 
increase in the mitochondrial content of skeletal muscle, and mitochondrial proliferation is 
characteristic of mitochondrial diseases and aging (Levak-Frank et al., 1995; Wallace, 2000; 
Wredenberg et al., 2002; Makris et al., 2007; Pipinos et al., 2008b). In skeletal muscle, an 
upregulation of mitochondrial biogenesis may be associated with and alteration of muscle 
fibre type toward the more oxidative type I and IIa fibres (Pipinos et al., 2008b).  
Defective mitochondria are central to this myopathy, through compromised performance as 
primary energy producers and regulators of oxygen radical species. Thus, PAD myopathy is 
characterized by an increased content of dysfunctional mitochondria having significant 
defects in electron transport chain complexes I, III, and IV (Pipinos et al., 2000; Pipinos et al., 
2008b). These defects are associated with a bioenergetic decline, characterized by inadequate 
oxidative phosphorylation, decreased ATP energy production, and increased oxidative 
stress (Makris et al., 2007; Pipinos et al., 2008b). Ischemic skeletal muscle sustains substantial 
oxidative injuries indicated by an increase in protein carbonylation and lipid peroxidation 
adducts. Under resting conditions, a large proportion of cellular reactive oxygen species is 
produced in the mitochondria (Wallace, 2000).  
Thus, ischemia/reperfusion is the central problem in animals with inflow arterial occlusion 
(Brevetti et al., 2001). Ischemia/reperfusion increases oxidative stress, triggers inflammation 
and oxidative damage to the tissues, and initiates mitochondrial injury and dysfunction. 
Mitochondrial dysfunction can then be perpetuated by repeated destructive cycles of 
ischemia/reperfusion, causing amplification of respiratory chain defects, compromised 
bioenergetics, increased reactive oxygen species production, diminished MnSOD 
antioxidant activity. The combination of compromised bioenergetics and worsening 
oxidative stress may then lead to progressive oxidative damage of structures in the 
myocytes (Brass, 1996; Brass & Hiatt, 2000; Makris et al., 2007; Pipinos et al., 2008a).  
There are non-invasive techniques that can evaluate in vivo the mitochondrial energy 
transformation by the monitoring of the tissue oxygen level: either directly with the 
31phosphorous magnetic resonance spectroscopy (Hands et al., 1990; Greiner et al., 2006), or 
indirectly with infrared spectroscopy (Hands et al., 1986; Watanabe et al., 2004; Ubbink & 
Koopman, 2006). The 31phosphorous magnetic resonance spectroscopy is used to determine 
the concentrations of metabolites involved in muscle energy metabolism (phosphocreatin, 
inorganic phosphate, and ATP). From these data, free ADP and pH may be calculated 
(Quistorff et al., 1993). The infrared spectroscopy is used to measure the state of oxygen 
saturation in hemoglobin and myoglobin in blood and muscle at a given time and a given 
location. It can be considered as an indirect measure of the muscle perfusion versus oxygen 
consumption (Comerota et al., 2003).   
Mitochondrial function may also be evaluated by respirometry on muscle biopsies. The 
feasibility, indications, contra-indications are now well known and such a technique become 
usual in specialized centers. Thus, skeletal muscle biopsies can be obtained during surgery, 
or they can be obtained under local anesthesia. Biopsy sites can be anesthetized with a 2% 
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changes, a drop in total protein content, and a trend toward decreased wet weight (Makris, 
et al., 2007 ; Pipinos, et al., 2008b). Peripheral arterial disease is characterized by a significant 
increase in the mitochondrial content of skeletal muscle, and mitochondrial proliferation is 
characteristic of mitochondrial diseases and aging (Levak-Frank et al., 1995; Wallace, 2000; 
Wredenberg et al., 2002; Makris et al., 2007; Pipinos et al., 2008b). In skeletal muscle, an 
upregulation of mitochondrial biogenesis may be associated with and alteration of muscle 
fibre type toward the more oxidative type I and IIa fibres (Pipinos et al., 2008b).  
Defective mitochondria are central to this myopathy, through compromised performance as 
primary energy producers and regulators of oxygen radical species. Thus, PAD myopathy is 
characterized by an increased content of dysfunctional mitochondria having significant 
defects in electron transport chain complexes I, III, and IV (Pipinos et al., 2000; Pipinos et al., 
2008b). These defects are associated with a bioenergetic decline, characterized by inadequate 
oxidative phosphorylation, decreased ATP energy production, and increased oxidative 
stress (Makris et al., 2007; Pipinos et al., 2008b). Ischemic skeletal muscle sustains substantial 
oxidative injuries indicated by an increase in protein carbonylation and lipid peroxidation 
adducts. Under resting conditions, a large proportion of cellular reactive oxygen species is 
produced in the mitochondria (Wallace, 2000).  
Thus, ischemia/reperfusion is the central problem in animals with inflow arterial occlusion 
(Brevetti et al., 2001). Ischemia/reperfusion increases oxidative stress, triggers inflammation 
and oxidative damage to the tissues, and initiates mitochondrial injury and dysfunction. 
Mitochondrial dysfunction can then be perpetuated by repeated destructive cycles of 
ischemia/reperfusion, causing amplification of respiratory chain defects, compromised 
bioenergetics, increased reactive oxygen species production, diminished MnSOD 
antioxidant activity. The combination of compromised bioenergetics and worsening 
oxidative stress may then lead to progressive oxidative damage of structures in the 
myocytes (Brass, 1996; Brass & Hiatt, 2000; Makris et al., 2007; Pipinos et al., 2008a).  
There are non-invasive techniques that can evaluate in vivo the mitochondrial energy 
transformation by the monitoring of the tissue oxygen level: either directly with the 
31phosphorous magnetic resonance spectroscopy (Hands et al., 1990; Greiner et al., 2006), or 
indirectly with infrared spectroscopy (Hands et al., 1986; Watanabe et al., 2004; Ubbink & 
Koopman, 2006). The 31phosphorous magnetic resonance spectroscopy is used to determine 
the concentrations of metabolites involved in muscle energy metabolism (phosphocreatin, 
inorganic phosphate, and ATP). From these data, free ADP and pH may be calculated 
(Quistorff et al., 1993). The infrared spectroscopy is used to measure the state of oxygen 
saturation in hemoglobin and myoglobin in blood and muscle at a given time and a given 
location. It can be considered as an indirect measure of the muscle perfusion versus oxygen 
consumption (Comerota et al., 2003).   
Mitochondrial function may also be evaluated by respirometry on muscle biopsies. The 
feasibility, indications, contra-indications are now well known and such a technique become 
usual in specialized centers. Thus, skeletal muscle biopsies can be obtained during surgery, 
or they can be obtained under local anesthesia. Biopsy sites can be anesthetized with a 2% 
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lidocaine solution, and 1.0 cm incisions can be made through the skin and gastrocnemius 
fascia. A modified 5 mm Bergstrom biopsy needle can then be inserted 10-15 mm and used 
to obtain 40 to 50 mg of skeletal muscle. Contraindications are essentially represented by 
bleeding disorders, infection at biopsy sites, or allergy to local anesthetics.  
3.2 Selected clinical data (Table 2) 
Author Journal Year Histology Oxidative stress Respirometry 
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Table 2. Clinical data.  
Previous studies have shown that PAD is associated with alterations in skeletal muscle 
histology (Brass & Hiatt, 2000; Makris et al., 2007; Pipinos et al., 2008b). Necrotic and 
regenerating fibres as well as inflammation have been seen in the diseased legs in 
comparison to contralateral legs of patients with unilateral peripheral arterial disease 
hospitalized for surgical evaluation. Furthermore, in the setting of aortic aneurysm repair in 
human, light microscopy revealed a consistent granulocyte infiltration in the ischemic and 
reperfused skeletal muscle. Ultrastructural damage to the muscle fibers was seen during 
ischemia and became more severe upon reperfusion. The recruitment of granulocytes into 
the muscle tissue paralleled the activation of the blood complement system and an increase 
in circulating neutrophils (Formigli L et al., 1992). 
3.2.1 Patients with functional ischemia 
The 31phosphorous magnetic resonance spectroscopy examination shows a higher inorganic 
phosphate/phosphocreatin ratio compared to control patients (Hands et al., 1986; Zatina et 
al., 1986; Hands et al., 1990). The infrared spectroscopy examination shows a large drop in 
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the oxygen saturation in the muscle and an increased oxygenation recovery time after 
exercise when compared to control patients (Kemp et al., 2001; Comerota et al., 2003).  
Histological examination shows more type I muscle fibres containing a high amount of 
mitochondria in the gastrocnemius muscle of patients with functional ischemia. In addition, 
the severity of the peripheral arterial disease was correlated with the increased percentage 
of type I fibres (Makitie & Teravainen, 1977). 
3.2.2 Patients with critical limb ischemia 
The 31phosphorous magnetic resonance spectroscopy examination shows a higher 
intracellular pH, and a higher inorganic phosphate/phosphocreatin ratio compared to 
control patients (Hands et al., 1986; Zatina et al., 1986; Hands et al., 1990). The infrared 
spectroscopy examination shows a large decrease in the oxygen saturation in the muscle and 
an increased oxygenation recovery after surgery. Respirometry shows a reduced 
mitochondrial respiratory rate in the gastrocnemius muscle compared to control patients 
(Pipinos et al., 2003; Pipinos et al., 2006). The reduced respiratory rate is specifically located 
to complexes I, III and IV enzymes of the respiratory chain; probably due to reactive oxygen 
species generated damage (Sjostrom et al., 1980; Pipinos et al., 2003). 
4. Improving mitochondrial function and reducing oxidative stress: selected 
experimental and clinical results (Table 3) 
 
Author Journal Year Type Histology Oxidative stress 
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exercise when compared to control patients (Kemp et al., 2001; Comerota et al., 2003).  
Histological examination shows more type I muscle fibres containing a high amount of 
mitochondria in the gastrocnemius muscle of patients with functional ischemia. In addition, 
the severity of the peripheral arterial disease was correlated with the increased percentage 
of type I fibres (Makitie & Teravainen, 1977). 
3.2.2 Patients with critical limb ischemia 
The 31phosphorous magnetic resonance spectroscopy examination shows a higher 
intracellular pH, and a higher inorganic phosphate/phosphocreatin ratio compared to 
control patients (Hands et al., 1986; Zatina et al., 1986; Hands et al., 1990). The infrared 
spectroscopy examination shows a large decrease in the oxygen saturation in the muscle and 
an increased oxygenation recovery after surgery. Respirometry shows a reduced 
mitochondrial respiratory rate in the gastrocnemius muscle compared to control patients 
(Pipinos et al., 2003; Pipinos et al., 2006). The reduced respiratory rate is specifically located 
to complexes I, III and IV enzymes of the respiratory chain; probably due to reactive oxygen 
species generated damage (Sjostrom et al., 1980; Pipinos et al., 2003). 
4. Improving mitochondrial function and reducing oxidative stress: selected 
experimental and clinical results (Table 3) 
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Table 3. Effects of pre- and post-conditioning. This table summarizes clinical studies realized 
on pre- or postconditioning. 
4.1 Ischemic pre- and post-conditioning 
Besides reducing preoperative ischemic time and surgery duration, ischemic 
preconditioning -defined as brief episodes of ischemia/reperfusion applied before sustained 
ischemia- decreases skeletal muscle mitochondrial dysfunction, enhances limb and remotes 
organ protections. Furthermore, remote and local ischemic preconditioning equivalently 
protects skeletal muscle mitochondrial function during experimental aortic cross-clamping 
(Mansour et al., in Press). Nevertheless, ischemia occurrence is difficult to predict and might 
limit a broader use of ischemic preconditioning. Controlled reperfusion appears thus as a 
valuable therapeutic approach after limb ischemia and ischemic post-conditioning, 
characterized by repeated cycles of IR performed at the onset of reperfusion, appeared safe 
and easy to perform.  
Ischemic preconditioning has been mainly elucidated in experimental cardiac ischemia. 
Ischemic preconditioning utilizes endogenous as well as distant mechanisms in skeletal 
muscle, liver, lung, kidney, intestine and brain in animal models to convey varying degrees 
of protection from ischemia/reperfusion injury (Ambros et al., 2007). Specifically, 
preconditioned tissues exhibit altered energy metabolism, better electrolyte homeostasis and 
genetic reorganization, as well as less oxygen-free radicals and activated neutrophils release, 
reduced apoptosis and better microcirculatory perfusion. To date, there are few human 
studies, but trials suggest that different organ in human such as heart, liver, lung and 
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skeletal muscle acquire protection after ischemia/reperfusion (Sjostrom et al., 1980; Ali et 
al.,2007; Cheung M et al., 1996; Kharbanda et al., 2002). It has been showed that ischemic 
preconditioning positively influenced muscle metabolism during reperfusion, and this, 
results in an increase in phosphocreatin production and higher oxygen consumption 
(Andreas et al., 2011). 
Experimental data showed that ischemic postconditioning confers protection against 
different organ injuries caused by longer circulatory occlusions during elective major 
vascular surgeries, because it causes a significant reduction in systemic inflammatory 
response (TNF-alpha, oxygen-derived free radicals) (Eberlin et al., 2009). Besides the heart 
(Skyschally et al.,2009), postconditioning is also effective in salvage of ischemic skeletal 
muscle from reperfusion injury and the mechanism likely involves inhibition of opening of 
the mPTP and/or reduced oxidative stress (Szijarto et al.,2009; Tsubota et al., 2010; Park et al., 
2010; Guyrkovic et al., 2011; Mc Allister et al., 2008; Charles et al., 2011). There are few human 
studies, but it has been showed that postconditioning by intermittent early reperfusion 
reduces ischemia/reperfusion injury, that might depend on K(ATP) channel activation, and 
is mimicked by inhibition of the mPTP at reperfusion (Okorie et al., 2011).  
4.2 Pharmacological protection of skeletal muscle in the setting of 
ischemia/reperfusion 
Although preconditioning is a powerful form of protection, its clinical application is limited 
because of practical reasons. In fact, the short ischemic insults in preconditioning have to be 
applied before the onset of sustained period of ischemia which cannot be precisely 
anticipated. On the contrary, the very brief insults in postconditioning have to be applied 
immediately after the end of the long ischemia thus making the intervention more easily 
applicable. Both mechanisms limit the reperfusion injury but easier approaches deserve to 
be studied. 
Pharmacological preconditioning and postconditioning represent ideal alternatives that may 
substitute the short ischemic insults for pharmaceuticals means. The components of 
preconditioning share two main pathways, one that involves the mitochondrial K(ATP) 
channels- free radicals and PKC and another one that involves adenosine and PKC. 
Reperfusion injury salvage kinases (RISK) prevent the mitochondrial permeability transition 
pores (mPTP) opening which destroy the mitochondria and cause cell death. PC via PKC 
and postconditioning via gradual restoration of pH at reperfusion up-regulate RISK and 
preserve viable part of the ischemic region. In order to confer pharmacological protection, 
novel therapeutic strategies, based on the knowledge of the ligands, of the receptors and of 
the intracellular signaling pathways have emerged (Addison et al., 2003; Gamboa et al., 2003; 
Martou et al., 2006; Andreadou et al., 2008b). Adenosine, nicorandil, tempol, coenzyme Q 
and other agents (Addison et al., 2003; Gamboa et al., 2003; Martou et al., 2006; Thaveau et al., 
2010) have been already used as pharmacological mimetics of ischemic preconditioning. 
Furthermore, agents that increase RISK or directly prevent mPTP are also under 
investigation as postconditioning analogues (Andreadou et al., 2008a; Tsubota et al., 2010; 
Tran et al., 2011). Antioxidant systems are also important: several endogenous antioxidant 
systems are found in muscle tissue, these include alpha-tocopherol, histidine-containing 
dipeptides, and antioxidant enzymes such as glutathione peroxidase, superoxide dismutase, 
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limit a broader use of ischemic preconditioning. Controlled reperfusion appears thus as a 
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skeletal muscle acquire protection after ischemia/reperfusion (Sjostrom et al., 1980; Ali et 
al.,2007; Cheung M et al., 1996; Kharbanda et al., 2002). It has been showed that ischemic 
preconditioning positively influenced muscle metabolism during reperfusion, and this, 
results in an increase in phosphocreatin production and higher oxygen consumption 
(Andreas et al., 2011). 
Experimental data showed that ischemic postconditioning confers protection against 
different organ injuries caused by longer circulatory occlusions during elective major 
vascular surgeries, because it causes a significant reduction in systemic inflammatory 
response (TNF-alpha, oxygen-derived free radicals) (Eberlin et al., 2009). Besides the heart 
(Skyschally et al.,2009), postconditioning is also effective in salvage of ischemic skeletal 
muscle from reperfusion injury and the mechanism likely involves inhibition of opening of 
the mPTP and/or reduced oxidative stress (Szijarto et al.,2009; Tsubota et al., 2010; Park et al., 
2010; Guyrkovic et al., 2011; Mc Allister et al., 2008; Charles et al., 2011). There are few human 
studies, but it has been showed that postconditioning by intermittent early reperfusion 
reduces ischemia/reperfusion injury, that might depend on K(ATP) channel activation, and 
is mimicked by inhibition of the mPTP at reperfusion (Okorie et al., 2011).  
4.2 Pharmacological protection of skeletal muscle in the setting of 
ischemia/reperfusion 
Although preconditioning is a powerful form of protection, its clinical application is limited 
because of practical reasons. In fact, the short ischemic insults in preconditioning have to be 
applied before the onset of sustained period of ischemia which cannot be precisely 
anticipated. On the contrary, the very brief insults in postconditioning have to be applied 
immediately after the end of the long ischemia thus making the intervention more easily 
applicable. Both mechanisms limit the reperfusion injury but easier approaches deserve to 
be studied. 
Pharmacological preconditioning and postconditioning represent ideal alternatives that may 
substitute the short ischemic insults for pharmaceuticals means. The components of 
preconditioning share two main pathways, one that involves the mitochondrial K(ATP) 
channels- free radicals and PKC and another one that involves adenosine and PKC. 
Reperfusion injury salvage kinases (RISK) prevent the mitochondrial permeability transition 
pores (mPTP) opening which destroy the mitochondria and cause cell death. PC via PKC 
and postconditioning via gradual restoration of pH at reperfusion up-regulate RISK and 
preserve viable part of the ischemic region. In order to confer pharmacological protection, 
novel therapeutic strategies, based on the knowledge of the ligands, of the receptors and of 
the intracellular signaling pathways have emerged (Addison et al., 2003; Gamboa et al., 2003; 
Martou et al., 2006; Andreadou et al., 2008b). Adenosine, nicorandil, tempol, coenzyme Q 
and other agents (Addison et al., 2003; Gamboa et al., 2003; Martou et al., 2006; Thaveau et al., 
2010) have been already used as pharmacological mimetics of ischemic preconditioning. 
Furthermore, agents that increase RISK or directly prevent mPTP are also under 
investigation as postconditioning analogues (Andreadou et al., 2008a; Tsubota et al., 2010; 
Tran et al., 2011). Antioxidant systems are also important: several endogenous antioxidant 
systems are found in muscle tissue, these include alpha-tocopherol, histidine-containing 
dipeptides, and antioxidant enzymes such as glutathione peroxidase, superoxide dismutase, 
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and catalase. The contribution of alpha-tocopherol to the oxidative stability of skeletal 
muscle is largely influenced by diet. Dietary supplementation of tocopherol has been shown 
to increase muscle alpha-tocopherol concentrations and to inhibit lipid oxidation. Dietary 
selenium supplementation has also been shown to increase the oxidative stability of muscle 
presumably by increasing the activity of glutathione peroxidase, and dietary restriction 
improves systemic and muscular oxidative stress (Rodrigues et al., 2011). The oxidative 
stability of skeletal muscle is also influenced by the histidine-containing dipeptides, 
carnosine and anserine (Chan & Decker, 1994).  
5. Conclusions / Perspectives 
Mitochondria are the main energy source of the cells and mitochondrial dysfunction is 
associated with cell and organ impairment. Consistently, IR has been shown to induce 
skeletal muscle mitochondrial dysfunctions in animals and humans and improving skeletal 
muscle mitochondrial function is an interesting and clinically pertinent therapeutic goal. 
Indeed, improving skeletal muscle mitochondrial function enhances walking capacities in 
patients suffering from peripheral arterial disease.  
Muscle biopsy allows to precisely determine the deleterious effects of IR on skeletal muscle 
and can be used to better stratify patient’s risk and to guide therapy. Ischemic pre- and post-
conditioning and pharmacologic conditioning allows protection of skeletal muscle in the 
setting of ischemia/reperfusion, decreasing mitochondrial respiratory chain injury, 
reducing reactive oxygen species (ROS) production and enhancing muscles antioxidant 
defence.  
Future work will be useful to determine whether even smaller biopsies, analyzed after being 
frozen, might yield the same information. 
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Investigation of muscle diseases has changed dramatically with the understanding 
of genetic basis of a wide range of muscle diseases. Muscle biopsy has become a 
powerful tool not only to provide diagnosis but to make tissue available for genetic 
studies and to basic scientists for biomedical research. Accurate interpretation of 
muscle biopsy to detect cell dysfunction/ damage/death or absence / abnormality of 
a protein or genetic defect by the sophisticated technologies is important to guide 
treatment of various muscle diseases. In this book on muscle biopsy various chapters 
deal with the procedure and interpretation of muscle biopsy, its use in the culture of 
myotubes and membrane transport studies.Muscle biopsy is an important technique 
to investigate mitochondrial dysfunction and the mitochondrial DNA integrity in 
oxidation. Phosphorylation in various metabolic diseases like obesity, type 2 diabetes 
mellitus and peripheral vascular disease is explored in the other chapters with detailed 
descriptions on methodology. This book provides the advances in the basic techniques 
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